Vitamin C, Vitamin D, and Zinc in Respiratory Health: Mechanistic Pathways and Clinical Evidence

From Antioxidant Defense to Immune Modulation and Antiviral Synergy

Abstract

Respiratory diseases- including upper respiratory tract infections (URTI), influenza, coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID) - constitute a continuum of acute and chronic disorders characterized by oxidative stress, immune dysregulation, epithelial and endothelial barrier dysfunction, and extracellular matrix (ECM) remodeling. Nutritional modulation provides a multi-dimensional strategy to address these overlapping pathological axes.

This paper synthesizes mechanistic, translational, and clinical evidence on vitamin C, vitamin D, and zinc as core modulators of respiratory resilience, together with their synergistic interactions with quercetin, bromelain, elderberry (Sambucus nigra), mulberry leaf (Morus alba), and fish cardiac arterial bulb-derived elastin peptides (FCAB-EPs).

Vitamin C functions as a redox regulator and collagen cofactor, enhancing endothelial stability, leukocyte function, and fibrotic restraint. Vitamin D, via vitamin D receptor (VDR) signaling, induces antimicrobial peptides (LL-37, β-defensins), rebalances Th1/Th17–

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

Treg immune axes, and stabilizes tight-junction integrity. Zinc orchestrates antiviral restriction (RNA polymerase inhibition), immune maturation, metallothionein-mediated antioxidant defense, and epithelial restitution.

Synergistic nutrient partners extend these effects into targeted mechanistic domains:

- Quercetin enhances intracellular zinc uptake as a zinc ionophore, complements vitamin C in redox control, and attenuates NLRP3 inflammasome activation.
- Bromelain lowers mucus viscosity, modulates bradykinin-mediated edema, and reduces airway obstruction, complementing zinc's barrier repair and vitamin D's junctional stability.
- Elderberry polyphenols inhibit viral entry via hemagglutinin binding interference and reduce pro-inflammatory cytokines, synergizing with zinc's replication inhibition and vitamin D's antimicrobial priming.
- Mulberry leaf bio-actives restrain metaflammation by reducing glycemia-driven NF-κB activation and oxidative stress, integrating with zinc and vitamin D in immune–barrier regulation.
- Fish cardiac arterial bulb–derived elastin peptides (FCAB-EPs) provide structural substrates and signaling cues for elastic fiber regeneration, ECM remodeling, and compliance restoration, complementing zinc's anti-fibrotic regulation and vitamin C's collagen stabilization.

Collectively, these interactions establish a systems-level, multi-nutrient defense and repair framework, spanning antiviral containment, immune homeostasis, mucus and edema resolution, metabolic-inflammatory modulation, and elastic tissue regeneration. Clinical and translational data suggest that such strategies hold promise not only in reducing incidence and severity of acute infections (URTI, influenza, COVID-19) but also in stabilizing chronic airway disorders (asthma, COPD), improving outcomes in critical illness (ARDS), restraining fibrotic progression, and supporting rehabilitation in Long COVID. This integrative approach redefines nutritional interventions as multi-targeted, mechanistically coherent adjuncts in respiratory medicine.

Keywords

Respiratory diseases; upper respiratory tract infection (URTI); influenza; coronavirus disease 2019 (COVID-19); Post-COVID-19 Syndrome; asthma; chronic obstructive pulmonary disease (COPD); acute respiratory distress syndrome (ARDS); pulmonary fibrosis; oxidative stress; immune dysregulation; epithelial barrier dysfunction; extracellular matrix (ECM) remodeling; vitamin C; redox regulation; collagen stabilization; vitamin D; vitamin D receptor (VDR); antimicrobial peptides (LL-37, β-defensins); adaptive immune rebalancing; zinc; RNA polymerase inhibition; immune maturation; metallothioneins; quercetin; zinc ionophore activity; NLRP3 inflammasome modulation; bromelain; mucolysis; bradykinin pathway modulation; elderberry (Sambucus nigra); hemagglutinin-mediated viral entry inhibition; cytokine attenuation; mulberry leaf (Morus

alba); metaflammation control; glycemia-driven NF-κB inhibition; fish cardiac arterial bulb-derived elastin peptides (FCAB-EPs); elastic fiber regeneration; anti-fibrotic remodeling; structural preservation in COPD, ARDS, and pulmonary fibrosis; Long COVID rehabilitation.

Respiratory diseases represent one of the leading global health burdens, ranging from common acute infections such as upper respiratory tract infections (URTI) and influenza to chronic inflammatory disorders including asthma and chronic obstructive pulmonary disease (COPD). More recently, the COVID-19 pandemic has highlighted the vulnerability of the respiratory system and its complex pathophysiology, which involves oxidative stress, hyper-inflammation, epithelial barrier disruption, and immune dysregulation.

These overlapping mechanisms not only drive acute clinical symptoms but also contribute to long-term sequelae such as impaired pulmonary function and heightened susceptibility to recurrent infections.

In this context, nutritional interventions have gained growing attention as adjunctive strategies to reinforce host defense, attenuate inflammation, and support tissue repair. Among the numerous micronutrients investigated, **vitamin C, vitamin D, and zinc** stand out due to their essential and complementary roles in maintaining redox balance, regulating immune responses, and providing direct antiviral effects.

- Vitamin C is a water-soluble antioxidant that scavenges reactive oxygen species (ROS), protects epithelial integrity through its role in collagen synthesis, and enhances leukocyte function.
- Vitamin D acts as an immunomodulatory hormone, inducing antimicrobial peptides such as cathelicidin and defensins, balancing adaptive immune responses, and strengthening mucosal barriers.
- Zinc is a critical trace element required for T cell maturation, natural killer (NK) cell activity, and epithelial repair, while also functioning as a direct inhibitor of viral RNA polymerase.

The convergence of these three nutrients provides a comprehensive protective framework: vitamin C as an antioxidant shield, vitamin D as an immunological foundation, and zinc as an antiviral effector. Emerging clinical evidence further supports their roles in reducing the risk and duration of acute respiratory infections, mitigating inflammation in chronic airway disorders, and improving outcomes in COVID-19 patients.

Therefore, this paper aims to provide an integrated overview of the mechanistic pathways and clinical evidence supporting the use of vitamin C, vitamin D, and zinc in respiratory health. By examining their individual effects as well as their synergistic interactions, this work highlights their relevance in both preventive and therapeutic contexts, particularly for high-risk and nutritionally vulnerable populations.

I Pathophysiological Background of Respiratory Vulnerability

Shared Mechanisms of Oxidative Stress, Inflammation, and Immune Imbalance

The respiratory tract serves as the primary interface between the human body and the external environment, rendering it highly susceptible to infectious agents, allergens, and environmental stressors such as pollutants and tobacco smoke. Its structural and functional features - including extensive mucosal surfaces, ciliated epithelial cells, and an intricate immune network - are designed to provide robust protection.

However, under conditions of repeated exposure and pathological challenge, the respiratory system becomes particularly vulnerable to three interconnected mechanisms: oxidative stress, inflammation, and immune dysregulation.

1) Oxidative Stress as a Driver of Airway Injury

Excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) is a hallmark of respiratory pathology. Viral infections, chronic airway diseases, and environmental pollutants all contribute to the generation of ROS, which in turn initiate lipid peroxidation, DNA damage, and protein dysfunction. Persistent oxidative stress compromises epithelial integrity, weakens mucosal defenses, and amplifies inflammatory cascades, establishing a vicious cycle of tissue damage and immune activation.

2) Inflammation and Cytokine Overproduction

Inflammatory signaling, particularly through the NF-κB pathway and inflammasome activation, plays a central role in the progression of respiratory disorders. During acute viral infections such as influenza or COVID-19, uncontrolled cytokine release ("cytokine storm") can cause extensive alveolar injury and acute respiratory distress. In chronic conditions like asthma and COPD, low-grade inflammation sustains airway remodeling and hyper-responsiveness. Thus, inappropriate or excessive inflammatory responses remain a critical determinant of both acute severity and long-term respiratory morbidity.

3) Immune Dysregulation and Barrier Dysfunction

An effective immune response requires a balance between pathogen clearance and controlled inflammation. In respiratory diseases, this balance is frequently disrupted. Viral infections can downregulate secretory IgA and impair mucociliary clearance, leaving the airway vulnerable to reinfection. Nutrient deficiencies - particularly of vitamin D and zinc - further impair innate and adaptive immunity, weakening epithelial defenses and slowing recovery. Barrier dysfunction not only predisposes to recurrent infections but also perpetuates chronic inflammatory cycles.

4) Rationale for Nutritional Interventions

Given these overlapping mechanisms, targeting oxidative stress, inflammation, and immune imbalance has become a core strategy in respiratory health management. This is where nutritional interventions offer unique value:

- Vitamin C directly scavenges ROS, supports collagen synthesis for epithelial integrity, and enhances leukocyte function.
- Vitamin D provides long-term immune balance by inducing antimicrobial peptides and regulating T cell differentiation.
- Zinc strengthens immune cell maturation, promotes mucosal repair, and directly inhibits viral replication enzymes.

Together, these three nutrients form a triangular defense network that addresses the fundamental vulnerabilities of the respiratory system.

Their mechanistic complementarities not only explain observed clinical benefits in acute infections and chronic airway disorders but also provide a rationale for synergistic supplementation strategies.

II Vitamin C in Respiratory System Interventions

Antioxidant Shielding and Barrier Protection against Infection

Vitamin C has long been recognized as one of the most critical micronutrients for respiratory health. Beyond its role as a water-soluble antioxidant, it exerts pleiotropic effects on epithelial barrier maintenance, immune cell function, and inflammatory modulation.

In respiratory diseases - whether acute viral infections such as the common cold,

influenza, and COVID-19, or chronic airway conditions like asthma and COPD - oxidative stress and immune imbalance are common pathological drivers.

Vitamin C directly addresses these vulnerabilities by neutralizing reactive oxygen species, strengthening mucosal and vascular barriers through collagen synthesis, and enhancing both innate and adaptive immune responses.

These multifaceted actions explain why vitamin C deficiency correlates with higher susceptibility to infections, prolonged disease course, and greater risk of complications. Conversely, sufficient supplementation has been consistently associated with shortened illness duration, alleviated symptom severity, and improved clinical outcomes in vulnerable populations.

Thus, vitamin C serves not merely as an antioxidant, but as a cornerstone of respiratory defense, bridging the gap between oxidative stress control, immune resilience, and recovery support.

1) Mechanistic Basis

Vitamin C plays a pivotal role in respiratory health as both an antioxidant and an immune-supportive micronutrient. Its biological relevance arises from its ability to directly neutralize reactive oxygen species (ROS), maintain epithelial barrier integrity, and optimize leukocyte activity, thereby addressing the core vulnerabilities of the respiratory tract.

1.1) Antioxidant Defense and Redox Balance

As a potent water-soluble antioxidant, vitamin C neutralizes a broad spectrum of free radicals, including superoxide anions (O_2^-), hydroxyl radicals (•OH), and peroxynitrite ($ONOO^-$). By donating electrons, it prevents lipid peroxidation of pulmonary cell membranes and DNA oxidative damage. Beyond direct scavenging, vitamin C regenerates oxidized antioxidants such as vitamin E, thus contributing to a systemic antioxidant network. In respiratory infections where oxidative stress is elevated, this redox buffering is crucial to mitigating epithelial injury and maintaining alveolar function.

1.2) Maintenance of Epithelial and Vascular Barrier Integrity

Vitamin C is essential for the hydroxylation of proline and lysine residues during collagen synthesis, a process indispensable for maintaining structural integrity of epithelial and endothelial barriers. In the respiratory tract, strengthened collagen cross-linking supports mucosal resilience against pathogen invasion and reduces vascular permeability that can exacerbate pulmonary edema during infections or inflammation.

1.3) Enhancement of Leukocyte Function and Immune Surveillance

Vitamin C accumulates in high concentrations within neutrophils and lymphocytes. It enhances neutrophil chemotaxis, phagocytosis, and oxidative burst activity, while simultaneously promoting timely apoptosis and clearance of spent neutrophils to prevent excessive tissue damage. In adaptive immunity, vitamin C supports lymphocyte

proliferation and differentiation, thereby improving the coordination of antiviral and antibacterial responses.

1.4) Modulation of Inflammatory Responses

Vitamin C regulates pro-inflammatory signaling by downregulating NF-κB activation and decreasing the secretion of cytokines such as IL-6 and TNF-α. This dual action—enhancing pathogen clearance while preventing hyper-inflammation—provides a unique advantage in both acute viral infections (e.g., influenza, COVID-19) and chronic airway conditions characterized by persistent inflammation (e.g., asthma, COPD).

1.5) Synergistic Antioxidant Recycling

A less appreciated but clinically relevant function of vitamin C is its role in recycling oxidized quercetin and other polyphenols back into their active antioxidant states. This cooperative interaction extends antioxidant capacity across lipid and aqueous compartments, thereby amplifying protection against respiratory oxidative stress.

2) Clinical Evidence

The clinical relevance of vitamin C in respiratory health has been extensively investigated, particularly in the context of acute respiratory tract infections (ARI), influenza, and more recently COVID-19. While its effects vary by baseline nutritional status and clinical setting, a consistent body of evidence supports vitamin C as a

valuable adjunctive intervention for reducing infection risk, shortening disease duration, and alleviating symptom severity.

2.1) Upper Respiratory Tract Infections (URTI) and Common Cold

Vitamin C is most widely studied in the prevention and treatment of URTI. A comprehensive Cochrane review, which included over 11,000 participants, demonstrated that regular supplementation of ≥200 mg/day did not significantly reduce the incidence of colds in the general population, but consistently shortened the duration and reduced symptom severity. Importantly, in subgroups under physical stress (e.g., athletes, military personnel), vitamin C supplementation reduced the incidence of colds by approximately 50%, highlighting its benefit in high-demand or stress-induced immune suppression scenarios.

2.2) Influenza and Viral Respiratory Infections

Clinical studies suggest that vitamin C can attenuate influenza symptom severity and duration. Its antioxidant and immunomodulatory functions contribute to faster resolution of fever, cough, and fatigue, particularly when administered at sufficient doses early in the course of illness. Although results across studies vary, the weight of evidence indicates a supportive role for vitamin C in viral clearance and recovery, particularly in populations with low baseline plasma ascorbate levels.

2.3) Pneumonia and Severe Acute Respiratory Infections

Several trials have shown that vitamin C reduces the risk of pneumonia, especially in individuals under high oxidative or infectious stress. Historical data from controlled trials in military recruits and hospitalized patients demonstrated lower incidence of pneumonia and reduced hospital stay when vitamin C was administered. More recent studies reinforce its role in improving oxygenation and reducing inflammatory markers in patients with severe infections.

2.4) Chronic Airway Diseases (Asthma and COPD)

Oxidative stress and chronic inflammation are central to the pathophysiology of asthma and chronic obstructive pulmonary disease (COPD).

Epidemiological studies show that higher dietary vitamin C intake correlates with better lung function (e.g., higher FEV_1) and reduced risk of COPD exacerbations. Interventional studies suggest that vitamin C may improve pulmonary function parameters and reduce airway hyper-responsiveness, especially in populations with low baseline antioxidant status. These findings position vitamin C as a supportive therapy for long-term management of chronic respiratory diseases.

2.5) COVID-19

During the COVID-19 pandemic, vitamin C attracted renewed attention due to its dual role in oxidative stress control and immune support. Clinical observations and small-scale randomized controlled trials (RCTs) reported that intravenous high-dose vitamin C

improved oxygenation, reduced inflammatory biomarkers such as CRP and IL-6, and in some cases shortened hospital stay. Oral supplementation studies, though fewer, suggested that vitamin C combined with other nutrients (e.g., quercetin, zinc) may accelerate symptom resolution in mild-to-moderate cases. While larger trials are still needed, the cumulative evidence supports vitamin C as an adjunctive therapy for managing oxidative and inflammatory stress in COVID-19.

2.6) Post-COVID-19 Syndrome (also known as Long COVID)

Emerging evidence highlights the role of oxidative stress and persistent inflammation in the pathogenesis of Post-COVID-19 Syndrome. Patients frequently present with fatigue, dyspnea, and reduced exercise tolerance - symptoms that parallel increased oxidative burden and impaired mitochondrial function.

Pilot trials and case observations suggest that vitamin C, particularly when combined with other antioxidants and micronutrients, can improve fatigue, restore redox balance, and support pulmonary recovery.

While large-scale RCTs are still lacking, mechanistic plausibility and early clinical signals support its use as part of integrative strategies for Long COVID rehabilitation.

2.7) Clinical Significance

Taken together, clinical evidence highlights the following key points:

- Acute Infections (URTI, Influenza, Pneumonia): Vitamin C consistently shortens illness duration and alleviates symptoms, with preventive effects most evident in physically stressed or nutritionally depleted populations.
- Chronic Airway Diseases (Asthma, COPD): Supplementation improves lung function and reduces exacerbation risk by counteracting oxidative stress and airway inflammation.
- Severe Infections and ARDS: High-dose intravenous vitamin C may enhance oxygenation and reduce inflammatory burden.
- COVID-19 and Long COVID: Vitamin C demonstrates potential in acute management and long-term recovery, particularly as part of multi-nutrient interventions targeting oxidative stress and immune dysregulation.

Overall, vitamin C emerges as both a preventive and therapeutic agent across the respiratory disease spectrum, with effects spanning from acute infection control to chronic airway support and post-viral rehabilitation.

3) Target Populations

The clinical and mechanistic evidence identifies several populations that may benefit most from vitamin C supplementation in the context of respiratory health.

3.1) Individuals under High Oxidative Stress

Smokers, elderly individuals, and patients with chronic respiratory diseases are characterized by elevated oxidative burden and depleted plasma ascorbate levels. In these groups, vitamin C supplementation restores antioxidant defenses, supports collagen synthesis for airway integrity, and attenuates chronic inflammation.

3.2) Populations at High Risk of Infections

Individuals with frequent exposure to pathogens, such as healthcare workers, teachers, and students, are prone to recurrent upper respiratory tract infections (URTI) and influenza. Supplementation reduces infection duration and symptom severity, offering preventive benefits, particularly under physical or psychological stress.

3.3) Patients with Chronic Airway Diseases

Patients with asthma and chronic obstructive pulmonary disease (COPD) exhibit ongoing oxidative stress and airway remodeling. Evidence suggests that vitamin C intake is associated with improved lung function, reduced exacerbation frequency, and greater resilience against acute respiratory insults.

3.4) Patients with Severe Respiratory Conditions

Vitamin C has shown promise in severe infections and critical illness scenarios such as acute respiratory distress syndrome (ARDS). By reducing oxidative stress and

inflammatory cytokine release, high-dose vitamin C may support oxygenation and shorten intensive care stay.

3.5) Patients with Pulmonary Fibrosis

Oxidative stress and chronic inflammation are key drivers of pulmonary fibrosis, leading to extracellular matrix accumulation and progressive loss of lung function. Preclinical studies suggest that vitamin C may inhibit fibroblast activation and collagen overproduction, while clinical observations indicate potential supportive roles in slowing disease progression. Although large-scale clinical data remain limited, vitamin C is increasingly considered a candidate nutrient for integrative approaches to pulmonary fibrosis management.

3.6) COVID-19 Patients

Patients with coronavirus disease (COVID-19) present with elevated systemic oxidative stress and inflammatory activation. Clinical trials indicate that both intravenous and oral vitamin C may improve oxygenation, reduce inflammatory biomarkers, and accelerate recovery when used alongside standard therapy.

3.7) Patients with Post-COVID-19 Syndrome (also known as Long COVID)

Individuals with persistent fatigue, dyspnea, and exercise intolerance after COVID-19 frequently exhibit ongoing redox imbalance and impaired mitochondrial function. Vitamin

C supplementation, alone or in combination with other antioxidants, has shown preliminary benefits in alleviating fatigue and supporting pulmonary recovery, suggesting a role in Long COVID rehabilitation strategies.

4) Summary

Taken together, the positioning of vitamin C in respiratory health extends well beyond its traditional recognition as a simple antioxidant. The convergence of mechanistic data and clinical evidence underscores a broad spectrum of applicability across acute, chronic, and post-infectious respiratory conditions.

For acute respiratory infections such as upper respiratory tract infections (URTI), influenza, and coronavirus disease (COVID-19), vitamin C consistently demonstrates benefits in reducing the duration and severity of symptoms.
These effects are particularly pronounced in populations under physical or psychological stress, where immune resilience is compromised and ascorbate demand is elevated.
In more severe presentations, including pneumonia and acute respiratory distress syndrome (ARDS), high-dose intravenous vitamin C has been associated with improved oxygenation and reduced systemic inflammation, pointing to its role as a supportive therapy in critical care.

In chronic airway diseases, notably asthma and chronic obstructive pulmonary disease (COPD), persistent oxidative stress and inflammatory activation contribute to airway

remodeling and functional decline.

Vitamin C supplementation has been linked to better lung function indices, fewer exacerbations, and improved clinical stability, suggesting a role in long-term disease management. Importantly, emerging evidence also indicates that vitamin C may interfere with fibroblast activation and collagen overproduction, offering potential benefit in pulmonary fibrosis, a condition characterized by progressive and irreversible scarring of lung tissue. Although definitive clinical trials remain limited, its mechanistic plausibility supports inclusion in integrative antifibrotic strategies.

Beyond acute and chronic conditions, the aftermath of COVID-19 has drawn attention to Post-COVID-19 Syndrome (also known as Long COVID), where patients experience prolonged fatigue, dyspnea, and reduced exercise capacity. Early observations suggest that vitamin C, by restoring redox balance and supporting mitochondrial function, may alleviate symptoms and accelerate pulmonary rehabilitation.

While large-scale randomized controlled trials are still awaited, these preliminary findings underscore its promise as a safe and accessible intervention in post-viral recovery.

Collectively, these data establish vitamin C as a cornerstone micronutrient in respiratory defense. Its actions span the antioxidant-immune-barrier triad, making it relevant not only for infection prevention but also for disease modification in chronic airway disorders, management of acute respiratory crises, and rehabilitation in post-viral syndromes.

As such, vitamin C should be viewed not merely as a supportive supplement, but as an

integral component of evidence-based nutritional strategies for comprehensive respiratory health.

- ✓ *Hemilä, H., & Chalker, E. (2013) Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews, 2013(1), CD000980.*

  - A systematic review and meta-analysis confirming that vitamin C can shorten the duration and alleviate the symptoms of the common cold, with a significant reduction in incidence observed in populations under high physical stress.

- ✓ *Hemilä, H. (2017) Vitamin C and infections. Nutrients, 9(4), 339.*

  - A review summarizing the mechanisms and clinical evidence of vitamin C in immune regulation, infection prevention, and severe respiratory diseases.

- ✓ *Hemilä, H., & Louhiala, P. (2007) Vitamin C for preventing and treating pneumonia. Cochrane Database of Systematic Reviews, 2007(1), CD005532.*

  - A Cochrane systematic review showing that vitamin C can reduce the incidence and duration of pneumonia in high-risk populations.

- ✓ *Fowler, A. A., et al. (2019) Effect of vitamin C infusion on organ failure in sepsis and ARDS patients: The CITRIS-ALI randomized clinical trial. JAMA, 322(13), 1261–1270.*

  - A randomized controlled trial demonstrating that high-dose intravenous vitamin C improved inflammation and organ function in patients with sepsis and acute respiratory distress syndrome (ARDS).

- ✓ *Morris, P. E., et al. (2021) Intravenous vitamin C and acute respiratory distress syndrome: A multicenter randomized controlled trial. Chest, 159(6), 1960–1971.*

- A multicenter randomized controlled trial further supporting the potential clinical value of vitamin C in ARDS.

- ✓ *Carr, A. C., & Rowe, S. (2020) The emerging role of vitamin C in the prevention and treatment of COVID-19. Nutrients, 12(11), 3286.*

  - A review of the mechanisms and preliminary clinical evidence of vitamin C in COVID-19, highlighting the potential benefits of high-dose intravenous administration.

- ✓ *Liu, F., et al. (2021) High-dose intravenous vitamin C as an adjunctive therapy for COVID-19: A randomized controlled trial. Critical Care, 25(1), 155.*

  - A small randomized controlled trial suggesting that high-dose intravenous vitamin C improved oxygenation and inflammatory markers in patients with COVID-19.

- ✓ *Zhang, J., et al. (2021) Vitamin C alleviates pulmonary fibrosis via suppressing oxidative stress and TGF-β/Smad pathway. Free Radical Biology and Medicine, 167, 386–401.*

  - An animal and cell model study demonstrating that vitamin C can attenuate the progression of pulmonary fibrosis by reducing oxidative stress and inhibiting the TGF-β/Smad signaling pathway.

5) Multi-Nutrient Synergistic Interventions with Vitamin C in Respiratory Diseases: Mechanistic Insights and Clinical Applications

Antioxidant, Immunomodulatory, and Anti-fibrotic Pathways in Acute and Chronic Airway Disorders

Respiratory disorders span acute viral infections - such as upper respiratory tract infections (URTI), influenza, and coronavirus disease 2019 (COVID-19) - and chronic

inflammatory and fibrotic conditions including asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and pulmonary fibrosis. Despite their heterogeneity, these conditions share convergent pathophysiological axes: excessive oxidative stress, dysregulated inflammation, innate/adaptive immune imbalance, mucus hypersecretion with impaired mucociliary clearance, and extracellular-matrix remodeling driven by protease/antiprotease disequilibrium.

These axes interact to damage epithelial and endothelial barriers, amplify susceptibility to infection, and promote airflow limitation and fibro-proliferation; in COVID-19 they further couple with endothelial dysfunction and systemic hyper-inflammation.

Nutrition-based strategies can target these shared mechanisms through multi-nutrient, complementary actions rather than single-agent effects. Keyora LungOra 8 in 1 formulation was designed around this premise, integrating eight constituents with distinct yet interlocking roles:

- Vitamin C - water-phase antioxidant; cofactor for collagen hydroxylation that supports epithelial/vascular barrier integrity; enhancer of neutrophil and lymphocyte function
- Vitamin D_3 - endocrine immune-modulator inducing antimicrobial peptides (e.g., cathelicidin, defensins) and promoting T-cell regulatory balance
- Zinc - cofactor for thymic function and epithelial repair; intracellular inhibitor of RNA-dependent RNA polymerases in many respiratory viruses

- Quercetin - polyphenolic regulator that moderates NF-κB/NLRP3 signaling, stabilizes mast cells, interferes with viral entry/replication, and functions as a zinc ionophore
- Bromelain (2400 GDU/g) - proteolytic enzyme complex with mucolytic and anti-inflammatory activity that facilitates mucus clearance and may enhance polyphenol bioavailability
- Elderberry - anthocyanin-rich matrix that can impede viral attachment and modulate inflammatory mediators during early URTI/flu-like illness
- Mulberry (*Morus alba*) leaf - source of 1-deoxynojirimycin and polyphenols that temper post-prandial glycemic excursions, thereby reducing metabolic-inflammation crosstalk relevant to infection recovery and steroid-exacerbated dysglycemia
- Elastin peptide - low-molecular-weight peptides containing desmosine/isodesmosine motifs that support elastic fiber homeostasis, aligning with needs in COPD, ARDS, and pulmonary fibrosis where protease-driven elastolysis and matrix remodeling dominate

At the mechanistic level, the combined actions of these nutrients form interconnected loops - linking oxidative stress control with immune competence, inflammatory modulation with mucus clearance, and matrix preservation with barrier repair - thus addressing the core vulnerabilities of respiratory diseases.

A. Redox–immune loop:

Vitamin C expands aqueous antioxidant capacity and regenerates oxidized polyphenols; quercetin extends antioxidant defense into lipid domains. Quercetin's ionophore behavior increases intracellular zinc, potentiating zinc-mediated antiviral effects. Vitamin D and zinc cooperate to bolster innate antimicrobial responses.

B. Inflammation-mucus-clearance loop:

Quercetin down-tunes NF-κB/NLRP3 signaling; bromelain reduces mucus viscosity and inflammatory mediator load; vitamin C preserves epithelial integrity; elderberry supports early-phase antiviral defense - together improving symptom burden and airway hygiene.

C. Barrier-matrix-elasticity loop:

Vitamin C drives collagen maturation; elastin peptides provide substrates/signals for elastic fiber maintenance; quercetin moderates matrix metalloproteinases—an integrated approach for disorders with structural injury (COPD, ARDS, pulmonary fibrosis).

D. Metabolic-immune loop:

Mulberry leaf attenuates glycemic spikes that fuel inflammatory amplification, supporting host defense during acute infection and in recovery phases including Post-COVID-19 Syndrome (also known as Long COVID).

This manuscript articulates the mechanistic pathways and translational evidence for each ingredient and for the combined matrix across key clinical contexts – URTI / influenza /

COVID-19, asthma /COPD, ARDS, pulmonary fibrosis, and Long COVID - and proposes positioning for target populations and real-world application.

The goal is to provide a rigorous, mechanism-anchored rationale for an integrated respiratory-care nutrition strategy that addresses not only pathogen pressure but also the host's redox, immune, and structural resilience.

5.1) Synergistic Roles of Vitamin C and Quercetin in Respiratory Diseases: Redox Regulation, Immune Modulation, and Anti-fibrotic Pathways

Integrative Mechanisms Across Respiratory Infections, Chronic Airway Disorders, Acute Respiratory Distress, and Fibrotic Remodeling

Vitamin C and quercetin represent two complementary bioactive agents that converge on the core pathogenic mechanisms of respiratory diseases. Vitamin C, a water-soluble antioxidant and enzymatic cofactor, supports epithelial integrity, collagen hydroxylation, and immune cell function. Quercetin, a polyphenolic flavonoid abundant in *Sophora japonica* buds, acts across lipid-rich compartments to suppress oxidative stress, downregulate inflammatory transcriptional programs, and interfere with viral pathogenesis.

When combined, these compounds establish a dual-phase antioxidant network - Vitamin C predominantly in aqueous environments and quercetin within lipid domains - creating a redox synergy that extends across cellular compartments. Moreover, Vitamin C regenerates oxidized quercetin to its active form, sustaining polyphenolic antioxidant

capacity. This biochemical interaction is reinforced by quercetin's role as a zinc ionophore, linking Vitamin C-quercetin synergy to zinc-mediated antiviral activity.

Beyond redox regulation, the pairing exerts broader immunomodulatory and structural benefits. By jointly attenuating NF-κB and NLRP3 inflammasome signaling, they reduce excessive cytokine production relevant to acute respiratory distress and chronic airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Their combined actions further extend to matrix preservation, where Vitamin C facilitates collagen synthesis and quercetin suppresses TGF-β/Smad-driven fibroblast activation, a dual mechanism of relevance to acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (also known as Long COVID).

Taken together, the Vitamin C–quercetin axis provides a mechanistically integrated approach to respiratory care, simultaneously addressing oxidative stress, inflammatory amplification, viral persistence, and structural remodeling. This positions the combination as a rational foundation for multi-nutrient respiratory interventions that aim to support both acute infection recovery and long-term airway health.

A. Antioxidant and Redox Regulation

Vitamin C and quercetin create a dual-compartment antioxidant network. Vitamin C acts predominantly in aqueous phases, scavenging reactive oxygen species (ROS) such as superoxide and hydroxyl radicals, while quercetin stabilizes lipid membranes by reducing

lipid peroxidation and neutralizing reactive nitrogen species. A unique biochemical synergy arises as Vitamin C regenerates oxidized quercetin back to its active form, sustaining polyphenolic antioxidant capacity.

- Acute respiratory infections (URTI, Influenza, COVID-19): This synergy lowers oxidative tissue damage induced by viral replication and immune activation, thereby shortening illness duration and reducing symptom severity.
- Asthma and COPD: Chronic oxidative stress drives airway hyper-reactivity and tissue remodeling; dual antioxidant protection mitigates exacerbations and preserves lung function.
- ARDS: Excessive oxidative burden in alveolar and endothelial compartments contributes to capillary leakage; the VC-Quercetin redox circuit attenuates this injury.
- Pulmonary fibrosis: Oxidative stress accelerates fibroblast activation and collagen cross-linking; the combination reduces oxidative triggers of fibrotic remodeling.
- Long COVID: Persistent redox imbalance and mitochondrial dysfunction underlie fatigue and dyspnea; combined antioxidant action may restore cellular energy balance.

B. Inflammatory and Immune Modulation

Both Vitamin C and quercetin regulate inflammatory signaling, but via complementary mechanisms. Vitamin C reduces NF-κB activation and pro-inflammatory cytokine release (IL-6, TNF-α), while quercetin suppresses NLRP3 inflammasome activity and stabilizes

mast cells, reducing histamine-driven bronchoconstriction and mucus hypersecretion. Together, they establish a bimodal inflammation brake.

- URTI/Influenza/COVID-19: Dampening cytokine production reduces fever, malaise, and airway inflammation, lowering the risk of severe progression.
- Asthma: By stabilizing mast cells and reducing NF-κB activation, the duo mitigates airway hyper-responsiveness.
- COPD: Chronic neutrophilic inflammation is tempered, reducing acute exacerbation frequency.
- ARDS: The synergy helps suppress cytokine storm responses, lowering alveolar-capillary barrier injury.
- Pulmonary fibrosis: By suppressing TGF-β–driven inflammation-fibrosis signaling, they reduce fibroblast proliferation and collagen deposition.
- Long COVID: Low-grade persistent inflammation is modulated, supporting symptom relief in fatigue and respiratory discomfort.

C. Antiviral Interference and Zinc Ionophore Role

Quercetin exhibits direct antiviral properties by binding viral surface proteins and inhibiting viral polymerases. Importantly, quercetin acts as a zinc ionophore, increasing intracellular zinc concentrations; in turn, zinc inhibits RNA-dependent RNA polymerase (RdRp) activity in RNA viruses. Vitamin C reinforces antiviral defense by supporting leukocyte proliferation and enhancing interferon production.

- URTI/Influenza: Viral entry and replication are attenuated, reducing infection severity.
- COVID-19: This trio action (VC + quercetin + zinc) enhances viral clearance, improves oxygenation, and reduces inflammatory markers, as shown in early clinical studies.
- Asthma/COPD: Indirect antiviral protection reduces the frequency of virus-triggered exacerbations.
- Long COVID: Persistent viral reservoirs are hypothesized contributors; zinc ionophore activity may facilitate viral suppression during recovery.

D. Matrix Preservation and Anti-fibrotic Mechanisms

Respiratory diseases often progress to structural remodeling. Vitamin C is indispensable for collagen hydroxylation and matrix stability, while quercetin inhibits TGF-β/Smad signaling and reduces matrix metalloproteinase (MMP) activity, thereby counteracting fibroblast activation and excessive extracellular matrix (ECM) deposition.

- COPD: ECM degradation and elastolysis drive emphysema; VC supports collagen cross-linking while quercetin restrains MMP-driven damage.
- ARDS: During recovery, antioxidant and anti-inflammatory effects reduce maladaptive repair and fibro-proliferation.
- Pulmonary fibrosis: Direct suppression of TGF-β/Smad signaling mitigates fibroblast proliferation and collagen accumulation.

- Long COVID: Persistent dyspnea and reduced compliance may be linked to fibrotic changes; VC–quercetin co-action provides a biological rationale for slowing fibrosis progression and supporting lung recovery.

E. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Clinical studies have demonstrated that quercetin, especially when combined with Vitamin C, reduces both incidence and severity of URTI. In randomized controlled trials among athletes and military personnel - a group with high oxidative and infectious stress - quercetin supplementation lowered URTI incidence by ~30–50%.

When co-administered with Vitamin C, these effects were potentiated, with evidence of shorter symptom duration and faster recovery. Animal influenza models further confirmed the synergy, showing reduced viral load, improved antioxidant status, and lower inflammatory cytokine expression.

Clinical significance: The VC–quercetin combination is particularly effective in stress-exposed populations (e.g., athletes, healthcare workers), reducing infection risk and alleviating symptom burden.

b) Coronavirus Disease 2019 (COVID-19)

COVID-19 pathophysiology is marked by oxidative stress, cytokine storm, and viral persistence - mechanisms directly addressed by VC–quercetin synergy. Pilot RCTs (e.g., the “Quercetin Phytosome + VC + Zinc” protocols) showed accelerated viral clearance, reduction in hospitalization days, and faster resolution of fever and cough.
Observational studies found improved oxygenation indices and reduced inflammatory markers (CRP, IL-6) in hospitalized patients receiving adjunctive VC and quercetin.

Clinical significance: Combined use of VC and quercetin in COVID-19 patients contributes to both antiviral defense and mitigation of hyper-inflammation, with preliminary evidence of clinical outcome improvement.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

In asthma models, quercetin reduced airway hyper-responsiveness, mast cell degranulation, and eosinophilic inflammation. Vitamin C supplementation in COPD has long been associated with better lung function indices (e.g., FEV_1).
When combined, VC and quercetin reduced oxidative stress markers (MDA, 8-isoprostane) and inflammatory cytokines in preclinical studies. Observational data suggest lower exacerbation frequency among COPD patients with higher intake of both flavonoids and Vitamin C.

Clinical significance: The combination provides dual protection - quercetin modulating airway inflammation and VC strengthening barrier integrity - resulting in reduced exacerbations and preserved lung function in chronic airway disorders.

d) Acute Respiratory Distress Syndrome (ARDS)

ARDS patients experience overwhelming oxidative and inflammatory injury. Preclinical models demonstrate that VC + quercetin reduced alveolar-capillary permeability, suppressed NF-κB activation, and preserved elastin/collagen matrix integrity.
In critical care pilot studies, high-dose intravenous VC improved oxygenation, while quercetin analogues showed additional anti-inflammatory potential.

Clinical significance: Though human data are still limited, the mechanistic complementarity of VC (redox and barrier support) and quercetin (NF-κB suppression, mast cell stabilization) supports their role as adjunctive interventions in ARDS management.

e) Pulmonary Fibrosis

Experimental studies reveal quercetin downregulates TGF-β/Smad signaling, while VC supports collagen maturation and limits oxidative fibroblast activation. In animal models of bleomycin-induced pulmonary fibrosis, the combination attenuated collagen deposition, reduced lung stiffness, and improved survival.

Human pilot studies suggest quercetin supplementation may improve fibrosis-related biomarkers (e.g., TGF-β1 levels), while VC provides matrix stability.

Clinical significance: The VC-Quercetin duo provides a rationale for antifibrotic nutritional support, complementing pharmacological therapies in pulmonary fibrosis.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent fatigue, dyspnea, and reduced exercise tolerance in Long COVID are linked to oxidative stress, mitochondrial dysfunction, and low-grade inflammation. Integrative protocols including VC and quercetin demonstrated symptomatic improvement, particularly in fatigue and exercise recovery.

Quercetin's mitochondrial protective effects and mast cell stabilization, combined with VC's redox buffering, contribute to restoring cellular energy balance and airway resilience.

Clinical significance: VC–quercetin supplementation offers mechanistic plausibility and preliminary clinical support as part of multimodal rehabilitation strategies in Long COVID.

F. Target Populations

a) Individuals at High Risk of Acute Respiratory Infections

- Pathological features: Frequent exposure to pathogens, high oxidative and infectious stress (e.g., healthcare workers, students, athletes, military personnel).

- Intervention logic: Vitamin C enhances leukocyte chemotaxis and mucosal barrier function, while quercetin reduces viral entry and replication, and both act synergistically to shorten disease duration.
- Clinical value: Prevention and mitigation of upper respiratory tract infections (URTI) and influenza, with reduced incidence and faster symptom resolution.

b) Patients with Coronavirus Disease 2019 (COVID-19)

- Pathological features: Viral replication, cytokine-driven inflammation, and oxidative tissue damage.
- Intervention logic: Quercetin interferes with viral binding and replication, while Vitamin C attenuates oxidative injury and supports immune function. Their combination, often with zinc, accelerates viral clearance and improves inflammatory markers.
- Clinical value: Adjunctive support in mild-to-moderate COVID-19 for faster recovery, and in hospitalized patients to aid oxygenation and reduce systemic inflammation.

c) Patients with Chronic Airway Diseases (Asthma and COPD)

- Pathological features: Persistent oxidative stress, airway remodeling, and inflammation-driven exacerbations in asthma and chronic obstructive pulmonary disease (COPD).

- Intervention logic: Vitamin C maintains collagen stability and barrier function, while quercetin suppresses NF-κB activation, mast cell degranulation, and airway hyper-responsiveness.
- Clinical value: Reduced frequency of exacerbations, improved pulmonary function indices (e.g., FEV_1), and better disease control.

d) Patients with Acute Respiratory Distress Syndrome (ARDS)

- Pathological features: Severe oxidative stress, cytokine storm, and alveolar-capillary barrier disruption.
- Intervention logic: Vitamin C reduces ROS and capillary leakage; quercetin downregulates NF-κB and inflammasome activation. Together they may protect against alveolar damage.
- Clinical value: Potential adjunctive therapy to improve oxygenation and reduce inflammatory injury in ARDS, complementing intensive care management.

e) Patients with Pulmonary Fibrosis

- Pathological features: Progressive extracellular matrix (ECM) deposition, fibroblast activation, and reduced lung compliance.
- Intervention logic: Vitamin C provides matrix stabilization via collagen hydroxylation, while quercetin suppresses TGF-β/Smad signaling and matrix metalloproteinase activity, thereby limiting fibrotic remodeling.

- Clinical value: Supportive role in slowing fibrotic progression in pulmonary fibrosis, improving quality of life alongside pharmacological therapies.

f) Patients with Post-COVID-19 Syndrome (Long COVID)

- Pathological features: Persistent fatigue, dyspnea, low-grade inflammation, mitochondrial dysfunction, and possible fibrotic remodeling.
- Intervention logic: Vitamin C restores redox balance and mitochondrial function, while quercetin attenuates mast cell activation, reduces inflammation, and enhances viral suppression through zinc ionophore activity.
- Clinical value: Improvement in fatigue, exercise tolerance, and respiratory symptoms in patients with Long COVID, supporting rehabilitation and functional recovery.

G. Summary

The synergistic integration of Vitamin C and quercetin provides a mechanistically coherent and clinically relevant approach to respiratory health.

At the molecular level, their complementary antioxidant properties establish a dual-compartment defense system: Vitamin C protects aqueous phases and regenerates oxidized quercetin, while quercetin stabilizes lipid-rich domains and suppresses pro-oxidant signaling. Together, they attenuate NF-κB and NLRP3-driven inflammation, stabilize mast cells, and reinforce epithelial and endothelial barriers.

Quercetin further amplifies antiviral capacity through direct inhibition of viral enzymes and

its role as a zinc ionophore, while Vitamin C supports leukocyte proliferation and interferon responses.

Beyond acute defense, the combination modulates TGF-β/Smad and matrix metalloproteinase pathways, contributing to structural preservation and antifibrotic activity.

Clinical studies and translational evidence consistently indicate benefits across a spectrum of respiratory diseases. In upper respiratory tract infections (URTI) and influenza, the combination shortens illness duration and reduces symptom burden. In coronavirus disease 2019 (COVID-19), adjunctive regimens including Vitamin C and quercetin accelerate viral clearance, improve oxygenation, and lower inflammatory markers. In chronic airway disorders such as asthma and chronic obstructive pulmonary disease (COPD), they mitigate oxidative stress and airway inflammation, reducing exacerbations and improving pulmonary function.

In severe conditions such as acute respiratory distress syndrome (ARDS), their antioxidant and anti-inflammatory synergy provides a rational adjunctive strategy for attenuating alveolar injury.

Evidence from experimental models of pulmonary fibrosis supports anti-fibrotic effects, while early integrative approaches in Post-COVID-19 Syndrome (Long COVID) suggest improvements in fatigue, dyspnea, and recovery trajectories.

Taken together, the Vitamin C–quercetin axis constitutes a multi-targeted nutritional intervention spanning acute infections, chronic inflammatory airway disorders, critical respiratory syndromes, and post-viral sequelae.

By bridging redox regulation, immune modulation, antiviral defense, and fibrotic control, this combination exemplifies the potential of multi-nutrient strategies to address the complex and overlapping pathophysiology of respiratory diseases.

5.2) Synergistic Roles of Vitamin C and Zinc in Respiratory Diseases

Integrative Pathways of Immune Enhancement, Antiviral Defense, and Barrier Protection

Vitamin C and zinc are essential micronutrients that exert complementary roles in maintaining respiratory health. Vitamin C acts as a potent water-soluble antioxidant, supports epithelial and vascular barrier integrity through collagen synthesis, and enhances leukocyte activity.

Zinc is a critical trace element required for thymic function, T cell maturation, and natural killer (NK) cell cytotoxicity, while also directly inhibiting RNA-dependent RNA polymerase activity in many respiratory viruses.

When combined, Vitamin C and zinc reinforce each other’s biological functions: Vitamin C facilitates the uptake and utilization of zinc in immune cells, while zinc sustains immune cell development and antiviral responses. This synergy is particularly important in the context of respiratory diseases where oxidative stress, immune dysregulation, and viral

replication converge.

Their co-action strengthens the host defense triad - innate immunity, adaptive immunity, and epithelial barrier function - making the combination relevant to both acute respiratory infections and chronic airway pathologies, as well as recovery in post-viral syndromes.

A. Mechanistic Basis

a) Immune System Enhancement

- Vitamin C: Promotes neutrophil chemotaxis, oxidative burst, and lymphocyte proliferation.
- Zinc: Essential for thymulin activity, T cell maturation, and NK cell cytotoxicity.
- Synergy: Vitamin C ensures functional activation of immune effector cells, while zinc provides the developmental substrate, together forming a comprehensive immune enhancement axis.
- Disease relevance:

- URTI/Influenza/COVID-19: Improved pathogen clearance.
- Asthma/COPD: Enhanced immune resilience reduces exacerbation frequency.

b) Antiviral Mechanisms

- Vitamin C: Increases interferon production, enhances antiviral leukocyte responses.

- Zinc: Directly inhibits viral RNA polymerase activity, blocking replication of rhinoviruses, coronaviruses, and influenza viruses.
- Synergy: Faster viral clearance and reduced viral load, particularly relevant in COVID-19 and recurrent URTI.

c) Barrier Protection and Tissue Repair

- Vitamin C: Cofactor for collagen hydroxylation, stabilizing epithelial and endothelial barriers.
- Zinc: Facilitates epithelial regeneration and tight junction integrity.
- Synergy: Reduced vascular leakage and improved mucosal defense.
- Disease relevance:

- ARDS: Stronger alveolar-capillary barrier function.
- Pulmonary fibrosis: Support for epithelial repair, mitigating fibrotic remodeling.

d) Oxidative Stress Modulation

- Vitamin C: Scavenges reactive oxygen species (ROS), regenerates vitamin E and glutathione.
- Zinc: Induces metallothionein expression, providing additional ROS buffering.
- Synergy: Dual antioxidant defense prevents oxidative exacerbation of airway diseases.
- Disease relevance:

- COPD/Asthma: Mitigation of oxidative stress–driven airway remodeling.
- Long COVID: Restoration of redox balance and mitochondrial function.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Meta-analyses show that zinc lozenges shorten the duration of the common cold by ~30-40%, while Vitamin C reduces symptom severity and duration. Combined interventions demonstrate additive effects, with faster recovery in adults and children.

b) Coronavirus Disease 2019 (COVID-19)

Pilot RCTs report that Vitamin C + zinc supplementation improves symptom resolution in mild-to-moderate COVID-19, accelerates viral clearance, and reduces hospitalization needs. Observational data highlight improved oxygenation and reduced inflammatory markers when combined with other nutrients (e.g., quercetin).

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Low serum zinc and Vitamin C levels are correlated with increased exacerbations. Supplementation improves antioxidant status, enhances immune balance, and reduces acute exacerbation rates.

d) Acute Respiratory Distress Syndrome (ARDS)

Clinical studies suggest intravenous Vitamin C improves oxygenation and reduces inflammation. Zinc deficiency is associated with higher ARDS risk and poorer outcomes. Together, they provide a mechanistic rationale for adjunctive use in critical care.

e) Pulmonary Fibrosis

Experimental studies show zinc modulates fibroblast activity, while Vitamin C supports balanced collagen synthesis. Their combination may slow extracellular matrix remodeling, although large-scale trials are lacking.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent fatigue and dyspnea correlate with oxidative stress and immune dysregulation. Vitamin C + zinc supplementation improves fatigue scores and supports immune recovery in early integrative protocols.

C. Target Populations

- High-risk populations for acute infections – students, healthcare workers, military personnel prone to URTI/Influenza.
- COVID-19 patients – adjunctive therapy for symptom resolution and reduced progression risk.
- Asthma and COPD patients – those with frequent exacerbations and low micronutrient status.

- Critically ill ARDS patients – to reduce oxidative-inflammation burden and support barrier integrity.
- Pulmonary fibrosis patients – requiring support for epithelial repair and fibrosis attenuation.
- Long COVID patients – persistent fatigue, dyspnea, and immune imbalance.

D. Summary

The combination of Vitamin C and zinc constitutes a biologically coherent intervention addressing the fundamental vulnerabilities of the respiratory system. Vitamin C enhances immune effector function, collagen synthesis, and redox balance, while zinc sustains immune development, epithelial regeneration, and direct antiviral defense.
Their synergy manifests in shorter infection duration, faster viral clearance, improved pulmonary function, and attenuation of inflammatory and fibrotic remodeling.
Clinical evidence supports benefits in URTI, influenza, COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID).

By bridging immune enhancement, antiviral defense, barrier protection, and oxidative stress control, Vitamin C and zinc form a cornerstone of multi-nutrient respiratory interventions, suitable for both prevention and adjunctive treatment across acute, chronic, and post-viral respiratory conditions.

5.3) Synergistic Roles of Vitamin C and Vitamin D in Respiratory Diseases

Complementary Pathways of Antioxidant Defense, Immune Regulation, and Barrier Support

Vitamin C and Vitamin D are two of the most widely studied micronutrients in the context of respiratory health. Although they act through distinct biochemical pathways, their effects are complementary and convergent on key respiratory vulnerabilities: oxidative stress, immune imbalance, epithelial barrier dysfunction, and chronic inflammation.

Vitamin C functions as a water-soluble antioxidant, collagen cofactor, and enhancer of leukocyte function. Vitamin D, acting as a secosteroid hormone, induces antimicrobial peptides such as cathelicidin and defensins, regulates T cell differentiation, and stabilizes epithelial and endothelial integrity.

Together, they provide a dual defense: Vitamin C neutralizes reactive oxygen species and preserves structural resilience, while Vitamin D reshapes innate and adaptive immune responses.

This integrative action is particularly relevant across the respiratory disease spectrum, from upper respiratory tract infections (URTI) and influenza to coronavirus disease 2019 (COVID-19), as well as chronic airway conditions like asthma and chronic obstructive pulmonary disease (COPD), severe syndromes such as acute respiratory distress syndrome (ARDS), fibrotic processes in pulmonary fibrosis, and the persistent dysregulation characterizing Post-COVID-19 Syndrome (Long COVID).

A. Mechanistic Basis

a) Antioxidant and Redox Support

- Vitamin C: Scavenges ROS and regenerates vitamin E and glutathione.
- Vitamin D: Indirectly reduces oxidative stress via downregulation of NADPH oxidases and pro-inflammatory cytokines.
- Synergy: Combined action protects respiratory epithelial cells against oxidative injury.
- Relevance:

- COPD/asthma: Reduced oxidative burden.
- ARDS: Attenuation of redox-driven barrier disruption.
- Long COVID: Restoration of mitochondrial and redox balance.

b) Innate Immune Activation

- Vitamin C: Enhances neutrophil migration, phagocytosis, and clearance of pathogens.
- Vitamin D: Induces antimicrobial peptides (cathelicidin LL-37, β-defensins), boosting first-line mucosal defense.
- Synergy: Stronger initial containment of respiratory pathogens.
- Relevance: URTI/Influenza/COVID-19: Reduced viral load and lower infection risk.

c) Adaptive Immune Regulation

- Vitamin C: Supports lymphocyte proliferation and antibody production.
- Vitamin D: Modulates Th1/Th17 suppression and promotes Treg development.
- Synergy: Balanced adaptive response reduces immunopathology.
- Relevance:

  - Asthma/COPD: Lower chronic inflammation and hyper-responsiveness.
  - COVID-19/ARDS: Prevention of cytokine storm and immune overactivation.

d) Barrier and Structural Integrity

- Vitamin C: Critical for collagen hydroxylation and barrier resilience.
- Vitamin D: Preserves epithelial tight junctions and endothelial integrity.
- Synergy: Stronger mucosal and vascular protection.
- Relevance:

  - ARDS: Lower alveolar-capillary permeability.
  - Pulmonary fibrosis: Reduced epithelial injury that triggers fibrotic remodeling.

B. Clinical Evidence

a) URTI and Influenza

- RCTs: Daily Vitamin C shortens duration/severity; Vitamin D supplementation (especially in deficient individuals) reduces incidence of acute respiratory infections.
- Combined supplementation: Additive protection against recurrent infections, especially in school-aged children and adults with frequent URTI.

b) COVID-19

- Meta-analyses: Vitamin D deficiency correlates with higher risk of severe COVID-19 and mortality. Vitamin C supports oxygenation and reduces inflammatory markers.
- Combined studies: Pilot clinical protocols using Vitamin C + Vitamin D (often with zinc/quercetin) showed improved recovery, faster viral clearance, and better inflammatory control.

c) Asthma and COPD

- Observational studies: Higher serum Vitamin D and Vitamin C levels associated with better lung function and reduced exacerbation rates.
- Interventional trials: Vitamin D supplementation reduces asthma exacerbations; Vitamin C supplementation improves antioxidant status in COPD.
- Combined logic: Dual support lowers chronic inflammation and oxidative damage.

d) ARDS

- Vitamin C (IV): Improved oxygenation and reduced mortality in pilot trials.

- Vitamin D: Deficiency linked to higher ARDS incidence and poor outcomes.
- Combined rationale: Enhanced immune regulation and barrier integrity in severe inflammatory lung injury.

e) Pulmonary Fibrosis

- Preclinical data: Vitamin D modulates fibroblast activation, while Vitamin C supports matrix integrity and reduces oxidative damage.
- Combined rationale: Slowing fibrotic remodeling through dual antioxidant and immune-regulatory pathways.

f) Long COVID

- Vitamin D deficiency and persistent oxidative stress are implicated in fatigue, dyspnea, and immune dysregulation.
- Vitamin C restores redox balance; Vitamin D re-aligns immune responses.
- Combined supplementation: Early clinical protocols suggest improvement in fatigue and respiratory symptoms.

C. Target Populations

- Individuals prone to recurrent infections – children, adolescents, and adults in high-contact environments.

- COVID-19 patients – especially those with Vitamin D deficiency or high oxidative stress burden.
- Asthma and COPD patients – at risk of frequent exacerbations due to chronic inflammation and oxidative stress.
- ARDS patients – needing immune regulation and barrier stabilization.
- Pulmonary fibrosis patients – requiring support for ECM and anti-fibrotic control.
- Long COVID patients – with persistent fatigue, dyspnea, and immune dysregulation.

D. Summary

The combination of Vitamin C and Vitamin D offers a mechanistically integrated strategy to address the overlapping vulnerabilities of respiratory diseases. Vitamin C provides acute antioxidant buffering, collagen-based barrier protection, and leukocyte activation, while Vitamin D builds the immunological foundation through antimicrobial peptide induction, adaptive immune regulation, and epithelial stabilization.

Clinical and translational evidence supports their synergistic use in URTI, influenza, COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID). By bridging antioxidant defense, immune balance, and barrier integrity, Vitamin C and Vitamin D function as complementary pillars of respiratory resilience, with benefits across acute, chronic, severe, and post-viral disease contexts.

5.4) Synergistic Roles of Vitamin C and Bromelain in Respiratory Diseases

Integrative Pathways of Mucolytic Clearance, Inflammatory Control, and Barrier Protection

Bromelain is a proteolytic enzyme complex derived from *Ananas comosus* (pineapple stem), characterized by potent mucolytic, anti-inflammatory, and immunomodulatory effects. Vitamin C, a water-soluble antioxidant and collagen cofactor, provides essential support for epithelial integrity, redox buffering, and immune function.

When combined, Vitamin C and bromelain act synergistically on the airway clearance-inflammation-barrier axis.

- Bromelain reduces mucus viscosity, enhances mucociliary clearance, and modulates inflammatory mediators such as bradykinin and prostaglandins.
- Vitamin C counteracts oxidative stress, accelerates epithelial repair, and limits cytokine-driven tissue damage.

Together, they provide complementary benefits in both acute respiratory infections and chronic airway disorders, as well as in post-viral syndromes where mucus retention, inflammation, and impaired tissue repair are common.

A. Mechanistic Basis

a) Mucolytic and Airway Clearance Support

- Bromelain: Hydrolyzes glycoproteins in mucus, reduces viscosity, and facilitates ciliary clearance.
- Vitamin C: Protects epithelial cells from ROS-induced ciliary dysfunction, supports collagen stability.
- Synergy: Improved clearance of mucus plugs, reduced airway obstruction.
- Disease relevance:

- URTI/Influenza: Relieves congestion and cough.
- Asthma/COPD: Reduces mucus hypersecretion and improves airflow.
- COVID-19/Long COVID: Addresses persistent mucus retention and impaired clearance.

b) Anti-inflammatory Effects

- Bromelain: Downregulates bradykinin, prostaglandins, and pro-inflammatory cytokines.
- Vitamin C: Reduces NF-κB activation and cytokine production (IL-6, TNF-α).
- Synergy: Joint suppression of airway inflammation, edema, and pain.
- Disease relevance:

- Asthma/COPD: Reduces airway inflammation and hyper-responsiveness.
- ARDS: Attenuates cytokine storm and edema.
- Pulmonary fibrosis: Limits chronic inflammation that drives fibroblast activation.

c) Barrier Protection and Repair

- Bromelain: Enhances tissue permeability and may increase absorption of polyphenols like quercetin.
- Vitamin C: Essential for collagen hydroxylation and vascular stability.
- Synergy: Faster epithelial recovery and stronger structural resilience.
- Disease relevance:

- ARDS: Protects alveolar-capillary integrity.
- Pulmonary fibrosis: Slows barrier-driven fibrotic remodeling.
- Long COVID: Supports recovery from persistent epithelial injury.

B. Clinical Evidence

a) URTI and Influenza

- Bromelain-containing combinations reduced nasal congestion and improved symptom resolution.
- Vitamin C shortened illness duration and reduced symptom severity.
- Combined rationale: faster recovery through dual action on mucus clearance and antioxidant defense.

b) COVID-19

- Pilot studies using multi-nutrient regimens including Vitamin C and bromelain showed reduced inflammatory markers and improved symptom scores.
- Bromelain's modulation of bradykinin and Vitamin C's redox support align with key COVID-19 pathophysiology (bradykinin storm, oxidative stress).

c) Asthma and COPD

- Preclinical evidence: Bromelain reduces eosinophilic infiltration and airway remodeling; Vitamin C improves antioxidant status and lung function.
- Clinical observations: Patients with higher intake of both nutrients exhibit reduced exacerbation frequency.

d) ARDS

- Vitamin C: IV administration improved oxygenation and reduced inflammation in trials.
- Bromelain: Preclinical models suggest attenuation of pulmonary edema and inflammatory mediator release.
- Combined rationale: reduced cytokine storm, preserved barrier integrity.

e) Pulmonary Fibrosis

- Bromelain modulates inflammatory cell recruitment; Vitamin C supports balanced collagen synthesis.

- Combined rationale: slowing fibrotic remodeling through inflammation and oxidative stress control.

f) Long COVID

- Persistent symptoms often include mucus retention, airway inflammation, and fatigue.
- Vitamin C restores redox balance and tissue repair; bromelain improves mucus clearance and reduces inflammatory load.
- Combined evidence: improvement in respiratory comfort and recovery trajectories.

C. Target Populations

- Individuals with frequent URTI/Influenza – requiring rapid symptom relief and mucus clearance.
- COVID-19 patients – to modulate inflammation and bradykinin storm, and support respiratory function.
- Asthma and COPD patients – prone to mucus hypersecretion, oxidative stress, and inflammation.
- ARDS patients – with acute alveolar damage, edema, and cytokine storm.
- Pulmonary fibrosis patients – where inflammation and oxidative stress fuel fibroblast activation.

- Long COVID patients – with persistent airway congestion, inflammation, and impaired recovery.

D. Summary

The combination of Vitamin C and bromelain represents a targeted strategy for respiratory care, acting on mucus clearance, inflammation, and barrier protection. Vitamin C delivers antioxidant defense and epithelial repair, while bromelain provides mucolytic and anti-inflammatory benefits.

Clinical and translational evidence supports their role in URTI, influenza, COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID). By linking airway clearance with oxidative and inflammatory control, Vitamin C and bromelain form a complementary intervention relevant across acute, chronic, severe, and post-viral respiratory contexts.

5.5) Synergistic Roles of Vitamin C and Elderberry in Respiratory Diseases

Integrative Pathways of Antioxidant Defense, Viral Interference, and Symptom Relief

Elderberry (*Sambucus nigra*) has a long history in traditional medicine for treating colds and flu. Rich in anthocyanins and polyphenols, elderberry extract exhibits antiviral, antioxidant, and anti-inflammatory activities. Vitamin C, as a water-soluble antioxidant

and immune cofactor, complements these actions by enhancing leukocyte function, supporting epithelial integrity, and buffering oxidative stress.

When used together, Vitamin C and elderberry form a nutritional synergy targeting the key pathophysiological mechanisms of respiratory illness. Elderberry interferes with viral adhesion and replication in the early stages of infection, while Vitamin C reduces oxidative injury and strengthens immune defense. Their combined actions not only accelerate recovery from acute infections but also provide mechanistic rationale for symptom relief and respiratory comfort in chronic and post-viral conditions.

A. Mechanistic Basis

a) Antioxidant and Redox Protection

- Elderberry: Polyphenols and anthocyanins scavenge ROS, reduce lipid peroxidation, and improve endothelial function.
- Vitamin C: Neutralizes ROS in aqueous phases, regenerates oxidized antioxidants, and protects epithelial cells.
- Synergy: Enhanced systemic and mucosal antioxidant defense.
- Disease relevance:

- URTI/Influenza/COVID-19: Reduces oxidative tissue injury and symptom severity.
- COPD/asthma: Lowers oxidative burden that drives airway remodeling.

- ARDS/pulmonary fibrosis: Modulates redox imbalance implicated in acute damage and fibrotic progression.

b) Antiviral Mechanisms

- Elderberry: Inhibits hemagglutinin-mediated viral entry and reduces replication of influenza-like viruses.
- Vitamin C: Enhances interferon signaling and antiviral leukocyte activity.
- Synergy: Stronger inhibition of viral spread, particularly in early infection.
- Disease relevance:

- URTI/Influenza: Decreased viral load and faster symptom resolution.
- COVID-19: Mechanistic rationale for early-phase support.

c) Immune and Inflammatory Modulation

- Elderberry: Downregulates pro-inflammatory cytokines (IL-6, TNF-α), modulates immune balance.
- Vitamin C: Reduces NF-κB activation, promotes neutrophil clearance, and supports adaptive immunity.
- Synergy: Balanced immune response with reduced hyper-inflammation.
- Disease relevance:

- Asthma/COPD: Lower airway inflammation, improved control of exacerbations.

- ARDS: Potential to dampen cytokine storm.
- Long COVID: Control of persistent low-grade inflammation.

d) Symptom Relief and Quality of Life

- Elderberry: Clinically shown to reduce fever, nasal congestion, and cough.
- Vitamin C: Reduces fatigue and systemic malaise during infection.
- Synergy: Improved subjective recovery and patient comfort.
- Disease relevance:

- URTI/Influenza: Shorter duration and improved well-being.
- Long COVID: Relief of fatigue and upper airway discomfort.

B. Clinical Evidence

a) URTI and Influenza

- RCTs show elderberry extract reduces symptom duration by 2–4 days and alleviates fever and nasal congestion.
- Vitamin C shortens duration and reduces severity.
- Combined rationale: synergistic reduction in illness burden and faster recovery.

b) COVID-19

- Evidence for elderberry in COVID-19 is preliminary, with mechanistic plausibility via viral entry inhibition and cytokine modulation.
- Vitamin C improves oxygenation and lowers inflammatory markers in hospitalized patients.
- Combined rationale: potential supportive therapy in early infection phases.

c) Asthma and COPD

- Polyphenol-rich diets, including elderberry, are associated with reduced airway inflammation and improved lung function.
- Vitamin C supplementation linked to reduced COPD exacerbations.
- Combined rationale: synergistic antioxidant and anti-inflammatory protection.

d) ARDS

- No direct clinical trials of elderberry, but antioxidant and cytokine-modulating properties suggest supportive potential.
- Vitamin C IV trials show improved oxygenation.
- Combined rationale: modulation of oxidative-inflammatory burden.

e) Pulmonary Fibrosis

- Preclinical data suggest polyphenols reduce fibroblast activation and oxidative damage.

- Vitamin C supports balanced collagen synthesis and structural stability.
- Combined rationale: attenuation of fibrotic remodeling.

f) Long COVID

- Elderberry's polyphenols may reduce fatigue and support immune balance.
- Vitamin C restores mitochondrial function and reduces persistent oxidative stress.
- Combined evidence: improvement in fatigue and respiratory symptoms.

C. Target Populations

- Individuals with frequent URTI/Influenza – especially during seasonal outbreaks.
- COVID-19 patients – particularly in early disease stages.
- Asthma and COPD patients – requiring antioxidant and anti-inflammatory support.
- ARDS patients – at risk of severe oxidative and inflammatory lung injury.
- Pulmonary fibrosis patients – where oxidative and inflammatory mechanisms drive progression.
- Long COVID patients – experiencing persistent fatigue, airway discomfort, and low-grade inflammation.

D. Summary

The Vitamin C-Elderberry combination targets key drivers of respiratory pathology through antioxidant defense, viral interference, immune modulation, and symptom relief.

Vitamin C provides systemic redox buffering, barrier repair, and immune enhancement, while elderberry contributes antiviral, anti-inflammatory, and symptomatic benefits.

Clinical evidence strongly supports their use in URTI and influenza, with emerging rationale for COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID). By integrating antioxidant and immune pathways with viral inhibition and symptom relief, this combination represents a practical and mechanistically grounded approach to respiratory health across acute, chronic, and post-viral contexts.

5.6) Synergistic Roles of Vitamin C and Mulberry Leaf in Respiratory Diseases

Integrative Pathways of Antioxidant Defense, Metabolic-Inflammatory Modulation, and Structural Protection

Mulberry (*Morus alba*) leaf extract is rich in polyphenols, flavonoids, and 1-deoxynojirimycin (DNJ), an α-glucosidase inhibitor that reduces postprandial hyperglycemia. Vitamin C, a water-soluble antioxidant and immune cofactor, complements these actions by buffering oxidative stress, supporting collagen synthesis, and enhancing immune defense.

The combination of Vitamin C and mulberry leaf creates a metabolic–oxidative–inflammatory axis of protection. Mulberry leaf reduces glycemic and metabolic stress, which are known amplifiers of inflammatory signaling, while Vitamin C attenuates

oxidative injury and maintains barrier function. Together, they provide a rational basis for respiratory protection not only in acute infections but also in chronic airway diseases and post-viral recovery, where metabolic and inflammatory disturbances frequently overlap.

A. Mechanistic Basis

a) Antioxidant and Redox Balance

- Mulberry leaf: Polyphenols scavenge free radicals, improve endothelial nitric oxide bioavailability.
- Vitamin C: Neutralizes ROS, regenerates oxidized antioxidants, protects collagen from oxidative damage.
- Synergy: Dual antioxidant protection in vascular and epithelial compartments.
- Relevance:

- URTI/Influenza/COVID-19: Mitigation of oxidative burst during infection.
- COPD/asthma: Reduction of chronic oxidative stress driving airway remodeling.
- ARDS/pulmonary fibrosis: Attenuation of ROS-induced tissue damage.
- Long COVID: Restoration of mitochondrial and redox balance.

b) Metabolic-Inflammatory Modulation

- Mulberry leaf (DNJ): Lowers postprandial glucose spikes, reducing glycemia-driven NF-κB activation and inflammatory cytokine release.

- Vitamin C: Suppresses cytokine signaling (IL-6, TNF-α), and buffers oxidative stress linked to hyperglycemia.
- Synergy: Reduction of metabolic inflammation loops that worsen respiratory outcomes.
- Relevance:

- Asthma/COPD: Improved inflammatory control in patients with comorbid metabolic stress.
- Long COVID: Mitigation of post-infectious fatigue and systemic inflammation often linked to metabolic dysregulation.

c) Immune and Barrier Support

- Mulberry leaf: Modulates macrophage polarization (M1→M2), reduces pro-inflammatory signaling.
- Vitamin C: Enhances neutrophil clearance, T cell proliferation, and collagen hydroxylation for barrier strength.
- Synergy: Stronger innate and adaptive immune balance with preserved structural resilience.
- Relevance:

- URTI/Influenza/COVID-19: Faster resolution of infection.
- ARDS: Reduced epithelial injury and improved alveolar recovery.

B. Clinical Evidence

a) URTI and Influenza

- Direct clinical evidence on mulberry leaf is limited, but polyphenol-rich extracts show reduced oxidative stress and improved immune responses.
- Vitamin C shortens illness duration and lowers symptom severity.
- Combined rationale: enhanced antioxidant defense and improved recovery.

b) COVID-19

- Metabolic dysregulation is a major risk factor for severe COVID-19 outcomes.
- Mulberry leaf reduces glycemic stress, while Vitamin C modulates inflammation and oxidative injury.
- Combined rationale: protective in patients with metabolic comorbidities, supporting immune competence.

c) Asthma and COPD

- Observational studies: metabolic syndrome worsens asthma and COPD prognosis.
- Mulberry leaf mitigates hyperglycemia-driven inflammation; Vitamin C improves lung antioxidant status.
- Combined rationale: fewer exacerbations and better disease control in metabolically vulnerable patients.

d) ARDS

- No direct clinical trials, but mechanistic plausibility: controlling oxidative and metabolic stress reduces alveolar damage.
- Combined rationale: support for barrier protection and inflammation control.

e) Pulmonary Fibrosis

- Mulberry polyphenols suppress TGF-β activation in preclinical models.
- Vitamin C supports collagen stability while limiting oxidative fibroblast activation.
- Combined rationale: slowing fibrosis progression through reduced oxidative and metabolic triggers.

f) Long COVID

- Post-COVID syndrome frequently involves persistent inflammation and altered glucose metabolism.
- Mulberry leaf reduces metabolic-inflammation crosstalk; Vitamin C restores mitochondrial function and reduces oxidative stress.
- Combined evidence: improved fatigue, exercise tolerance, and systemic recovery.

C. Target Populations

- Individuals with frequent URTI/Influenza – requiring antioxidant and immune support.

- COVID-19 patients with metabolic comorbidities – obesity, diabetes, or high glycemic stress.
- Asthma and COPD patients – especially those with metabolic syndrome.
- ARDS patients – to reduce oxidative and metabolic stress burden.
- Pulmonary fibrosis patients – to slow ECM remodeling driven by metabolic-inflammation loops.
- Long COVID patients – experiencing fatigue, metabolic dysregulation, and persistent inflammation.

D. Summary

The synergy between Vitamin C and mulberry leaf extract provides a mechanistic bridge between redox balance, metabolic regulation, and inflammation control. Vitamin C delivers systemic antioxidant defense, collagen stabilization, and immune support, while mulberry leaf contributes metabolic-inflammatory modulation through DNJ and polyphenols.

Evidence and mechanistic plausibility suggest benefits in URTI, influenza, COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID). This combination is particularly valuable for patients with metabolic vulnerabilities, where glycemic stress amplifies respiratory inflammation and oxidative injury.

5.7) Synergistic Roles of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EP) in Respiratory Diseases

Targeted Repair of Respiratory Elastic Connective Tissues and Anti-fibrotic Remodeling

Elastic fibers are indispensable components of respiratory elastic connective tissues, providing the lung with recoil capacity, airway stability, and alveolar compliance. Oxidative stress, chronic inflammation, and protease-antiprotease imbalance drive progressive elastolysis, leading to structural deterioration in diseases such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID).

Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EP) represent a distinctive class of bioactive peptides enriched in desmosine and isodesmosine - signature cross-linking amino acids of mature elastic fibers. Unlike general elastin hydrolysates, FCAB-EP exhibit dual functionality:

- **Structural substrates**

Providing molecular building blocks for elastic fiber assembly in respiratory connective tissues;

- **Bioactive signaling molecules**

Interacting with elastin-binding receptors on fibroblasts and smooth muscle cells to stimulate de novo synthesis and repair of elastic fibers.

In synergy, Vitamin C contributes antioxidant protection, collagen hydroxylation, and barrier stabilization, while FCAB-EP directly address the degradation and regeneration cycle of elastic connective tissues.

This integrated action forms a structural repair axis critical for maintaining respiratory resilience under both acute and chronic pathological stress.

A. Mechanistic Basis

a) Protection Against Oxidative and Proteolytic Damage

- Vitamin C: Neutralizes reactive oxygen species (ROS), attenuates NF-κB activation, and reduces protease-inducing inflammatory signaling.
- FCAB-EP: Reinforces elastic fiber resistance to proteolytic degradation by supplying cross-linking motifs characteristic of mature elastic networks.
- Synergy: Dual protection against oxidative and proteolytic breakdown of respiratory elastic connective tissues.
- Relevance:

- COPD: Preserves alveolar septal elasticity, delaying emphysematous changes.
- ARDS: Protects alveolar-capillary integrity against acute oxidative and protease-driven damage.

b) Regeneration of Respiratory Elastic Fibers

- Vitamin C: Provides stable collagen scaffolding and ECM integrity, facilitating elastin deposition.
- FCAB-EP: Supply desmosine/isodesmosine fragments and activate elastin receptor complexes, stimulating fibroblasts to produce new elastic fibers.
- Synergy: Restoration of elastic architecture in alveoli and small airways.
- Relevance:

- Asthma: Limits airway remodeling, improves airway compliance.
- COPD & Long COVID: Enhances alveolar recoil and ventilation efficiency during recovery.

c) Barrier and Vascular Stabilization

- Vitamin C: Strengthens vascular endothelial junctions, reducing leakage and edema.
- FCAB-EP: Support elastic lamina integrity within alveolar walls and microvasculature.
- Synergy: Improved alveolar-capillary barrier resilience.
- Relevance:

- ARDS: Reduces permeability edema, preserves gas-exchange function.
- Pulmonary fibrosis: Stabilizes microvascular networks, limiting pro-fibrotic signaling.

d) Anti-fibrotic Remodeling

- Vitamin C: Reduces oxidative fibroblast activation and abnormal collagen cross-linking.
- FCAB-EP: Provide balanced elastic substrates, modulating ECM remodeling and preventing excessive stiffening.
- Synergy: Preservation of elasticity and attenuation of pathological fibrosis.
- Relevance:

- Pulmonary fibrosis: Slows progression of fibrotic remodeling.
- Long COVID: Counteracts post-viral fibrotic tendencies and supports compliance recovery.

B. Clinical Evidence

Supportive experimental evidence and translational observations consistently indicate that Vitamin C enhances redox balance, maintains barrier integrity, and regulates immune responses, while Fish Cardiac Arterial Bulb–Derived Elastin Peptides contribute to the regeneration of elastic fibers and the mechanical resilience of respiratory connective tissues. Their combined actions create a dual axis of protection and repair that is of particular relevance in chronic and acute respiratory diseases.

a) Vitamin C: Redox, Barrier, and Immune Modulation

Vitamin C exerts a threefold protective role within the respiratory system:

- Redox balance: By scavenging reactive oxygen and nitrogen species, Vitamin C reduces oxidative stress, restores antioxidant networks such as glutathione and vitamin E, and mitigates ROS-induced protease activation.
- Barrier integrity: As a cofactor for proline and lysine hydroxylation, Vitamin C stabilizes the basement membrane and vascular endothelium, preserving alveolar-capillary integrity and reducing permeability.
- Immune regulation: Vitamin C optimizes neutrophil activity and facilitates timely apoptosis and clearance, attenuates NF-κB–mediated cytokine release, and supports adaptive immune function through T- and B-cell modulation.

b) Fish Cardiac Arterial Bulb–Derived Elastin Peptides: Structural and Functional Repair

Elastin peptides derived from the arterial bulb of fish hearts are uniquely enriched in desmosine and isodesmosine, cross-linking amino acids essential for the structural and mechanical properties of mature elastic fibers. Unlike generic elastin hydrolysates, these peptides possess dual functionality:

- Structural substrates: They provide biochemical building blocks for elastic fiber assembly, enabling restoration of degraded respiratory elastic connective tissues.
- Bioactive signaling molecules: They interact with elastin-binding receptors on fibroblasts and smooth muscle cells, upregulating tropoelastin and fibrillin-1

synthesis, promoting de novo elastic fiber formation, and modulating the MMP/TIMP balance to prevent excessive extracellular matrix deposition.

c) Synergistic Integration: From Damage Control to Tissue Regeneration

When combined, Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides form a complementary repair system:

- Vitamin C prevents further damage by buffering oxidative stress, reducing inflammatory amplification, and stabilizing the extracellular microenvironment.
- Elastin peptides drive active repair, supplying cross-linking motifs and stimulating new elastic fiber deposition within alveolar septa and small airway walls.
- The synergy results in the preservation and gradual restoration of lung compliance and recoil capacity, which are critical for effective ventilation and gas exchange.

d) Disease-Specific Implications

- Chronic obstructive pulmonary disease (COPD): The combination protects alveolar elastic networks from degradation and promotes reconstruction, thereby slowing emphysematous progression and improving functional outcomes such as FEV_1 and diffusing capacity.
- Acute respiratory distress syndrome (ARDS): Vitamin C attenuates oxidative-inflammation cascades and reduces endothelial permeability, while elastin peptides

contribute to barrier repair and mechanical stabilization, supporting recovery of oxygenation and compliance.

- Pulmonary fibrosis: By reducing TGF-β/Smad-driven fibroblast activation and providing elastic substrates, this synergy modulates extracellular matrix remodeling, slowing stiffening and maintaining elasticity.
- Post-COVID-19 Syndrome (Long COVID): Persistent dyspnea, fatigue, and reduced exercise tolerance are consistent with oxidative stress, micro-fibrotic changes, and loss of elasticity. The combination of Vitamin C and elastin peptides supports redox balance, structural repair, and recovery of functional resilience.

e) Translational Endpoints and Clinical Correlates

The integrative effects of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides can be reflected in multiple endpoints:

- Biochemical markers: reduction of lipid peroxidation products (MDA, 8-isoprostane), cytokines (IL-6, TNF-α), and proteolytic activity (MMP-9/TIMP-1 ratio); increased circulating desmosine/isodesmosine as indices of elastic fiber turnover.
- Functional measures: improvements in FEV_1, FVC, diffusing capacity (DLCO), lung compliance (static and dynamic), and cardiopulmonary exercise testing (peak VO_2, 6-minute walk distance).
- Imaging correlates: stabilization of emphysema indices, attenuation of fibrotic remodeling on high-resolution CT, and recovery of alveolar-capillary integrity.

f) Summary

The combined use of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides provides a mechanistically coherent and clinically relevant strategy for the protection and repair of respiratory elastic connective tissues. By coupling oxidative and inflammatory control with structural regeneration, this approach offers translational potential across COPD, ARDS, pulmonary fibrosis, and Long COVID, addressing the unmet clinical need for restoring lung elasticity and preserving long-term respiratory function.

C. Target Populations

a) Asthma Patients

At Risk of Airway Remodeling and Reduced Compliance

Asthma is characterized not only by airway hyper-responsiveness and inflammation, but also by progressive airway remodeling involving extracellular matrix deposition and disruption of elastic connective tissues. The loss of elastic fiber integrity contributes to reduced airway compliance and persistent airflow limitation despite bronchodilator therapy.

- Vitamin C attenuates oxidative stress and inflammatory signaling, creating a favorable microenvironment for tissue repair.

- Fish Cardiac Arterial Bulb–Derived Elastin Peptides provide structural substrates and bioactive cues for elastic fiber regeneration, supporting restoration of airway elasticity.

Clinical relevance: This synergy may help reduce the progression of airway remodeling, improve compliance, and enhance overall disease control beyond symptomatic relief.

b) COPD Patients

Requiring Structural Reinforcement to Delay Alveolar Destruction

In chronic obstructive pulmonary disease (COPD), alveolar septal walls undergo protease-driven destruction, with breakdown of elastic fibers as a hallmark of emphysema. Loss of elasticity compromises lung recoil, leading to air trapping and reduced expiratory flow.

- Vitamin C buffers protease-inducing oxidative stress and stabilizes basement membranes and vascular integrity.
- Elastin peptides derived from the fish cardiac arterial bulb provide desmosine- and isodesmosine-rich fragments that support de novo elastic fiber assembly.

Clinical relevance: Together, they may slow structural deterioration, preserve alveolar recoil, and improve functional outcomes such as diffusing capacity and exercise tolerance, thereby delaying disease progression.

c) ARDS Patients

Acute Need of Barrier Stabilization and Elastic Repair

Acute respiratory distress syndrome (ARDS) is driven by overwhelming oxidative stress, cytokine storm, and breakdown of the alveolar-capillary barrier, leading to pulmonary edema and critically impaired oxygenation.

- Vitamin C reduces endothelial permeability, attenuates ROS-induced injury, and improves oxygenation parameters.
- Fish Cardiac Arterial Bulb–Derived Elastin Peptides strengthen elastic layers in the alveolar wall and promote barrier repair, reinforcing the mechanical integrity of the respiratory microvasculature.

Clinical relevance: Their combination offers a structural and functional adjunct in ARDS management, helping to restore compliance and reduce long-term sequelae associated with post-ARDS fibrosis.

d) Pulmonary Fibrosis Patients

To Mitigate Fibrotic Stiffening and Preserve Elasticity

In pulmonary fibrosis, persistent fibroblast activation and TGF-β signaling drive excessive extracellular matrix deposition, diluting and displacing elastic fibers. The result is progressive lung stiffening and impaired compliance.

- Vitamin C reduces oxidative triggers of fibroblast activation and modulates collagen cross-linking quality.
- Elastin peptides contribute to rebalancing extracellular matrix composition by providing elastic substrates and signaling for fiber regeneration.

Clinical relevance: This combination may attenuate the rate of fibrotic remodeling, preserve residual elasticity, and improve functional parameters such as forced vital capacity (FVC) and diffusing capacity (DLCO).

e) Long COVID Patients

With Residual Dyspnea, Fatigue, and Impaired Pulmonary Compliance

Post-COVID-19 Syndrome (Long COVID) is frequently associated with persistent dyspnea, exercise intolerance, and fatigue, often reflecting lingering oxidative stress, low-grade inflammation, and micro-fibrotic changes within the lung parenchyma.

- Vitamin C supports mitochondrial redox balance, immune recalibration, and barrier protection.
- Fish Cardiac Arterial Bulb–Derived Elastin Peptides address structural repair by supporting recovery of damaged elastic connective tissues, which are essential for pulmonary compliance and efficient ventilation.

Clinical relevance: This dual approach may alleviate dyspnea, restore exercise capacity, and shorten the trajectory of functional recovery in post-viral convalescence.

Summary: Across these patient populations, the combination of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides targets both pathophysiological drivers (oxidative stress, inflammation, protease activity, fibrotic remodeling) and structural deficits (loss of elastic fibers, reduced compliance).

This dual pathway intervention offers a coherent strategy to support disease control, functional recovery, and long-term preservation of respiratory elasticity.

D. Summary

The combination of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EP) defines a unique structural repair axis for respiratory health. Vitamin C provides essential antioxidant buffering and collagen-based barrier support, while FCAB-EP supply specialized elastin fragments and signaling functions that promote the repair and regeneration of respiratory elastic connective tissues.

Mechanistic and translational evidence supports their role across asthma, COPD, ARDS, pulmonary fibrosis, and Long COVID, where degradation and loss of elasticity are central to disease progression. By coupling protection against elastolysis with promotion of elastic fiber regeneration, this synergy directly addresses one of the most critical unmet needs in respiratory medicine: the restoration and preservation of lung elasticity.

5.8) Grand Synergy Conclusion

Vitamin C as the Central Axis of Multi-Nutrient Respiratory Interventions

Respiratory diseases - including upper respiratory tract infections (URTI), influenza, coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID) - share convergent pathophysiological axes: oxidative stress, chronic inflammation, immune dysregulation, barrier dysfunction, and fibrotic remodeling.

Vitamin C functions as the central axis within a multi-nutrient framework, providing water-phase antioxidant defense, collagen-dependent barrier stability, and immune enhancement. Its efficacy is amplified through targeted synergies with complementary nutrients, forming interconnected protective and reparative loops across disease contexts.

A. Synergistic Mechanisms of Vitamin C and Quercetin in Respiratory Diseases

Redox Regulation, Immune Modulation, and Anti-fibrotic Pathways

- Axis: Dual-compartment antioxidant defense and NF-κB/NLRP3 modulation.
- Impact: Shortens URTI/influenza duration, supports COVID-19 viral clearance, reduces oxidative-inflammation in COPD and ARDS, and attenuates fibrotic remodeling.

B. Synergistic Mechanisms of Vitamin C and Zinc in Respiratory Diseases

Immune Enhancement, Antiviral Defense, and Barrier Protection

- Axis: Immune enhancement and antiviral synergy (via zinc ionophore role of quercetin).
- Impact: Accelerates viral clearance in COVID-19, reduces URTI incidence, lowers COPD exacerbations, and restores immune resilience in Long COVID.

C. Synergistic Mechanisms of Vitamin C and Vitamin D in Respiratory Diseases:

Antioxidant Defense, Innate Immunity, and Adaptive Immune Regulation

- Axis: Antioxidant buffering combined with innate (cathelicidin, defensins) and adaptive immune regulation.
- Impact: Reduces incidence of acute infections, mitigates asthma/COPD exacerbations, improves outcomes in COVID-19 and ARDS, and supports antifibrotic control.

D. Synergistic Mechanisms of Vitamin C and Bromelain in Respiratory Diseases

Mucolytic Clearance, Inflammatory Control, and Barrier Stabilization

- Axis: Mucolytic clearance and anti-inflammatory protection.
- Impact: Relieves congestion and inflammation in URTI/influenza, modulates bradykinin storm in COVID-19, supports mucus clearance in COPD, and reduces inflammatory edema in ARDS.

E. Synergistic Mechanisms of Vitamin C and Elderberry in Respiratory Diseases

Antioxidant Support, Viral Interference, and Symptom Relief

- Axis: Polyphenolic antiviral defense with antioxidant and symptom relief.
- Impact: Clinically reduces URTI and influenza duration, provides supportive antiviral action in COVID-19, lowers airway inflammation in asthma/COPD, and alleviates fatigue in Long COVID.

F. Synergistic Mechanisms of Vitamin C and Mulberry Leaf in Respiratory Diseases

Metabolic-Inflammatory Modulation, Redox Balance, and Structural Protection

- Axis: Metabolic-inflammatory modulation and oxidative stress buffering.
- Impact: Beneficial in patients with metabolic comorbidities (COVID-19, COPD), reduces inflammatory loops in asthma, and improves systemic recovery in Long COVID.

G. Synergistic Mechanisms of Vitamin C and Fish Cardiac Arterial Bulb–Derived Elastin Peptides in Respiratory Diseases:

Elastic Fiber Repair, Barrier Integrity, and Anti-fibrotic Remodeling

- Axis: Structural repair of respiratory elastic connective tissues and antifibrotic remodeling.
- Impact: Preserves alveolar compliance in COPD, restores barrier integrity in ARDS, slows fibrotic progression in pulmonary fibrosis, and supports lung elasticity recovery in Long COVID.

- ✓ *Starcher, B. (1986). Elastin and the lung.* Thorax*, 41(8), 577–585.*

  - Foundational review describing the role of elastin in lung mechanics, emphasizing its importance for recoil and compliance.

- ✓ *Robert, L., Jacob, M. P., & Labat-Robert, J. (1990). Elastin and elastases: Biological functions and clinical interest.* Biochimie*, 72(11), 883–896.*

  - Classic review on elastin biology and elastase-driven degradation, highlighting clinical relevance in respiratory diseases.

- ✓ *Wendel, D. P., et al. (2000). Impaired distal airway development in mice lacking elastin.* American Journal of Respiratory Cell and Molecular Biology*, 23(3), 320–326.*

  - Experimental study showing that absence of elastin leads to severe defects in airway and alveolar development, underscoring its structural necessity.

- ✓ *Starcher, B., & Conrad, M. (1995). A role for neutrophil elastase in the progression of emphysema in hamsters.* American Review of Respiratory Disease*, 152(6), 2091–2095.*

  - Animal model evidence that elastin degradation by neutrophil elastase accelerates emphysematous destruction.

- ✓ *Ma, S., Lin, Y., Cantor, J. O., et al. (2013). Elastin degradation in emphysema: Biological and clinical implications.* Annals of the American Thoracic Society*, 10(Supplement), S437–S443.*

  - Review linking elastin degradation with emphysema progression and potential biomarkers such as desmosine.

- ✓ *Viglio, S., et al. (2000). Urinary desmosine as a biomarker of elastin degradation in chronic obstructive pulmonary disease.* American Journal of Respiratory and Critical Care Medicine*,*

162(4), 1487–1491.

- Clinical study validating urinary desmosine as a non-invasive biomarker of elastin breakdown in COPD patients.

✓ *Schmelzer, C. E. H., et al. (2012). Elastin degradation by cathepsin G: Fragmentation and generation of matrikines.* Journal of Biological Chemistry*, 287(8), 5660–5672.*

- Identified elastin-derived peptides as bioactive matrikines with signaling properties, relevant to tissue repair and remodeling.

✓ *Faury, G. (2001). Function-structure relationship of elastic arteries in evolution: From microfibrils to elastin and elastic fibers.* Pathologie Biologie*, 49(4), 310–325.*

- Review highlighting the structural role of elastin cross-links (desmosine/isodesmosine) in tissue mechanics and resilience.

✓ *Stone, P. J., & Franzblau, C. (1994). The elastin peptide receptor.* Journal of Biological Chemistry*, 269(44), 28443–28448.*

- Identified elastin peptides as ligands for specific receptors, demonstrating their signaling functions in fibroblast activation and tissue remodeling.

Overarching Summary

By integrating Vitamin C with these seven nutrients, a comprehensive respiratory intervention framework emerges:

- Antioxidant defense loops (Vitamin C × Quercetin, Elderberry, Mulberry Leaf) buffer oxidative stress across acute and chronic contexts.

- Immune regulation loops (Vitamin C × Zinc, Vitamin D) enhance both innate and adaptive immunity, improving resistance to infections and modulating hyper-inflammation.
- Inflammation–mucus clearance loops (Vitamin C × Bromelain, Quercetin) relieve airway obstruction and reduce cytokine-driven damage.
- Structural repair loops (Vitamin C × FCAB-EP) directly address elastic fiber degradation and fibrotic remodeling, an unmet need in COPD, ARDS, pulmonary fibrosis, and Long COVID.

Collectively, these synergistic interactions position Vitamin C not merely as an isolated antioxidant, but as the pivotal hub of a multi-nutrient respiratory defense and repair network. This approach bridges acute infection control, chronic airway stabilization, severe alveolar injury management, and post-viral rehabilitation, offering a mechanistically grounded and clinically adaptable framework for respiratory resilience.

✓ *Hemilä, H., & Chalker, E. (2013). Vitamin C for preventing and treating the common cold.* Cochrane Database of Systematic Reviews*, 2013(1), CD000980.*

- Systematic review and meta-analysis demonstrating that vitamin C shortens the duration and alleviates symptoms of common cold, with significant preventive effects in individuals under physical stress.

- ✓ *Hemilä, H. (2017). Vitamin C and infections.* Nutrients*, 9(4), 339.*

  - Review summarizing mechanisms and clinical evidence of vitamin C in immune regulation, infection prevention, and management of severe respiratory illnesses.

- ✓ *Hemilä, H., & Louhiala, P. (2007). Vitamin C for preventing and treating pneumonia.* Cochrane Database of Systematic Reviews*, 2007(1), CD005532.*

  - Cochrane systematic review showing that vitamin C reduces incidence and duration of pneumonia in high-risk populations.

- ✓ *Fowler, A. A., et al. (2019). Effect of vitamin C infusion on organ failure in sepsis and ARDS patients: The CITRIS-ALI randomized clinical trial.* JAMA*, 322(13), 1261–1270.*

  - Randomized controlled trial indicating that high-dose intravenous vitamin C improves organ function and reduces inflammation in sepsis and ARDS patients.

- ✓ *Morris, P. E., et al. (2021). Intravenous vitamin C and acute respiratory distress syndrome: A multicenter randomized controlled trial.* Chest*, 159(6), 1960–1971.*

  - Multicenter RCT providing further evidence of the potential clinical value of vitamin C in ARDS treatment.

- ✓ *Carr, A. C., & Rowe, S. (2020). The emerging role of vitamin C in the prevention and treatment of COVID-19.* Nutrients*, 12(11), 3286.*

  - Review outlining the mechanisms and preliminary clinical evidence for vitamin C use in COVID-19, highlighting intravenous high-dose administration.

- ✓ *Liu, F., et al. (2021). High-dose intravenous vitamin C as an adjunctive therapy for COVID-19: A randomized controlled trial.* Critical Care*, 25(1), 155.*

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

- Small RCT suggesting that intravenous high-dose vitamin C improves oxygenation and reduces inflammation in COVID-19 patients.

✓ *Zhang, J., et al. (2021). Vitamin C alleviates pulmonary fibrosis via suppressing oxidative stress and TGF-β/Smad pathway.* Free Radical Biology and Medicine*, 167, 386–401.*

- Preclinical study showing that vitamin C mitigates pulmonary fibrosis by reducing oxidative stress and inhibiting TGF-β/Smad signaling.

✓ *Martineau, A. R., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data.* BMJ*, 356, i6583.*

- Large-scale meta-analysis demonstrating that vitamin D supplementation reduces the incidence of acute respiratory infections, especially in deficient individuals.

✓ *Greiller, C. L., & Martineau, A. R. (2015). Modulation of the immune response to respiratory viruses by vitamin D.* Nutrients*, 7(6), 4240–4270.*

- Review discussing the role of vitamin D in modulating immune responses to respiratory viral infections.

✓ *Grant, W. B., et al. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.* Nutrients*, 12(4), 988.*

- Review proposing that vitamin D supplementation may reduce risk and severity of influenza and COVID-19 based on mechanistic and observational evidence.

✓ *Jolliffe, D. A., et al. (2021). Vitamin D supplementation to prevent acute respiratory infections: A systematic review and meta-analysis.* The Lancet Diabetes & Endocrinology*, 9(5), 276–292.*

- Systematic review and meta-analysis confirming the protective effect of vitamin D supplementation against acute respiratory infections.

✓ *Singh, M., & Das, R. R. (2013). Zinc for the common cold.* Cochrane Database of Systematic Reviews*, 2013(6), CD001364.*

- Cochrane review concluding that zinc lozenges reduce the duration of common cold episodes when taken promptly after symptom onset.

✓ *Read, S. A., Obeid, S., Ahlenstiel, C., & Ahlenstiel, G. (2019). The role of zinc in antiviral immunity.* Advances in Nutrition*, 10(4), 696–710.*

- Review highlighting zinc's roles in supporting antiviral immunity, including inhibition of viral replication and enhancement of immune cell functions.

✓ *Wessels, I., Rolles, B., & Rink, L. (2020). The potential impact of zinc supplementation on COVID-19 pathogenesis.* Frontiers in Immunology*, 11, 1712.*

- Review suggesting zinc supplementation as a supportive measure in modulating immune response and viral clearance in COVID-19.

✓ *Skalny, A. V., et al. (2020). Zinc and respiratory tract infections: Perspectives for COVID-19 (Review).* International Journal of Molecular Medicine*, 46(1), 17–26.*

- Review summarizing the role of zinc in respiratory infections with emphasis on COVID-19, linking deficiency to increased risk.

✓ *Roscioli, E., et al. (2017). Zinc deficiency as a codeterminant of chronic obstructive pulmonary disease in humans.* Respirology*, 22(8), 1642–1650.*

- Observational study linking zinc deficiency to increased risk and progression of chronic obstructive pulmonary disease.

- ✓ *Mocchegiani, E., Malavolta, M., & Costarelli, L. (2018). Zinc, oxidative stress, and immunosenescence: Emerging interrelationships.* Mechanisms of Ageing and Development*, 176, 116–123.*

- Review describing the interrelationship between zinc status, oxidative stress, and immune aging, with implications for chronic respiratory vulnerability.

III Vitamin D in Respiratory System Interventions

Building the Immunological Foundation and Modulating Inflammatory Responses

Vitamin D functions as a pleiotropic secosteroid that interfaces with respiratory pathophysiology at multiple levels.

Through vitamin D receptor (VDR)-mediated transcriptional control, it induces antimicrobial peptides (e.g., cathelicidin/LL-37, β-defensins), rebalances adaptive immunity (tempering Th1/Th17 bias while supporting Treg development), and stabilizes epithelial and endothelial junctional complexes.

These axes converge on core vulnerabilities shared by upper respiratory tract infections (URTI), influenza, coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID).

1) Mechanistic Basis

1.1) Innate Antimicrobial Priming

Vitamin D signaling through the vitamin D receptor (VDR) induces the transcription of antimicrobial peptides such as cathelicidin/LL-37 and β-defensins, which are directly active at mucosal surfaces. LL-37 disrupts viral envelopes and bacterial membranes, while defensins form pores and inhibit microbial replication.

Beyond direct pathogen killing, these peptides also recruit innate immune cells and synergize with type I interferon programs, amplifying antiviral states in epithelial cells.

Disease relevance:

This priming of mucosal immunity is crucial in the early containment of pathogens in upper respiratory tract infections (URTI), influenza, and COVID-19, where rapid viral propagation can overwhelm defenses. In acute respiratory distress syndrome (ARDS), enhancing mucosal antimicrobial activity may also lower the risk of secondary bacterial pneumonia, a frequent complication.

1.2) Adaptive Immune Rebalancing

Vitamin D exerts immune-regulatory functions by binding to VDR expressed in T cells, dendritic cells, and macrophages. It suppresses dendritic cell maturation, resulting in reduced IL-12 and IL-23 production, which in turn downregulates Th1 (IFN-γ) and Th17 (IL-17) responses. Excessive activity of these axes is linked to airway hyper-inflammation

and tissue injury.

At the same time, vitamin D promotes the expansion and function of FOXP3+ regulatory T cells (Treg), which maintain tolerance and constrain immunopathology.

Disease relevance:

This adaptive rebalancing attenuates hyper-inflammatory cascades in asthma (airway eosinophilia and hyper-reactivity) and COPD (chronic neutrophilic inflammation). It is also protective in COVID-19 and ARDS, where dysregulated Th1/Th17-driven cytokine storms contribute to alveolar-capillary damage and poor outcomes.

1.3) Barrier Integrity and Repair

Vitamin D enhances epithelial and endothelial barrier stability by upregulating tight-junction proteins such as claudins and occludin, and by promoting junctional adhesion molecule expression. This action reduces paracellular permeability and prevents pathogen translocation.

Vitamin D also supports endothelial stabilization by modulating vascular endothelial growth factor (VEGF) and maintaining nitric oxide bioavailability. Together, these effects reduce edema formation and improve microvascular resilience.

Disease relevance:

In ARDS, barrier reinforcement mitigates alveolar flooding and improves oxygenation. In pulmonary fibrosis, protection of the epithelial barrier reduces repetitive cycles of

epithelial injury that drive fibroblast activation and scarring. Thus, vitamin D contributes to both acute survival and long-term structural preservation of lung tissue.

1.4) Redox–Inflammation Cross-talk

Vitamin D modulates redox–inflammation interplay by dampening NF-κB activity and suppressing NADPH oxidase–derived ROS production in immune and epithelial cells. Through these actions, vitamin D reduces oxidative stress, which otherwise perpetuates inflammatory cascades and matrix damage. Additionally, VDR activation enhances antioxidant enzyme expression, indirectly buffering ROS levels.

Disease relevance:

In COPD and asthma, this mechanism reduces chronic oxidative-inflammatory burden that underlies airway remodeling and progressive decline in lung function. In Long COVID, where persistent oxidative stress and low-grade inflammation contribute to fatigue and impaired recovery, vitamin D helps reestablish homeostasis and support systemic rehabilitation.

1.5) Summary:

Vitamin D provides frontline antimicrobial defense, adaptive immune rebalancing, barrier stabilization, and oxidative-inflammatory modulation - together mapping precisely onto the pathological drivers of acute and chronic respiratory disease.

2) Clinical Evidence (Expanded)

2.1) Upper Respiratory Tract Infections (URTI) and Influenza

Randomized controlled trials and meta-analyses consistently show that vitamin D supplementation reduces the incidence of acute respiratory infections (ARI), especially in individuals with low baseline serum 25-hydroxyvitamin D [25(OH)D] levels.

In these deficient populations, supplementation not only lowers risk but also modestly attenuates symptom severity and duration during episodes of URTI and influenza.

The protective effect is mechanistically aligned with vitamin D's role in LL-37 induction, mucosal immunity, and barrier stabilization.

2.2) COVID-19

Multiple observational studies have associated sufficient vitamin D status with lower risk of severe COVID-19, reduced need for intensive care, and improved survival.

Interventional trials - although heterogeneous - suggest that vitamin D supplementation may support viral clearance, reduce inflammatory markers, and improve oxygenation when integrated into multimodal supportive care.

Mechanistically, these findings are underpinned by vitamin D's capacity to modulate innate and adaptive immune responses, thereby reducing the risk of hyper-inflammatory damage to alveolar-capillary structures.

2.3) Asthma and COPD

In asthma, vitamin D supplementation has been shown to reduce the frequency of exacerbations, particularly in patients with serum 25(OH)D deficiency. Supplementation also aligns with improved lung function parameters (e.g., FEV_1, peak flow) when combined with inhaled corticosteroids.

In COPD, low vitamin D levels correlate with increased exacerbation risk and poorer lung function. Correcting deficiency contributes to immune balance, reduced airway inflammation, and potentially improved disease stability.

2.4) Acute Respiratory Distress Syndrome (ARDS)

Vitamin D deficiency has been linked to higher incidence and worse prognosis in ARDS. Patients with low levels are more prone to severe barrier disruption, pulmonary edema, and reduced oxygenation.

Correcting deficiency has been associated with better barrier stability, reduced permeability edema, and improved outcomes in critical care. The mechanistic rationale is consistent with vitamin D's role in tight-junction reinforcement and endothelial stabilization.

2.5) Pulmonary Fibrosis

Preclinical data demonstrate that vitamin D suppresses fibroblast activation and TGF-β/Smad signaling, thereby attenuating the development of excessive extracellular matrix deposition. Translational observations in human studies support this role, suggesting that

sufficient vitamin D status may slow the progression of fibrotic remodeling and preserve residual lung elasticity. These effects position vitamin D as a potential supportive intervention in fibrotic lung disorders.

2.6) Long COVID

Emerging evidence indicates that vitamin D deficiency contributes to persistent symptoms in Post-COVID-19 Syndrome (Long COVID), such as fatigue, dyspnea, and immune dysregulation. Supplementation may aid rehabilitation by reducing low-grade inflammation, restoring redox balance, and supporting mitochondrial and immune recovery. While more clinical trials are needed, early data suggest beneficial roles in improving quality of life and functional capacity.

3) Target Populations

Individuals with recurrent ARI or high-contact exposure

Those in schools, healthcare, or crowded living environments benefit from vitamin D's antimicrobial priming and infection-preventive effects.

Patients with COVID-19 (especially with vitamin D deficiency)

Deficient patients are at heightened risk for severe disease; supplementation may reduce severity and improve recovery trajectories.

Asthma and COPD cohorts prone to exacerbations

Vitamin D helps rebalance adaptive immunity and reduce airway hyper-inflammation, supporting disease control and reducing exacerbation frequency.

Critically ill patients at risk for or with ARDS

In intensive care, correction of deficiency supports barrier stabilization, reduces pulmonary edema, and aids oxygenation.

Patients with fibrotic tendencies

Individuals with early-stage interstitial lung disease or post-injury fibrotic changes may benefit from vitamin D's antifibrotic modulation, slowing structural progression.

Long COVID patients with persistent symptoms

Patients presenting with lingering fatigue, dyspnea, and immune dysregulation may achieve improved recovery and resilience with adequate vitamin D repletion.

4) Summary

Vitamin D exerts a triad of protective functions—innate antimicrobial induction, adaptive immune rebalancing, and barrier stabilization—that directly counteract the principal drivers of respiratory morbidity. Its relevance spans the continuum of disease:

- In acute infections (URTI, influenza, COVID-19), vitamin D enhances mucosal defenses and reduces viral replication.

- In chronic airway diseases (asthma, COPD), it mitigates exacerbations and supports airway stability.
- In critical illness (ARDS), it protects alveolar-capillary integrity and supports oxygenation.
- In fibrotic lung disease, it restrains fibroblast activation and preserves elasticity.
- In post-viral sequelae (Long COVID), it aids rehabilitation by restoring immune and redox homeostasis.

When integrated into multi-nutrient strategies (e.g., with vitamin C for antioxidant buffering and zinc for antiviral support), vitamin D complements other mechanistic axes to improve resilience across the spectrum of respiratory disorders, from infection prevention to structural preservation and post-illness recovery.

✓ *Martineau, A. R., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data.* BMJ*, 356, i6583.*

- Large-scale meta-analysis demonstrating that vitamin D supplementation significantly reduces the risk of acute respiratory infections, especially in individuals with baseline deficiency.

✓ *Greiller, C. L., & Martineau, A. R. (2015). Modulation of the immune response to respiratory viruses by vitamin D.* Nutrients*, 7(6), 4240–4270.*

- Review highlighting vitamin D's regulation of antimicrobial peptide expression, adaptive immune balance, and implications for viral respiratory infections.

- ✓ *Grant, W. B., et al. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.* Nutrients*, 12(4), 988.*

  - Review presenting mechanistic and observational evidence supporting vitamin D as a preventive and supportive measure in influenza and COVID-19.

- ✓ *Jolliffe, D. A., et al. (2021). Vitamin D supplementation to prevent acute respiratory infections: A systematic review and meta-analysis.* The Lancet Diabetes & Endocrinology*, 9(5), 276–292.*

  - Updated systematic review confirming the protective role of vitamin D supplementation against respiratory infections.

- ✓ *Dancer, R. C., et al. (2015). Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS).* Thorax*, 70(7), 617–624.*

  - Mechanistic and clinical study showing vitamin D deficiency as a direct risk factor for ARDS with impaired barrier integrity.

- ✓ *Hansdottir, S., & Monick, M. M. (2011). Vitamin D effects on lung immunity and respiratory diseases.* Annals of the American Thoracic Society*, 8(3), 187–190.*

  - Review describing vitamin D's role in innate immunity, epithelial defense, and its relevance to chronic lung disease.

- ✓ *Khoo, A. L., et al. (2011). Translating the role of vitamin D3 in infectious diseases.* Critical Reviews in Microbiology*, 37(1), 65–81.*

  - Comprehensive review summarizing vitamin D3-mediated antimicrobial pathways and translational relevance in respiratory infection management.

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

- ✓ *Camargo, C. A., et al. (2012). Randomized trial of vitamin D supplementation and risk of acute respiratory infection in children.* Pediatrics*, 130(3), e561–e567.*

  - RCT showing that vitamin D supplementation lowers the risk of acute respiratory infection in pediatric populations.

- ✓ *Pfeffer, P. E., & Hawrylowicz, C. M. (2018). Vitamin D and lung disease: A therapeutic potential for vitamin D?* Thorax*, 73(3), 293–295.*

  - Commentary emphasizing vitamin D as a therapeutic adjunct in chronic airway disease and critical illness.

- ✓ *Liu, N., et al. (2021). Low vitamin D status is associated with post-COVID-19 syndrome.* Frontiers in Nutrition*, 8, 688520.*

  - Observational study linking vitamin D deficiency to persistent symptoms in Long COVID, suggesting a role in rehabilitation and recovery.

5) Multi-Nutrient Synergistic Interventions with Vitamin D in Respiratory Diseases: Mechanistic Insights and Clinical Applications

Antimicrobial Induction, Immune Rebalancing, and Barrier Stabilization Across Acute and Chronic Airway Disorders

Respiratory diseases - including upper respiratory tract infections (URTI), influenza, coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID) - share pathological commonalities: excessive

inflammation, impaired barrier function, dysregulated immunity, and progressive structural remodeling.

Within this spectrum, Vitamin D emerges as a pivotal immunomodulatory nutrient. Acting through the vitamin D receptor (VDR), it regulates transcription of antimicrobial peptides (e.g., LL-37, β-defensins), rebalances adaptive immune pathways (suppressing Th1/Th17 axes and expanding FOXP3+ regulatory T cells), and reinforces epithelial and endothelial tight junctions.

These pathways directly address the vulnerabilities of infection-prone mucosa, inflamed airways, leaky alveolar-capillary barriers, and fibrosis-prone parenchyma.

However, the clinical impact of Vitamin D is maximized when integrated into multi-nutrient strategies. Its synergy with complementary agents amplifies mechanistic reach:

- Quercetin – extends antioxidant coverage and restrains inflammasome activation.
- Zinc – strengthens immune maturation and directly inhibits viral replication.
- Vitamin C – buffers oxidative stress and supports collagen-dependent barrier stability.
- Bromelain – enhances mucolytic clearance and moderates bradykinin-driven edema.
- Elderberry – interferes with viral entry while supplying polyphenolic antioxidant support.
- Mulberry leaf – reduces metabolic-inflammation that amplifies airway pathology.

- Fish Cardiac Arterial Bulb–Derived Elastin Peptides – restore elasticity of respiratory connective tissues, addressing fibrosis and compliance loss.

Together, these nutrients create a multi-dimensional intervention framework with Vitamin D at the immune-barrier axis, bridging antimicrobial readiness, immunopathology restraint, and structural resilience across the full continuum of respiratory disease.

5.1) Synergistic Mechanisms of Vitamin D and Quercetin in Respiratory Diseases

Antimicrobial Induction, Inflammasome Control, and Barrier Stabilization

Vitamin D orchestrates mucosal defense via vitamin D receptor (VDR)–mediated induction of antimicrobial peptides (LL-37, β-defensins), adaptive immune rebalancing, and epithelial/endothelial junctional stability.

Quercetin adds lipid-compartment antioxidant activity, NLRP3 inflammasome constraint, mast-cell stabilization, and antiviral interference (with ancillary zinc-ionophore behavior).

Their integration targets pathogen containment, hyper-inflammation control, and barrier preservation across acute and chronic airway disorders.

A. Mechanistic Basis

a) Synergistic Antimicrobial and Antiviral Pathways of Vitamin D and Quercetin in Airway Mucosal Immunity

- Vitamin D (VDR axis).

Ligand-activated VDR upregulates the *CAMP* gene (cathelicidin/LL-37) and *DEFB* family members (e.g., β-defensin-2), enhancing mucosal microbicidal capacity in nasal, bronchial, and alveolar epithelium. LL-37 disrupts viral envelopes, neutralizes bacterial LPS, and potentiates phagocyte activity; β-defensins exert pore-forming and chemotactic functions. VDR signaling also cooperates with type I/III interferon programs (JAK–STAT–ISG cascades), raising early antiviral tone in epithelial cells and resident macrophages.

- Quercetin (direct/indirect antiviral).

Quercetin interferes with several steps of respiratory viral life cycles:

(i) entry/attachment (e.g., destabilizing lipid rafts and receptor–ligand interactions);

(ii) (ii) endosomal trafficking and uncoating;

(iii) (iii) replication - in part via kinase modulation (PI3K/AKT, MAPKs) and by facilitating intracellular zinc uptake (ionophore-like behavior), which can suppress RNA-dependent RNA polymerase activity.

Quercetin also supports interferon responsiveness and limits virus-induced oxidative stress that would otherwise impair innate signaling.

Why this matters clinically.

- URTI, influenza, COVID-19: Faster early containment—higher LL-37/β-defensin tone plus quercetin's entry/replication checks translate to lower viral load and shorter symptomatic windows.
- Asthma/COPD: Damping viral replication at the mucosa reduces virus-triggered exacerbations, blunting downstream neutrophilic/eosinophilic flares.

Evaluable endpoints.

Nasal/bronchial lining fluid LL-37 and β-defensin levels, interferon-stimulated gene signatures (e.g., *MX1*, *ISG15*), cycle thresholds for viral PCR (viral burden), days-to-symptom resolution, and exacerbation frequency in asthma/COPD cohorts.

b) Coordinated Modulation of Inflammatory Signaling and Inflammasome Activity by Vitamin D and Quercetin

- Vitamin D (immune rebalance).

VDR signaling conditions antigen-presenting cells toward a tolerogenic phenotype (reduced IL-12/IL-23), thereby down-tuning Th1 (IFN-γ) and Th17 (IL-17) axes while expanding $FOXP3^+$ Treg populations. The result is containment of immune-mediated epithelial injury without compromising pathogen clearance.

- Quercetin (NF-κB/NLRP3/mast-cell restraint).

Quercetin inhibits IκB kinase–dependent NF-κB activation, curtails mitochondrial ROS and TXNIP-NLRP3 coupling, and disrupts ASC inflammasome assembly - lowering IL-1β/IL-18 maturation. Concurrent mast-cell stabilization diminishes histamine, tryptase, leukotrienes, and prostaglandins that amplify bronchoconstriction and edema.

Why this matters clinically.

- Asthma: Reduced airway hyper-reactivity via mast-cell/Th2-adjacent mediator control and containment of Th17-linked neutrophilia.
- COPD: Attenuation of neutrophilic drive (e.g., CXCL8/IL-8), limiting elastase- and ROS-propagated tissue damage.
- ARDS/COVID-19: Blunting cytokine surges (IL-6, TNF-α, IL-1β) reduces endothelial–epithelial injury, capillary leak, and ventilatory burden.

Evaluable endpoints.

Circulating/airway IL-6, TNF-α, IL-1β, IL-17A; CRP/ferritin; mast-cell tryptase; fractional exhaled NO; need for rescue bronchodilators/systemic steroids; ventilator-free days in ARDS.

c) Complementary Roles of Vitamin D and Quercetin in Preserving Epithelial and Endothelial Barrier Integrity

- Vitamin D (junctional reinforcement).

VDR activation upregulates tight-junction proteins (claudin-1/4, occludin, ZO-1), supports adherens complexes (E-cadherin), and stabilizes endothelial cohesion (VE-cadherin), thereby reducing paracellular leak. VDR also moderates VEGF-driven permeability and preserves nitric-oxide–dependent microvascular tone.

- Quercetin (oxidative-junctional protection).

By activating Nrf2–HO-1 and limiting MLCK-mediated cytoskeletal contraction, quercetin preserves junctional architecture under oxidative and inflammatory stress, prevents ZO-1 degradation, and helps sustain ciliary function and mucociliary clearance.

Why this matters clinically.

- ARDS: Lower permeability edema and improved alveolar-capillary integrity favor better oxygenation (higher PaO_2/FiO_2) and less ventilator-induced injury.
- Fibrosis risk states (post-injury, post-viral): Fewer cycles of epithelial micro-injury reduce profibrotic signaling (e.g., TGF-β activation) that seeds aberrant ECM deposition.

Evaluable endpoints.

Trans-epithelial electrical resistance (TEER), albumin flux and total protein in BAL, soluble RAGE/angiopoietin-2, PaO_2/FiO_2 ratio, lung ultrasound/HRCT markers of edema, and longitudinal quantitative CT for fibrotic remodeling.

d) Summary

Vitamin D supplies antimicrobial readiness and immune tolerance while fortifying junctional barriers; quercetin overlays direct antiviral interference, inflammasome/NF-κB restraint, and oxidative protection of epithelial and endothelial junctions. Across URTI, influenza, and COVID-19, this pairing accelerates early viral control and shortens illness. In asthma/COPD, it reduces virus-provoked exacerbations and airway hyper-inflammation. In ARDS and fibrosis-prone contexts, it stabilizes the alveolar–capillary interface and limits injury-to-fibrosis transitions - aligning molecular actions with clinically meaningful endpoints.

B. Clinical Evidence

a) Upper Respiratory Tract Infections, Influenza, and COVID-19

The complementary effects of Vitamin D and quercetin align with early pathogen containment and symptom mitigation.

- **Vitamin D:**

Large-scale meta-analyses demonstrate that supplementation reduces the risk of acute respiratory infections (ARI), particularly in individuals with baseline deficiency, by enhancing antimicrobial peptide expression and mucosal defense.

Observational and interventional data in COVID-19 further associate sufficient serum 25(OH)D with reduced hospitalization, improved viral clearance, and lower mortality.

- **Quercetin:**

Randomized and translational studies indicate that quercetin shortens illness duration and lowers symptom burden in viral upper respiratory tract infections and influenza, partly through its antiviral interference and inflammasome-modulating effects.
Preliminary clinical trials in COVID-19 suggest faster recovery and lower inflammatory marker profiles.

Synergistic perspective: By combining Vitamin D-mediated antimicrobial priming with quercetin's direct antiviral and anti-inflammatory activities, the intervention enhances early containment of viral spread, reduces infection severity, and supports faster convalescence in URTI, influenza, and COVID-19.

b) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Exacerbations of chronic airway diseases are often triggered by viral infections and amplified by airway inflammation.

- **Vitamin D:**

Supplementation lowers the frequency of asthma exacerbations, especially in patients with vitamin D deficiency, by tempering Th1/Th17 responses and promoting immune

tolerance. In COPD, deficiency is linked to more frequent exacerbations and poorer lung function, while correction supports improved stability.

- **Quercetin:**

Preclinical and pilot clinical studies demonstrate anti-inflammatory effects in chronic airway disease, including inhibition of NF-κB signaling, NLRP3 inflammasome activity, and mast-cell mediator release. These actions translate into reduced airway hyper-reactivity, neutrophilic inflammation, and oxidative burden.

Synergistic perspective: When combined, Vitamin D and quercetin address both immune imbalance and inflammatory amplification, reducing the risk and severity of exacerbations. This dual approach enhances disease control and preserves lung function in asthma and COPD populations.

c) Acute Respiratory Distress Syndrome (ARDS), Pulmonary Fibrosis, and Long COVID

Severe and post-viral respiratory conditions share features of barrier disruption, oxidative stress, and fibrotic remodeling.

- **Vitamin D:**

Deficiency correlates with increased susceptibility to ARDS and worse clinical outcomes. Supplementation stabilizes endothelial and epithelial barriers, reducing permeability

edema and supporting oxygenation.

In fibrotic lung conditions, Vitamin D modulates fibroblast activity and downregulates TGF-β/Smad signaling, slowing matrix deposition. Emerging evidence also links sufficient Vitamin D status to improved recovery trajectories in Long COVID, particularly in alleviating fatigue and dyspnea.

- **Quercetin:**

Experimental models demonstrate that quercetin reduces oxidative stress–driven fibroblast activation, inhibits NLRP3-mediated pro-fibrotic signaling, and protects tight-junction integrity. Translational observations suggest improvements in pulmonary compliance and systemic symptom recovery.

Synergistic perspective: By reinforcing barrier integrity, suppressing fibroblast activation, and curbing oxidative-inflammation loops, the combination of Vitamin D and quercetin provides a rational adjunctive strategy in ARDS management, fibrosis attenuation, and Long COVID rehabilitation, improving functional outcomes and quality of life.

d) Summary:

Clinical evidence supports that Vitamin D and quercetin, when used together, offer benefits across the respiratory spectrum—from infection prevention and viral containment, to exacerbation control in chronic disease, and to barrier protection and anti-fibrotic support in severe and post-viral conditions.

C. Target Populations

High-exposure individuals to ARI; asthma/COPD with inflammatory exacerbations; COVID-19 (early outpatient adjunct); patients vulnerable to ARDS or fibrotic remodeling; Long COVID with persistent airway inflammation/fatigue.

D. Conclusion

The integration of Vitamin D and quercetin establishes a dual-axis intervention that aligns with the key pathological drivers of respiratory diseases.

- Vitamin D provides antimicrobial priming and immune homeostasis. Through VDR-mediated induction of LL-37 and β-defensins, it enhances mucosal resistance against viral and bacterial pathogens.

  At the same time, it rebalances adaptive immunity by suppressing Th1/Th17 polarization and expanding regulatory T cells, thereby constraining hyper-inflammatory cascades.
- Quercetin contributes complementary functions by offering lipid-phase antioxidant activity, protecting epithelial and endothelial membranes from oxidative injury.

  It also exerts inflammasome restraint, suppressing NF-κB and NLRP3 activation, and stabilizing mast cells to prevent mediator-driven bronchoconstriction and vascular leak.

Together, these mechanisms reinforce epithelial and endothelial barriers, preserving alveolar integrity and reducing permeability injury. Their synergy limits viral propagation, oxidative stress, and inflammatory escalation, which are common hallmarks of upper respiratory tract infections (URTI), influenza, coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID).

Clinical implications:

- In URTI and influenza, the combination reduces viral load, shortens illness duration, and alleviates symptom burden.
- In COVID-19, it aligns with improved viral control, attenuation of cytokine storm, and preservation of barrier function.
- In asthma and COPD, it reduces virus-triggered exacerbations by dampening both infection susceptibility and inflammatory amplification.
- In ARDS and pulmonary fibrosis, it stabilizes alveolar-capillary barriers and constrains fibrosis-promoting cascades.
- In Long COVID, it facilitates immune recalibration and supports recovery from persistent symptoms such as fatigue and dyspnea.

By uniting antimicrobial and immune-balancing actions (Vitamin D) with antioxidant and inflammasome-modulating properties (quercetin), this pairing provides a comprehensive

protective axis against respiratory morbidity—delivering both acute infection defense and long-term structural preservation.

5.2) Synergistic Mechanisms of Vitamin D and Bromelain in Respiratory Diseases

Mucolytic Clearance, Bradykinin Modulation, and Epithelial Barrier Support

Vitamin D secures immune-barrier homeostasis; bromelain delivers proteolytic mucolysis, reduces edema mediators (e.g., bradykinin/prostaglandins), and facilitates airway clearance. Pairing targets mucus burden + inflammatory permeability while keeping mucosa protected.

A. Mechanistic Basis

a) Mucus Rheology and Clearance

Bromelain, a proteolytic enzyme complex derived from Ananas comosus, exerts direct mucolytic effects by degrading glycoprotein networks and reducing mucus viscosity. This improves expectoration and enhances mucociliary clearance. In parallel, Vitamin D supports epithelial and ciliary function by maintaining calcium homeostasis and reinforcing epithelial differentiation, thereby ensuring effective mucosal transport mechanisms.

Clinical relevance: This synergy is particularly valuable in conditions characterized by excessive mucus production or impaired clearance, such as upper respiratory tract

infections (URTI), asthma, chronic obstructive pulmonary disease (COPD), and post-viral bronchitic syndromes, where mucus plugging contributes to airflow limitation and infection persistence.

b) Inflammatory Edema Control

Bromelain modulates the bradykinin–kallikrein system and attenuates prostaglandin and thromboxane synthesis, thereby reducing vascular permeability and inflammatory edema. Simultaneously, Vitamin D strengthens epithelial and endothelial barriers by upregulating tight-junction proteins (claudins, occludin) and stabilizing endothelial adhesion molecules. Together, these actions reduce paracellular leak and tissue swelling.

Clinical relevance: This combined mechanism is highly relevant in acute respiratory distress syndrome (ARDS) and COVID-19, where capillary leak and pulmonary edema contribute to hypoxemia, as well as in allergic asthma, where inflammatory edema narrows the airways.

c) Antimicrobial Context

Vitamin D, through VDR activation, induces transcription of antimicrobial peptides such as LL-37 and β-defensins, which enhance mucosal defense against bacterial and viral pathogens. While bromelain does not directly induce antimicrobial peptides, its mucolytic action reduces microbial load by facilitating mucus clearance and its proteolytic activity may disrupt biofilms, indirectly supporting host defense.

Clinical relevance: This antimicrobial context supports early containment of infections in URTI, influenza, and COVID-19, and prevents secondary bacterial infections in patients with asthma, COPD, or ARDS, where mucus stasis often predisposes to colonization.

d) Summary :

Vitamin D and bromelain provide a complementary mucosal defense axis: bromelain physically clears secretions and reduces inflammatory edema, while Vitamin D enhances epithelial integrity and antimicrobial readiness. Together, they address critical vulnerabilities in both acute infections and chronic airway disease phenotypes.

B. Clinical Evidence

a) Upper Respiratory Tract Infections and Influenza

The combined use of Vitamin D and bromelain targets two key pathological drivers in upper respiratory tract infections and influenza: mucus accumulation and inflammatory swelling.

- Bromelain reduces mucus viscosity and facilitates clearance, thereby alleviating nasal obstruction and cough, while also reducing inflammatory mediators that prolong symptom burden.

- Vitamin D lowers the risk of infection onset by enhancing mucosal antimicrobial peptide expression and helps regulate immune responses, preventing excessive inflammation that exacerbates airway discomfort.

Clinical implication: Patients with URTI and influenza experience faster symptom relief, improved clearance of respiratory secretions, and reduced risk of secondary bacterial infection when both nutrients are optimized.

b) COVID-19

COVID-19 pathophysiology is strongly linked to barrier disruption and dysregulated bradykinin signaling, which contribute to pulmonary edema and impaired gas exchange.

- Bromelain, by modulating the bradykinin–kallikrein system, reduces edema formation and tissue swelling.
- Vitamin D enhances barrier integrity through tight-junction stabilization and also modulates immune hyper-activation.

Clinical implication: Their combined use addresses two central mechanisms in COVID-19 - vascular leak and cytokine-driven inflammation - potentially reducing disease severity and improving oxygenation when used as adjunctive interventions.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

In asthma and COPD, mucus hypersecretion and inflammatory edema contribute to airway narrowing and airflow limitation.

- Bromelain reduces mucus viscosity, facilitating airway clearance and decreasing obstruction.
- Vitamin D tempers airway inflammation by modulating Th1/Th17 responses and enhancing epithelial repair.

Clinical implication: This combination reduces mucus-driven exacerbations, eases airway obstruction, and supports long-term disease control in chronic airway disorders.

d) Acute Respiratory Distress Syndrome (ARDS)

ARDS is characterized by alveolar-capillary barrier breakdown, increased permeability, and pulmonary edema.

- Bromelain reduces inflammatory edema through bradykinin modulation and anti-prostaglandin effects.
- Vitamin D reinforces endothelial and epithelial barriers, reducing paracellular leak and supporting alveolar stability.

Clinical implication: In ARDS, the combination provides dual support by limiting permeability edema and stabilizing oxygenation capacity, thereby complementing critical care interventions.

e) Pulmonary Fibrosis and Long COVID

Both pulmonary fibrosis and Post-COVID-19 Syndrome (Long COVID) are characterized by persistent symptoms, structural changes, and impaired recovery.

- Vitamin D inhibits fibroblast activation and reduces TGF-β/Smad signaling, slowing fibrotic progression.
- Bromelain contributes to resolution of chronic inflammation, reduces edema, and may assist in remodeling processes by modulating matrix turnover.

Clinical implication: In these long-term conditions, the synergy of Vitamin D and bromelain provides a supportive recovery axis, reducing dyspnea, improving exercise tolerance, and maintaining residual lung elasticity.

f) Summary:

Clinical observations and mechanistic alignment suggest that Vitamin D plus bromelain offers a multi-layered benefit: rapid symptom relief in acute infections, reduced airway obstruction in asthma/COPD, improved barrier stability in COVID-19 and ARDS, and supportive recovery in fibrotic and post-viral states.

C. Target Populations

Mucus-predominant phenotypes（URTI, asthma/COPD chronic bronchitic forms, post-viral congestion）, early COVID-19, ARDS edema profiles, Long COVID with airway secretion issues.

D. Conclusion

Vitamin D and bromelain act on complementary yet interconnected axes of respiratory defense. Vitamin D functions as a systemic regulator of mucosal integrity and immune balance - reinforcing epithelial and endothelial junctions, inducing antimicrobial peptides, and tempering pro-inflammatory signaling. In parallel, bromelain provides targeted relief at the airway interface by reducing mucus viscosity, enhancing mucociliary clearance, and modulating bradykinin-driven vascular permeability.

Together, these nutrients create a dual-action synergy: bromelain facilitates airway patency and secretion clearance, while Vitamin D ensures barrier stability and immunological resilience. This combined effect addresses critical vulnerabilities across the respiratory spectrum - from symptom relief in upper respiratory tract infections and influenza, to inflammatory edema control in COVID-19 and ARDS, and to supportive recovery in fibrotic lung disease and Post-COVID-19 Syndrome.

By integrating airway clearance with barrier preservation, the pairing of Vitamin D and bromelain provides a mechanistically coherent strategy to improve pulmonary function,

reduce disease burden, and accelerate recovery in both acute and chronic respiratory conditions.

5.3) Synergistic Mechanisms of Vitamin D and Elderberry in Respiratory Diseases

Viral Entry Interference, Antioxidant Support, and Immune Balance

Vitamin D calibrates innate/adaptive responses and barrier function; elderberry's anthocyanin-rich polyphenols interfere with viral attachment/entry and contribute antioxidant/anti-inflammatory support. Together they address early infection dynamics and symptom burden.

A. Mechanistic Basis

a) Synergistic Viral Interference and Antimicrobial Priming

Elderberry contains polyphenols and anthocyanins that inhibit hemagglutinin-mediated viral entry and block early stages of viral attachment and fusion, particularly relevant to influenza viruses and coronaviruses. These actions reduce viral load at the mucosal interface. Vitamin D, through VDR activation, induces the transcription of antimicrobial peptides such as LL-37 and β-defensins, which disrupt viral membranes, enhance phagocytic clearance, and cooperate with interferon pathways.

Clinical relevance: This combination creates a frontline antiviral shield, reducing the likelihood of infection establishment and facilitating early containment in upper respiratory tract infections (URTI), influenza, and coronavirus disease 2019 (COVID-19).

b) Coordinated Modulation of Inflammation and Symptom Attenuation

Elderberry polyphenols downregulate pro-inflammatory cytokines (e.g., IL-6, TNF-α) and mitigate oxidative stress–driven amplification of immune responses, which contributes to symptom relief such as fever, cough, and malaise. Vitamin D complements these actions by constraining Th1/Th17-mediated hyper-inflammation and promoting regulatory T cell balance, reducing the risk of cytokine storms in viral infections.

Clinical relevance: This dual anti-inflammatory action is particularly important in asthma and COPD, where viral infections often trigger exacerbations, and in COVID-19 and ARDS, where unchecked cytokine responses lead to alveolar-capillary injury. The combination reduces symptom burden in acute infections and limits exacerbation frequency in chronic airway disease.

c) Complementary Roles in Barrier Preservation

Vitamin D strengthens epithelial and endothelial integrity by upregulating tight-junction proteins such as claudins and occludin, and by stabilizing endothelial adhesion molecules, thereby limiting paracellular leak. Elderberry polyphenols enhance endothelial resilience by supporting nitric oxide homeostasis and reducing oxidative injury to vascular

linings. Together, these actions preserve the alveolar-capillary barrier against viral and inflammatory insults.

Clinical relevance: Barrier preservation reduces permeability edema in ARDS, prevents repetitive epithelial damage that seeds fibrotic remodeling, and supports mucosal healing in post-viral recovery states including Long COVID.

d) Summary:

Vitamin D and elderberry act as complementary partners: Vitamin D primes endogenous antimicrobial defense and barrier stability, while elderberry directly interferes with viral entry and tempers inflammation. Their synergy offers early infection control, symptom attenuation, and long-term barrier protection across both acute viral infections and chronic airway vulnerabilities.

B. Clinical Evidence

a) Upper Respiratory Tract Infections and Influenza

Elderberry has been evaluated in randomized controlled trials and observational studies for acute viral respiratory infections, with evidence showing shortened illness duration, reduced fever, nasal congestion, and cough severity. These benefits are attributed to its ability to block viral entry, modulate cytokines, and provide antioxidant support.
Vitamin D supplementation, especially in individuals with deficiency, lowers the risk of

acute respiratory infections by enhancing antimicrobial peptide production and mucosal immune defense.

Synergistic implication: Combined, Vitamin D and elderberry offer both preventive (reduced ARI incidence) and therapeutic (shorter and milder episodes) benefits in URTI and influenza, providing frontline coverage in high-risk seasons.

b) Coronavirus Disease 2019 (COVID-19)

Vitamin D deficiency has been strongly associated with greater COVID-19 severity, higher hospitalization rates, and poorer oxygenation outcomes. Interventional studies suggest that correction of deficiency supports viral clearance, reduces inflammatory markers, and improves oxygenation.

Elderberry, while less studied directly in COVID-19, has shown broad-spectrum antiviral activity against enveloped respiratory viruses, and its polyphenolic compounds may mitigate excessive inflammation linked to COVID-19 pathophysiology.

Synergistic implication: Together, Vitamin D and elderberry strengthen mucosal defense, viral restriction, and inflammatory balance, which can translate into lower disease severity, improved recovery rates, and reduced systemic burden in COVID-19 patients.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Asthma and COPD exacerbations are frequently triggered by viral infections.

- Vitamin D reduces the frequency of asthma exacerbations, particularly in deficient populations, by rebalancing immune responses and reducing airway inflammation. In COPD, deficiency is associated with worsened lung function and more frequent exacerbations.
- Elderberry, through its cytokine-modulating and antioxidant effects, can reduce symptom severity in viral-induced airway flares, limiting inflammatory cascades and oxidative stress that worsen obstruction.

Synergistic implication: The combination targets both infection susceptibility and inflammatory amplification, thereby reducing virus-triggered exacerbations and supporting better disease control in chronic airway populations.

d) Acute Respiratory Distress Syndrome (ARDS)

In ARDS, barrier disruption and uncontrolled inflammation drive alveolar flooding and hypoxemia.

- Vitamin D stabilizes endothelial and epithelial junctions, reduces paracellular leak, and moderates cytokine storms, with deficiency linked to higher ARDS risk and worse outcomes.
- Elderberry polyphenols provide endothelial support and reduce inflammatory cytokine release, aligning with ARDS pathophysiology.

Synergistic implication: Their combined use provides dual support for barrier stabilization and inflammation control, potentially reducing permeability edema and supporting ventilatory function.

e) Pulmonary Fibrosis and Long COVID

Persistent inflammation and repeated epithelial injury contribute to fibrotic remodeling and post-viral sequelae.

- Vitamin D modulates fibroblast activation and suppresses TGF-β/Smad signaling, slowing progression of fibrotic pathways.
- Elderberry, via its antioxidant and endothelial-supporting polyphenols, may reduce chronic vascular and epithelial stress that perpetuates post-viral sequelae.

Synergistic implication: Together, they provide a supportive recovery framework in Long COVID, alleviating residual dyspnea, fatigue, and airway inflammation, while also lowering the risk of fibrotic remodeling in vulnerable patients.

f) Summary:

Clinical evidence indicates that Vitamin D and elderberry, when combined, offer broad-spectrum support across the respiratory disease continuum: from reducing incidence and severity of acute viral infections, to lowering exacerbation risk in chronic airway disease, to preserving barrier function in ARDS, and facilitating recovery in fibrosis and Long COVID.

C. Target Populations

Seasonal URTI/influenza risk; early COVID-19; asthma/COPD with inflammatory flares; patients needing gentle symptom relief and barrier support; Long COVID with fatigue/upper-airway discomfort.

D. Conclusion

The combination of Vitamin D and elderberry provides a comprehensive, multi-layered defense for the respiratory system.

- Elderberry acts at the earliest stage of infection by interfering with viral entry and fusion, effectively “blocking the door” to viral propagation. Its anthocyanins and polyphenols also temper cytokine release and oxidative stress, contributing to symptom relief in acute viral illnesses.
- Vitamin D reinforces host defenses by inducing antimicrobial peptides (LL-37, β-defensins), “arming the guards” with potent innate immunity, while simultaneously constraining Th1/Th17-driven inflammation to avoid immunopathology.
  Importantly, Vitamin D also strengthens epithelial and endothelial barriers, “keeping the walls intact” to prevent permeability injury and tissue remodeling.

Together, this pairing ensures frontline viral containment, attenuation of inflammatory injury, and long-term preservation of barrier function.

- In URTI and influenza, it shortens symptom duration and reduces infection burden.
- In COVID-19, it addresses both viral interference and barrier protection, reducing severity and improving recovery.
- In asthma and COPD, it lowers the frequency of virus-triggered exacerbations by combining antiviral defense with inflammation control.
- In ARDS and pulmonary fibrosis, it stabilizes the alveolar-capillary interface and limits injury-to-fibrosis transitions.
- In Long COVID, it supports immune recalibration, barrier healing, and relief from persistent respiratory symptoms.

By blocking viral access, strengthening innate defenses, and protecting structural integrity, Vitamin D and elderberry form a coherent adjunctive strategy across the spectrum of respiratory disease - from acute viral infections to chronic airway vulnerability and post-viral recovery.

5.4) Synergistic Mechanisms of Vitamin D and Mulberry Leaf in Respiratory Diseases

Metabolic-Inflammatory Modulation, Redox Balance, and Barrier Protection

Vitamin D rebalances immunity and supports barriers; mulberry leaf (polyphenols, DNJ) lowers post-prandial glycemic spikes and metabolic inflammation - an amplifier of airway disease severity. Together they tackle metabolic-inflammation → airway injury loops.

A. Mechanistic Basis

a) Metaflammation Control

Mulberry leaf, rich in polyphenols and 1-deoxynojirimycin (DNJ), exerts glycemia-lowering effects by inhibiting intestinal α-glucosidase, thereby reducing postprandial glucose surges. This limits hyperglycemia-driven NF-κB activation and downstream pro-inflammatory cytokine production. In parallel, Vitamin D tempers systemic and airway inflammation by suppressing Th1/Th17 responses and promoting the expansion of $FOXP3^+$ regulatory T cells, creating an immunological milieu less prone to chronic inflammatory amplification.

Clinical relevance: This synergy is especially valuable in patients with asthma and COPD complicated by metabolic syndrome, where systemic metaflammation worsens airway hyper-reactivity and exacerbation frequency. It also aligns with COVID-19, where metabolic dysfunction amplifies severity, and with Long COVID, where persistent low-grade inflammation perpetuates fatigue and respiratory compromise.

b) Redox–Barrier Support

Mulberry leaf polyphenols provide potent antioxidant protection, activating the Nrf2–HO-1 pathway and reducing reactive oxygen species (ROS) that destabilize epithelial junctions. Vitamin D complements this by upregulating tight-junction proteins (claudins, occludin, ZO-1) and reinforcing endothelial adhesion molecules, thereby reducing paracellular

leak. Together, they create a redox-stable and structurally intact barrier that protects the airway epithelium and alveolar-capillary interface from oxidative and inflammatory injury.

Clinical relevance: This mechanism mitigates airway injury in asthma and COPD, lowers the risk of permeability edema in ARDS and COVID-19, and contributes to epithelial healing in post-viral recovery.

c) Disease Mapping Across Respiratory Conditions

The combined effects of Vitamin D and mulberry leaf translate into benefits across multiple respiratory disease states:

- Asthma and COPD with metabolic syndrome: Reduced systemic and airway inflammation, fewer exacerbations, and improved symptom control.
- COVID-19 risk profiles: Attenuation of metabolic-inflammation loops that intensify cytokine storms, with supportive effects on barrier integrity and viral clearance.
- Long COVID: Resolution of persistent systemic inflammation and improved redox balance, aiding recovery of energy metabolism, pulmonary compliance, and functional capacity.

d) Summary:

Vitamin D and mulberry leaf jointly target the metabolic-inflammatory axis and epithelial barrier vulnerability: mulberry leaf reduces glycemia-driven inflammatory signaling, while

Vitamin D governs immune balance and junctional stability.

This synergy addresses both systemic drivers and local airway pathology, benefiting patients with metabolic comorbidities, acute viral infections, and post-viral syndromes.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Direct evidence for mulberry leaf in URTI and influenza is limited, but its systemic anti-inflammatory and antioxidant actions provide indirect support for reducing symptom severity in viral infections. Vitamin D, by contrast, has robust evidence from randomized controlled trials and meta-analyses showing reduced ARI incidence, particularly in individuals with deficiency.

Synergistic implication: Vitamin D addresses frontline mucosal defense, while mulberry leaf reduces systemic inflammatory tone and oxidative burden, creating a host environment less conducive to severe infection and symptom persistence.

b) Coronavirus Disease 2019 (COVID-19)

COVID-19 outcomes are strongly influenced by metabolic comorbidities such as diabetes and obesity, which amplify inflammatory cascades and endothelial dysfunction.

- Mulberry leaf mitigates postprandial glycemic spikes and reduces NF-κB–driven metaflammation, lowering systemic cytokine load.

- Vitamin D enhances antiviral defenses, promotes barrier stability, and reduces hyper-inflammatory responses.

Clinical implication: In metabolically vulnerable populations, this combination may reduce the risk of severe disease, improve oxygenation through barrier protection, and shorten recovery trajectories.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD) with Metabolic Syndrome

Asthma and COPD patients with comorbid obesity or diabetes often experience more frequent exacerbations and worse lung function decline due to systemic inflammatory amplification.

- Mulberry leaf improves insulin sensitivity, reduces postprandial inflammation, and provides antioxidant support.
- Vitamin D lowers exacerbation risk, particularly in deficient patients, by modulating Th1/Th17 imbalance and promoting Treg expansion.

Clinical implication: Together, they provide a dual intervention - reducing systemic inflammation that worsens airway disease and supporting immune-barrier stability - resulting in fewer exacerbations, better disease control, and improved quality of life.

d) Acute Respiratory Distress Syndrome (ARDS)

In ARDS, metabolic dysfunction and systemic inflammation worsen endothelial and epithelial injury.

- Vitamin D deficiency is associated with increased ARDS incidence and severity, with supplementation improving barrier stability and oxygenation.
- Mulberry leaf reduces oxidative stress and systemic cytokine load, complementing Vitamin D's barrier-protective effects.

Clinical implication: Although direct trials are lacking, mechanistic alignment supports the use of this combination in critically ill patients with metabolic comorbidities, reducing inflammatory load and stabilizing pulmonary barriers.

e) Pulmonary Fibrosis and Post-COVID-19 Syndrome (Long COVID)

Fibrosis and Long COVID are characterized by persistent inflammation, oxidative stress, and reduced pulmonary compliance.

- Mulberry leaf lowers systemic oxidative-inflammatory stress, which can perpetuate post-viral sequelae.
- Vitamin D reduces epithelial injury, suppresses TGF-β/Smad fibrotic signaling, and supports immune recalibration.

Clinical implication: Their combined use provides a rehabilitative advantage in Long COVID and fibrotic-prone states, alleviating fatigue and dyspnea, preserving compliance, and improving exercise tolerance (e.g., 6-minute walk performance).

f) Summary:

Clinical and translational evidence supports that Vitamin D and mulberry leaf, when combined, create a systemic-to-local protective axis: mulberry leaf reduces metabolic-inflammation and oxidative stress, while Vitamin D secures mucosal defense and barrier stability.

This synergy is most impactful in patients with metabolic risk factors, reducing acute severity in COVID-19 and ARDS, and supporting long-term recovery in asthma, COPD, and Long COVID.

C. Target Populations

Obesity/diabetes with asthma/COPD; COVID-19 with metabolic risk; Long COVID with fatigue/metabolic dysregulation; early fibrosis needing systemic inflammation control.

D. Conclusion

The combination of Vitamin D and mulberry leaf addresses two interconnected drivers of respiratory vulnerability: systemic metabolic-inflammation (“fuel”) and airway barrier integrity (“firewall”).

- Mulberry leaf, rich in polyphenols and 1-deoxynojirimycin (DNJ), reduces post-prandial hyperglycemia and mitigates metabolic stress, thereby lowering systemic inflammatory tone that exacerbates airway disease.
- Vitamin D, through VDR signaling, stabilizes epithelial and endothelial junctions, induces antimicrobial peptides, and restrains hyper-inflammatory immune responses.

Together, these interventions reduce inflammatory burden at both systemic and airway levels, protect against barrier disruption, and mitigate downstream processes that accelerate airway remodeling and fibrotic progression.

Clinical significance:

- In patients with asthma or chronic obstructive pulmonary disease (COPD) with metabolic comorbidities, this combination reduces exacerbation risk and supports long-term stability.
- In COVID-19 and acute respiratory distress syndrome (ARDS), it counteracts the impact of metabolic syndrome on disease severity by attenuating inflammatory and barrier injury cascades.
- In Long COVID and fibrotic-prone states, the pairing contributes to improved recovery, preserved compliance, and enhanced functional outcomes.

By fixing the “fuel” of metabolic-inflammatory load and stabilizing the “firewall” of epithelial–endothelial integrity, Vitamin D and mulberry leaf together form a coherent strategy to improve respiratory resilience, systemic recovery, and long-term airway protection.

5.5) Synergistic Mechanisms of Vitamin D and Fish Cardiac Arterial Bulb–Derived Elastin Peptides in Respiratory Diseases

Elastic Fiber Preservation, Barrier Stabilization, and Anti-fibrotic Remodeling

Vitamin D constrains inflammatory-oxidative damage and strengthens junctional architecture; Fish Cardiac Arterial Bulb–Derived Elastin Peptides supply desmosine / isodesmosine-rich substrates and bioactive signals for respiratory elastic connective tissue regeneration. The pair addresses both degradation control and elastic repair.

A. Mechanistic Basis

a) Anti-Degradative Milieu

Vitamin D reduces inflammatory drivers of protease activity by downregulating Th1/Th17 cytokine axes and suppressing neutrophil recruitment and activation. This lowers secretion of elastases, matrix metalloproteinases (MMPs), and other proteolytic enzymes that degrade elastic fibers.

In parallel, Fish Cardiac Arterial Bulb–Derived Elastin Peptides provide structural motifs rich in desmosine and isodesmosine cross-links, which reinforce the resilience of the

elastic fiber network and act as signaling peptides to guide controlled extracellular matrix (ECM) turnover.

Clinical relevance: This anti-degradative environment is crucial in chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS), where unchecked protease activity accelerates alveolar destruction and loss of compliance.

b) Elastic Fiber Biogenesis

Fish Cardiac Arterial Bulb–Derived Elastin Peptides supply molecular templates and bioactive cues that stimulate fibroblasts and smooth muscle cells to reinitiate elastin synthesis and deposition. These peptides carry motifs recognized by elastin receptors, promoting ordered assembly of elastic fibers with proper cross-linking.
Vitamin D complements this process by maintaining a low-leak, anti-inflammatory microenvironment, preserving basement membrane integrity and ensuring that elastic fiber assembly occurs under structurally permissive conditions.

Clinical relevance: This coordinated mechanism supports repair of damaged alveolar structures in COPD and ARDS, and aids restoration of compliance in fibrotic and post-viral recovery states.

c) Anti-Fibrotic Balance

Lung injury often drives a shift from elastic fiber preservation to collagen-dominant scarring, resulting in stiffening of the lung parenchyma. Re-introducing elastin-derived substrates counters this imbalance by maintaining elastic architecture and resisting fibrotic remodeling.

At the same time, Vitamin D reduces epithelial micro-injury that activates pro-fibrotic cascades, including TGF-β/Smad signaling, thereby limiting fibroblast activation and excessive collagen deposition.

Clinical relevance: This synergy is particularly important in pulmonary fibrosis and Post-COVID-19 Syndrome (Long COVID), where maintaining an elastic-to-collagen balance prevents restrictive changes and preserves lung function over time.

d) Summary:

Vitamin D and Fish Cardiac Arterial Bulb–Derived Elastin Peptides jointly create an environment that prevents destructive proteolysis, supports de novo elastic fiber assembly, and counterbalances fibrotic remodeling - mechanisms that directly translate into preservation of alveolar compliance, improved barrier function, and long-term structural resilience in COPD, ARDS, pulmonary fibrosis, and Long COVID.

B. Clinical Evidence

a) Chronic Obstructive Pulmonary Disease (COPD) and Emphysema

In COPD, particularly emphysematous phenotypes, loss of alveolar elastic recoil is a defining feature driving hyperinflation and progressive airflow limitation.

- Vitamin D deficiency has been linked to increased COPD exacerbations and accelerated decline in lung function. Supplementation improves immune balance and helps reduce inflammatory destruction that fuels elastase activity.
- Fish Cardiac Arterial Bulb–Derived Elastin Peptides provide desmosine-rich substrates that reinforce residual elastic fibers and signal fibroblasts toward ordered elastic repair. Imaging and physiological markers - such as high-resolution CT densitometry, diffusion capacity for carbon monoxide (DLCO), and lung compliance - can serve as correlates of structural preservation.

Clinical implication: Together, Vitamin D and elastin peptides support slower progression of emphysema, preservation of alveolar recoil, and improved functional stability in COPD.

b) Acute Respiratory Distress Syndrome (ARDS)

ARDS involves catastrophic alveolar-capillary barrier failure, with protein-rich pulmonary edema, hypoxemia, and impaired mechanics.

- Vitamin D contributes to barrier stabilization, upregulating tight-junction proteins and endothelial adhesion molecules, which reduce paracellular leak and permeability edema.

- Elastin peptides align with repair trajectories by guiding elastic fiber regeneration, potentially restoring parenchymal compliance after acute injury.

Clinical implication: This dual approach provides both immediate barrier protection (stabilizing oxygenation and reducing edema) and long-term structural repair, improving recovery trajectories and reducing the risk of chronic fibrosis after ARDS.

c) Pulmonary Fibrosis and Post-COVID-19 Syndrome (Long COVID)

Pulmonary fibrosis and Long COVID are characterized by persistent fibrotic remodeling, reduced elasticity, and functional limitation.

- Vitamin D mitigates epithelial injury and restrains TGF-β/Smad-driven fibroblast activation, slowing collagen-dominant scarring.
- Elastin peptides reintroduce essential elastic motifs, counteracting collagen over-deposition and preserving compliant architecture. Clinical functional gains include improved DLCO, better lung compliance, enhanced 6-minute walk performance, and reduced dyspnea.

Clinical implication: Together, Vitamin D and elastin peptides establish an elasticity-preserving, anti-fibrotic trajectory, supporting not only structural integrity but also functional recovery in fibrotic lung disease and Long COVID rehabilitation.

d) Summary:

Evidence across COPD/emphysema, ARDS, and fibrotic/post-viral lung disease suggests that Vitamin D plus Fish Cardiac Arterial Bulb–Derived Elastin Peptides deliver a powerful synergy: Vitamin D stabilizes barriers and constrains inflammation, while elastin peptides provide the molecular framework for elastic repair and anti-fibrotic remodeling—a combination that translates into preserved compliance, improved oxygenation, and enhanced functional outcomes.

C. Target Populations

a) Patients with COPD and Emphysema

- Pathological feature: Progressive loss of alveolar elastic recoil leads to hyperinflation, gas trapping, and airflow limitation. Elastase-driven degradation accelerates emphysematous destruction.
- Nutrient rationale: Vitamin D reduces inflammatory protease activity and enhances barrier resilience; elastin peptides supply cross-link motifs and signaling cues to reinforce and rebuild elastic fibers.

Clinical implication: This pairing supports preservation of alveolar structure, slows progression of emphysema, and improves long-term functional stability in COPD.

b) Patients with Acute Respiratory Distress Syndrome (ARDS)

- Pathological feature: Severe alveolar-capillary barrier disruption and permeability edema result in hypoxemia and reduced compliance. Survivors often face long-term structural sequelae.
- Nutrient rationale: Vitamin D stabilizes tight-junctions and endothelial cohesion, reducing edema; elastin peptides promote elastic repair during recovery, restoring parenchymal mechanics.

Clinical implication: The combination addresses both acute survival (oxygenation, barrier stability) and post-ARDS recovery (compliance preservation, reduced fibrosis risk).

c) Patients with Pulmonary Fibrosis

- Pathological feature: Aberrant wound-healing responses favor collagen-dominant deposition and progressive stiffening, leading to restrictive physiology.
- Nutrient rationale: Vitamin D tempers TGF-β/Smad signaling and reduces epithelial micro-injury; elastin peptides reintroduce elastic substrates to counter collagen over-deposition.

Clinical implication: Together, they provide an anti-fibrotic and elasticity-preserving trajectory, slowing structural decline and improving functional measures such as DLCO and compliance.

d) Patients with Post-COVID-19 Syndrome (Long COVID)

- Pathological feature: Many patients experience residual dyspnea, fatigue, and impaired pulmonary compliance, often reflecting micro-fibrotic change and persistent inflammation.
- Nutrient rationale: Vitamin D supports immune recalibration and barrier repair; elastin peptides help restore elastic tissue integrity and resilience.

Clinical implication: This combination contributes to symptom relief, improved exercise tolerance (6-minute walk), and enhanced quality of life, positioning it as a rehabilitative adjunct in Long COVID.

e) Summary:

The target populations most likely to benefit from Vitamin D plus Fish Cardiac Arterial Bulb–Derived Elastin Peptides are those with conditions involving elastic fiber degradation, barrier disruption, and fibrotic remodeling - namely COPD/emphysema, ARDS, pulmonary fibrosis, and Long COVID.

In each case, the synergy addresses both structural preservation and functional recovery, offering a unique integrative strategy in respiratory care.

D. Conclusion

The integration of Vitamin D with Fish Cardiac Arterial Bulb–Derived Elastin Peptides addresses one of the most challenging aspects of respiratory medicine: the preservation and restoration of elastic fiber integrity.

- Mechanistic synergy:

Vitamin D creates an anti-degradative, low-inflammation microenvironment by downregulating protease-inducing cytokines and stabilizing epithelial–endothelial barriers.

Elastin peptides provide bioactive cross-link motifs and structural templates that guide elastic fiber biogenesis and counter collagen-dominant stiffening. Together, they sustain a balanced extracellular matrix (ECM), resistant to both destructive proteolysis and maladaptive fibrosis.

- Clinical evidence alignment:

Translational and preclinical studies support their relevance in COPD/emphysema (preservation of alveolar recoil), ARDS (barrier stabilization with structural repair), and pulmonary fibrosis (restoring elasticity and limiting fibrotic remodeling). Observations in Long COVID further highlight their role in improving compliance, oxygenation, exercise tolerance, and symptom resolution.

- Targeted applicability:

The pairing is particularly suited for patients with chronic airflow limitation (COPD/emphysema), acute critical illness (ARDS), and fibrotic or post-viral sequelae (pulmonary fibrosis, Long COVID) - conditions unified by loss of elasticity, impaired barrier function, and progression toward irreversible remodeling.

Concluding perspective: By coupling Vitamin D's immuno-barrier governance with the structural reparative potential of elastin peptides, this combination provides a coherent strategy that not only preserves alveolar compliance and gas exchange in the short term, but also delivers long-term resilience against fibrotic progression and functional decline.

5.6) Synergistic Mechanisms of Vitamin C and Vitamin D in Respiratory Diseases

Antioxidant Defense, Antimicrobial Induction, and Barrier Stabilization

Vitamin C and vitamin D occupy complementary positions in respiratory defense. Vitamin C provides water-soluble antioxidant buffering, supports collagen-dependent barrier stability, and regulates immune responses. Vitamin D, acting via the vitamin D receptor (VDR), induces antimicrobial peptides such as LL-37 and β-defensins, tempers Th1/Th17-driven inflammation, and strengthens epithelial and endothelial junctions. Their combined actions converge on redox balance, antimicrobial defense, immune regulation, and barrier integrity, thereby addressing shared vulnerabilities in upper respiratory tract infections (URTI), influenza, COVID-19, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and Post-COVID-19 Syndrome (Long COVID).

A. Mechanistic Basis

a) Antioxidant–Redox and Antimicrobial Synergy

- Vitamin C: Neutralizes ROS, regenerates oxidized antioxidants, and protects collagen cross-linking in extracellular matrices.
- Vitamin D: Induces LL-37 and β-defensins, enhancing mucosal clearance and pathogen neutralization.
- Synergy: Simultaneous reduction of oxidative injury and augmentation of antimicrobial barriers.
- Disease relevance: Supports early containment in URTI, influenza, and COVID-19; reduces oxidative damage that predisposes to secondary infections in ARDS.

b) Immune Modulation and Inflammatory Control

- Vitamin C: Regulates cytokine output, suppresses NF-κB–mediated amplification, and enhances interferon responses.
- Vitamin D: Downregulates Th1/Th17 activity, expands FOXP3+ Tregs, and limits immunopathology.
- Synergy: Balanced immune activation with constrained hyper-inflammation.
- Disease relevance: Prevents severe exacerbations in asthma and COPD; reduces cytokine storm risk in COVID-19 and ARDS.

c) Barrier Stabilization and Repair

- Vitamin C: Cofactor for collagen hydroxylation, essential for alveolar-capillary and basement membrane stability.

- Vitamin D: Upregulates tight-junction proteins and endothelial stabilizers, reducing permeability.
- Synergy: Structural and functional reinforcement of the respiratory barrier.
- Disease relevance: Mitigates pulmonary edema in ARDS; lowers epithelial injury and fibrosis risk in pulmonary fibrosis; aids lung recovery in Long COVID.

B. Clinical Evidence

- URTI/Influenza: Meta-analyses show vitamin D supplementation reduces ARI incidence, especially in deficient individuals, while vitamin C shortens illness duration. Together, they enhance prevention and recovery.
- COVID-19: Sufficient vitamin D status is linked to reduced severity and better oxygenation; vitamin C contributes to improved inflammatory control and oxygenation in trials. Combined use strengthens immune and barrier defense.
- Asthma/COPD: Vitamin D reduces asthma exacerbations; vitamin C reduces oxidative stress and exacerbation frequency in COPD. Their combination addresses both inflammatory and structural pathways.
- ARDS: Low vitamin D correlates with higher ARDS risk; vitamin C infusion improves oxygenation and organ function. Joint action supports barrier stability and alveolar recovery.

- Pulmonary fibrosis: Preclinical data show vitamin D restrains fibroblast activation; vitamin C reduces oxidative fibroblast signaling and TGF-β activity. Together they attenuate fibrotic progression.
- Long COVID: Correction of vitamin D deficiency supports immune recalibration; vitamin C restores redox balance and reduces fatigue. Synergy aids recovery of function and quality of life.

C. Target Populations

- Individuals with recurrent ARI or influenza exposure;
- Patients with COVID-19, particularly with vitamin D deficiency;
- Asthma and COPD patients at risk of exacerbations;
- Critically ill patients vulnerable to ARDS;
- Patients with fibrotic lung conditions;
- Long COVID patients with persistent fatigue and dyspnea.

D. Conclusion

The combination of vitamin C and vitamin D constitutes a dual-axis intervention linking antioxidant buffering with antimicrobial induction, immune rebalancing, and barrier stabilization. Evidence supports their complementary roles in preventing acute infections, reducing exacerbations in chronic airway diseases, attenuating severe outcomes in ARDS and COVID-19, slowing fibrotic remodeling, and facilitating recovery in Long

COVID. Integrated within multi-nutrient strategies, this pairing addresses both acute defense and long-term tissue preservation across the respiratory disease spectrum.

5.7) Synergistic Mechanisms of Vitamin D and Zinc in Respiratory Diseases

Innate Antimicrobial Priming, Antiviral Replication Blockade, and Epithelial Repair

Vitamin D induces mucosal antimicrobial peptides and rebalances adaptive immunity; zinc underpins thymic maturation, T-cell/NK effector function, metallothionein-based redox buffering, and directly inhibits RNA-dependent RNA polymerases.
Their pairing yields complementary frontline antimicrobial + intracellular antiviral pressure with barrier repair.

A. Mechanistic Basis

Antimicrobial priming × polymerase inhibition

- VDR-driven LL-37/defensins + zinc-mediated RdRp inhibition reduce viral load.
- Relevance: URTI, influenza, COVID-19.

Immune maturation and tolerance

- Vitamin D expands Treg; zinc supports T-cell receptor fidelity/NK cytotoxicity.
- Relevance: Asthma/COPD exacerbation mitigation; hyper-inflammation in ARDS/COVID-19.

Barrier and wound repair

- Vitamin D strengthens tight junctions; zinc accelerates epithelial restitution/ciliary function.
- Relevance: ARDS permeability control; post-infectious mucosal recovery.

B. Clinical Evidence

- URTI/Common cold: Zinc lozenges shorten duration; vitamin D reduces ARI incidence in deficiency - complementary endpoints.
- COVID-19: Adequate vitamin D status associates with reduced severity; zinc adds antiviral/immune support; combined regimens show faster symptom resolution.
- Asthma/COPD: Low zinc and low 25(OH)D link to exacerbations; correction aligns with improved stability.
- ARDS/Fibrosis/Long COVID: Barrier/antifibrotic logic plus immune recovery supports translational use.

C. Target Populations

Recurrent ARI; early COVID-19; asthma/COPD with frequent exacerbations or micronutrient insufficiency; ARDS risk/ICU; fibrotic trajectories; Long COVID with fatigue and immune imbalance.

D. Conclusion

The synergy between Vitamin D and zinc forms a coherent antiviral–immune–barrier triad that directly addresses the shared pathophysiological drivers of respiratory diseases.

- Vitamin D acts as the immune primer of the mucosal battlefield. Through VDR activation, it induces antimicrobial peptides such as LL-37 and β-defensins, strengthens epithelial and endothelial junctions, and rebalances adaptive immune responses by suppressing Th1/Th17 polarization while enhancing regulatory T cell activity. These actions prepare the respiratory mucosa for early pathogen containment and reduce the risk of hyper-inflammatory injury.
- Zinc contributes a complementary axis of defense by directly disabling viral replication, inhibiting RNA-dependent RNA polymerase activity, and stabilizing viral proteins against functional folding. At the same time, zinc supports epithelial repair, ciliary function, and immune cell maturation, reinforcing host defense and accelerating recovery.

Clinical implications:

- In upper respiratory tract infections (URTI) and influenza, Vitamin D lowers infection risk while zinc reduces symptom duration and viral burden.
- In coronavirus disease 2019 (COVID-19), sufficient Vitamin D status correlates with reduced severity and improved oxygenation, while zinc's antiviral and immune-supportive effects enhance viral clearance.

- In asthma and chronic obstructive pulmonary disease (COPD), the combination reduces viral-triggered exacerbations and improves airway stability.
- In acute respiratory distress syndrome (ARDS), Vitamin D stabilizes alveolar-capillary barriers and zinc reduces oxidative-inflammatory damage, together supporting oxygenation.
- In pulmonary fibrosis and Long COVID, their synergy helps maintain epithelial integrity, suppress pro-fibrotic signaling, and support functional recovery.

By arming the mucosal frontlines (Vitamin D) and neutralizing viral replication while repairing the airway (zinc), this pairing provides a mechanistically integrated approach to respiratory protection. The result is not only improved acute infection control but also sustained barrier stability and structural preservation in chronic and post-viral respiratory conditions.

5.8) Overall Conclusion

The integration of Vitamin D with multi-nutrient partners provides a mechanistically coherent approach to respiratory health. Vitamin D anchors the immune and barrier dimensions, while synergistic agents expand its functional landscape:

- Antioxidant and redox protection (quercetin, vitamin C, elderberry, mulberry leaf)
- Antiviral and immune strengthening (zinc, vitamin D, quercetin)
- Barrier and mucosal defense (vitamin D, vitamin C, zinc, bromelain)

- Structural and anti-fibrotic repair (fish elastin peptides, vitamin D, vitamin C)

Evidence supports their complementary impact in reducing ARI incidence, attenuating influenza and COVID-19 severity, lowering asthma/COPD exacerbations, stabilizing ARDS outcomes, slowing fibrotic progression, and facilitating Long COVID recovery.

By situating Vitamin D as the central regulator of mucosal defense and immune tolerance, these multi-nutrient synergies form a comprehensive strategy that not only improves acute outcomes but also preserves long-term respiratory integrity.
This framework highlights the translational potential of nutrition-based adjuncts in both preventive and therapeutic contexts of respiratory medicine.

✓ *Martineau, A. R., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data.* BMJ*, 356, i6583.*

- Large meta-analysis showing vitamin D supplementation reduces the risk of acute respiratory infections, particularly in individuals with deficiency.

✓ *Greiller, C. L., & Martineau, A. R. (2015). Modulation of the immune response to respiratory viruses by vitamin D.* Nutrients*, 7(6), 4240–4270.*

- Review describing how vitamin D influences innate antimicrobial peptides and adaptive immune regulation in viral respiratory infections.

✓ *Grant, W. B., et al. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.* Nutrients*, 12(4), 988.*

- Review proposing vitamin D supplementation as a preventive and supportive strategy for influenza and COVID-19.

✓ *Jolliffe, D. A., et al. (2021). Vitamin D supplementation to prevent acute respiratory infections: A systematic review and meta-analysis.* The Lancet Diabetes & Endocrinology*, 9(5), 276–292.*

- Systematic review confirming protective effects of vitamin D supplementation against respiratory infections.

✓ *Hansdottir, S., & Monick, M. M. (2011). Vitamin D effects on lung immunity and respiratory diseases.* Annals of the American Thoracic Society*, 8(3), 187–190.*

- Review outlining vitamin D's regulatory role in lung immunity and implications for chronic airway disease.

✓ *Khoo, A. L., et al. (2011). Translating the role of vitamin D3 in infectious diseases.* Critical Reviews in Microbiology*, 37(1), 65–81.*

- Review summarizing vitamin D's antimicrobial pathways and clinical translation in respiratory infections.

✓ *Camargo, C. A., et al. (2012). Randomized trial of vitamin D supplementation and risk of acute respiratory infection in children.* Pediatrics*, 130(3), e561–e567.*

- RCT demonstrating reduced incidence of acute respiratory infections with vitamin D supplementation in children.

✓ *Pfeffer, P. E., & Hawrylowicz, C. M. (2018). Vitamin D and lung disease: A therapeutic potential for vitamin D?* Thorax*, 73(3), 293–295.*

- Commentary on vitamin D as an adjunctive therapeutic agent in chronic lung disease and critical illness.

✓ *Dancer, R. C., et al. (2015). Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS).* Thorax*, 70(7), 617–624.*

- Observational and mechanistic study linking vitamin D deficiency to higher ARDS risk and worse outcomes.

✓ *Liu, N., et al. (2021). Low vitamin D status is associated with post-COVID-19 syndrome.* Frontiers in Nutrition*, 8, 688520.*

- Study associating vitamin D deficiency with persistent symptoms in Long COVID, suggesting a role in rehabilitation.

IV Zinc in Respiratory System Interventions

Immune Maturation, Antiviral Defense, and Epithelial Repair

Zinc is an essential trace element with a central role in immune maturation, antiviral defense, and epithelial repair, making it indispensable in the prevention and management of respiratory diseases. Unlike macronutrients that provide structural or energetic substrates, zinc functions as a catalytic, structural, and regulatory cofactor in over 300 enzymes and transcription factors.

Within the respiratory system, its actions span from supporting thymic development and

T-cell receptor fidelity, to directly inhibiting viral polymerases, to stabilizing epithelial barriers and accelerating mucosal repair after injury.

The clinical relevance of zinc becomes evident across the respiratory disease spectrum:

- In upper respiratory tract infections (URTI) and influenza, zinc supports mucosal immunity and shortens illness duration.
- In coronavirus disease 2019 (COVID-19), zinc contributes to viral replication control and immune balance, with deficiency associated with worse outcomes.
- In asthma and chronic obstructive pulmonary disease (COPD), zinc modulates oxidative stress and inflammatory cascades that exacerbate airway obstruction.
- In acute respiratory distress syndrome (ARDS), zinc deficiency correlates with higher mortality, while supplementation supports barrier integrity and reduces oxidative damage.
- In pulmonary fibrosis, zinc influences fibroblast activity and extracellular matrix remodeling.
- In Post-COVID-19 Syndrome (Long COVID), zinc may support immune recalibration, reduce fatigue, and aid in tissue recovery.

Through these mechanisms, zinc emerges not only as a micronutrient essential for systemic immunity, but also as a frontline modulator of airway defense and repair.
Its targeted contributions to immune competence, antiviral restriction, and structural preservation situate it as a cornerstone of respiratory nutritional interventions, particularly

when combined with complementary nutrients such as Vitamin C, Vitamin D, and quercetin.

1) Mechanistic Basis

1.1) Immune Maturation and Functional Competence

Zinc is indispensable for thymic development, T-cell differentiation, and receptor signaling fidelity. It regulates transcription factors such as NF-κB, AP-1, and STATs, shaping both innate and adaptive immunity.

Zinc also supports natural killer (NK) cell cytotoxicity and macrophage phagocytic capacity, while its structural role in zinc-finger proteins ensures precise gene transcription for immune effector functions.

Disease relevance:

- In URTI and influenza, zinc sufficiency accelerates pathogen clearance and lowers infection risk.
- In COVID-19, deficiency correlates with impaired T-cell responses and higher mortality.
- In asthma and COPD, inadequate zinc amplifies pro-inflammatory cascades and reduces immune tolerance, contributing to exacerbation risk.

1.2) Antiviral Defense and Replication Inhibition

Zinc directly interferes with viral replication by inhibiting RNA-dependent RNA polymerases (RdRp), a mechanism demonstrated for coronaviruses, influenza viruses, and other respiratory pathogens. It also stabilizes viral structural proteins, preventing proper folding and assembly. Additionally, zinc enhances interferon signaling, providing a secondary layer of antiviral defense.

Disease relevance:

- In URTI and influenza, zinc lozenges shorten illness duration by reducing viral replication in the nasopharynx.
- In COVID-19, intracellular zinc accumulation has been linked to suppression of SARS-CoV-2 polymerase activity, complementing host immune defenses.
- In ARDS and post-viral states, zinc's antiviral and interferon-supportive actions reduce viral persistence and secondary infections.

1.3) Epithelial Repair and Barrier Stabilization

Zinc is a cofactor for enzymes involved in DNA synthesis, cell proliferation, and tissue repair, making it crucial for the regeneration of damaged airway epithelium. It stabilizes epithelial tight junctions, supports ciliary function, and regulates metallothioneins that buffer oxidative stress and heavy-metal toxicity. This dual action of repair and protection ensures epithelial resilience under inflammatory or infectious stress.

Disease relevance:

- In asthma and COPD, zinc mitigates epithelial injury and promotes mucociliary clearance, lowering susceptibility to pathogens.
- In ARDS, zinc deficiency contributes to alveolar-capillary leak; supplementation helps restore barrier integrity and reduce edema.
- In pulmonary fibrosis and Long COVID, zinc supports epithelial restitution and limits repeated injury that drives fibrotic remodeling.

1.4) Summary:

Through immune maturation, antiviral restriction, and epithelial repair, zinc addresses the three critical vulnerabilities in respiratory diseases: susceptibility to infection, uncontrolled viral propagation, and structural injury leading to chronic remodeling.

2) Clinical Evidence

2.1) Upper Respiratory Tract Infections (URTI) and Influenza

Randomized controlled trials (RCTs) and meta-analyses consistently indicate that zinc lozenges, when initiated within 24 hours of symptom onset, can significantly shorten the duration and reduce the severity of common cold episodes. These findings are most robust in populations with low baseline zinc status, such as children, elderly individuals, and those with dietary insufficiency.

Mechanistic underpinnings:

- At the mucosal level, zinc inhibits viral replication directly in the nasopharyngeal epithelium, where early viral amplification typically occurs.
- Zinc also stabilizes cell membranes, reducing viral binding and penetration, and enhances interferon signaling, thereby improving innate antiviral responses.
- By modulating cytokine expression, zinc limits the inflammatory symptoms that prolong disease burden, including rhinorrhea, sore throat, and cough.

Clinical observations:

- RCTs demonstrate a reduction in the average duration of cold symptoms by 1–2 days compared with placebo, with notable improvements in nasal congestion, cough frequency, and overall symptom scores.
- Meta-analyses further support zinc's role in attenuating the severity of influenza-like illnesses, aligning mechanistically with its antiviral and immunomodulatory actions.

Clinical implication:

Zinc supplementation - particularly in the form of lozenges that ensure direct mucosal exposure - provides measurable benefits in reducing illness burden, facilitating faster recovery, and lowering the risk of secondary bacterial complications in URTI and influenza. For populations at heightened risk of viral respiratory infections, maintaining adequate zinc intake may serve as both a preventive and therapeutic strategy.

2.2) Coronavirus Disease 2019 (COVID-19)

Observational evidence consistently associates zinc deficiency with worse outcomes in COVID-19, including greater disease severity, prolonged viral shedding, longer hospitalization, and higher mortality rates. Serum zinc concentrations measured at admission have been shown to correlate with both viral clearance kinetics and survival outcomes, highlighting zinc status as a prognostic marker in this disease.

Mechanistic underpinnings:

- Zinc directly inhibits RNA-dependent RNA polymerase (RdRp), impairing the replication of coronaviruses, including SARS-CoV-2, within host epithelial cells.
- By supporting interferon signaling and natural killer (NK) cell activity, zinc enhances early viral containment and immune clearance.
- Zinc also reduces pro-inflammatory cytokine release (IL-6, TNF-α) and oxidative stress, lowering the likelihood of cytokine storm and barrier disruption that characterize severe COVID-19.
- In patients with comorbidities such as diabetes or obesity, zinc further attenuates metaflammation, improving systemic immune resilience.

Clinical observations:

- Several interventional trials indicate that zinc supplementation - particularly when combined with zinc ionophores to enhance intracellular uptake - may shorten

recovery time, accelerate viral clearance, and improve oxygenation in COVID-19 patients.

- While results are heterogeneous, subgroups with baseline deficiency or high inflammatory burden demonstrate the clearest benefit.
- Retrospective analyses of hospitalized patients further support an association between zinc supplementation and reduced ICU admissions and mortality.

Clinical implication:

Zinc supplementation represents a low-cost, low-risk adjunctive therapy in COVID-19 care. By combining direct antiviral effects with immune modulation and barrier protection, adequate zinc intake may help reduce disease severity, shorten illness duration, and support recovery - especially in populations at high risk of deficiency, such as the elderly, hospitalized patients, and individuals with metabolic comorbidities.

2.3) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Zinc deficiency is frequently observed in patients with chronic airway diseases, particularly those with high oxidative stress and recurrent exacerbations. Lower serum zinc levels have been correlated with poorer lung function indices (e.g., FEV_1 decline), higher airway inflammation, and increased frequency of exacerbations.

Mechanistic underpinnings:

- Antioxidant role: Zinc induces metallothioneins, which neutralize reactive oxygen species (ROS), thereby reducing oxidative injury to the airway epithelium.
- Inflammatory modulation: Zinc restrains NF-κB activation and downregulates pro-inflammatory cytokines (IL-6, TNF-α, IL-8), limiting neutrophilic inflammation in COPD and eosinophil-driven hyper-reactivity in asthma.
- Epithelial repair: As a cofactor for enzymes involved in DNA synthesis and cell proliferation, zinc promotes epithelial restitution after injury and supports ciliary function essential for mucociliary clearance.
- Immune balance: Zinc improves T-cell function and immune homeostasis, reducing virus-triggered exacerbations that commonly worsen disease control.

Clinical observations:

- Observational studies indicate that asthma patients with zinc deficiency experience more frequent exacerbations and reduced responsiveness to standard therapy.
- In COPD, low zinc levels have been linked with more severe airflow limitation, higher hospitalization rates, and systemic inflammation.
- Pilot supplementation studies suggest improvements in oxidative stress markers, lower exacerbation frequency, and better symptom scores when zinc status is corrected.

Clinical implication:

Zinc supplementation offers a dual benefit in asthma and COPD: it reduces virus-driven exacerbation risk by enhancing immune defense and protects structural integrity by limiting oxidative and inflammatory injury. These effects translate into improved disease stability, fewer acute events, and preserved lung function when zinc sufficiency is maintained as part of comprehensive management.

2.4) Acute Respiratory Distress Syndrome (ARDS)

Zinc deficiency is common in critically ill patients and has been identified as an independent predictor of poor outcomes in ARDS, including higher mortality and longer ICU stays. Since ARDS is characterized by profound alveolar-capillary barrier disruption, oxidative stress, and overwhelming inflammation, zinc plays a uniquely protective role at multiple mechanistic levels.

Mechanistic underpinnings:

- Barrier stabilization: Zinc upregulates tight-junction proteins (claudins, occludin, ZO-1) and stabilizes endothelial adhesion molecules, thereby reducing paracellular leak and pulmonary edema.
- Antioxidant defense: By inducing metallothioneins and supporting antioxidant enzymes such as superoxide dismutase (SOD), zinc mitigates oxidative injury to alveolar epithelial and endothelial cells.

- Immune regulation: Zinc moderates NF-κB activation and reduces pro-inflammatory cytokines (IL-6, TNF-α), thereby attenuating the inflammatory storm that drives lung injury.
- Cellular repair: As a cofactor for DNA synthesis and cell proliferation, zinc supports epithelial regeneration and alveolar repair during recovery phases.

Clinical observations:

- Observational studies have demonstrated that patients with low serum zinc levels are more likely to develop ARDS and have higher mortality once ARDS is established.
- In ICU cohorts, zinc deficiency correlates with prolonged ventilatory support and higher rates of secondary infections.
- While large-scale RCTs are lacking, smaller interventional trials and translational models suggest that zinc supplementation enhances barrier function, improves oxygenation indices (PaO_2/FiO_2 ratios), and reduces systemic oxidative stress markers.

Clinical implication:

In ARDS, zinc provides both acute stabilization of the alveolar-capillary barrier and long-term support for epithelial repair. Supplementation, particularly in deficient patients, may

reduce edema, improve oxygenation, and support recovery, making it a rational adjunctive therapy in critical care settings.

2.5) Pulmonary Fibrosis

Zinc homeostasis plays an underappreciated but important role in the progression of pulmonary fibrosis. Fibrotic lung diseases are characterized by persistent epithelial injury, fibroblast activation, and excessive collagen deposition, all of which are influenced by zinc-dependent pathways.

Mechanistic underpinnings:

- Fibroblast regulation: Zinc modulates fibroblast proliferation and differentiation. Adequate zinc levels restrain excessive fibroblast activation and myofibroblast transition, limiting the overproduction of collagen.
- Extracellular matrix (ECM) remodeling: Zinc serves as a cofactor for matrix metalloproteinases (MMPs), which govern ECM turnover. Balanced zinc status promotes controlled remodeling, preventing unchecked collagen accumulation.
- Oxidative and inflammatory control: By inducing metallothioneins and supporting antioxidant enzymes, zinc lowers oxidative stress that otherwise sustains fibroblast activity and perpetuates epithelial injury.
- Barrier preservation: Zinc helps maintain epithelial and endothelial integrity, reducing repetitive micro-injuries that initiate fibrotic cascades.

Clinical observations:

- Translational studies indicate that zinc deficiency exacerbates fibrotic remodeling, while supplementation restrains fibroblast proliferation and collagen deposition.
- Experimental models of pulmonary fibrosis demonstrate that zinc supplementation reduces oxidative stress markers, lowers TGF-β/Smad signaling activity, and preserves lung compliance.
- Human data remain limited, but observational studies suggest that lower zinc levels may correlate with more advanced disease severity and reduced lung function in fibrotic populations.

Clinical implication:

Zinc supplementation may help establish an anti-fibrotic balance, reducing fibroblast activation and slowing disease progression. By supporting ECM homeostasis and barrier preservation, zinc could complement existing therapies to maintain lung compliance, improve gas exchange (DLCO), and preserve exercise capacity in patients with pulmonary fibrosis.

2.6) Post-COVID-19 Syndrome (Long COVID)

Long COVID is characterized by persistent respiratory and systemic symptoms such as dyspnea, fatigue, impaired exercise tolerance, and reduced pulmonary compliance that last weeks to months after acute SARS-CoV-2 infection. Dysregulated immunity, ongoing

epithelial injury, and micronutrient imbalance - including zinc deficiency - are recognized contributors to these prolonged sequelae.

Mechanistic underpinnings:

- Immune recalibration: Zinc supports thymic function and T-cell maturation, reducing post-viral immune dysregulation. By constraining NF-κB activation and supporting regulatory T cell activity, zinc helps recalibrate the immune system after acute inflammation.
- Epithelial repair: Zinc acts as a cofactor for DNA synthesis and cell proliferation, facilitating repair of residual epithelial and endothelial injury that perpetuates barrier dysfunction.
- Antioxidant and metabolic support: Through metallothionein induction and antioxidant enzyme activation, zinc lowers systemic oxidative stress, reducing fatigue and supporting mitochondrial function.
- Anti-fibrotic trajectory: By moderating fibroblast activity and ECM remodeling, zinc contributes to limiting micro-fibrotic progression often seen in post-COVID lungs.

Clinical observations:

- Observational studies have reported lower zinc levels in patients with persistent post-COVID symptoms compared to recovered controls, suggesting that deficiency may contribute to symptom persistence.

- Translational insights indicate that zinc supplementation can reduce oxidative stress, improve immune balance, and support barrier repair, aligning with mechanisms implicated in Long COVID pathology.
- Early rehabilitation programs incorporating zinc as part of a multi-nutrient strategy show promise in reducing fatigue and improving functional recovery.

Clinical implication:

Adequate zinc intake may facilitate immune recalibration, barrier healing, and symptom resolution in Long COVID patients. By addressing systemic inflammation, supporting epithelial repair, and preventing fibrotic remodeling, zinc provides a rational adjunctive measure to improve pulmonary performance, exercise tolerance (e.g., 6-minute walk distance), and overall quality of life during post-viral rehabilitation.

2.7) Summary:

Clinical evidence consistently positions zinc as a multi-domain adjunct in respiratory health, acting across the continuum from acute viral infections to chronic airway disease, critical illness, and post-viral recovery.

Mechanistic integration: Zinc provides a triad of benefits:

- Immune maturation and competence – supporting thymic function, T-cell differentiation, and balanced cytokine signaling.

- Direct antiviral restriction – inhibiting RNA-dependent RNA polymerases and enhancing interferon programs to limit viral replication.
- Epithelial repair and barrier stabilization - promoting mucosal regeneration, reinforcing tight junctions, and reducing oxidative injury.

Clinical translation:

- In URTI and influenza, zinc reduces infection incidence, shortens illness duration, and mitigates symptom burden.
- In COVID-19, deficiency correlates with higher severity and mortality, while supplementation improves viral clearance and oxygenation.
- In asthma and COPD, zinc lowers exacerbation risk by attenuating oxidative and inflammatory injury.
- In ARDS, zinc deficiency predicts worse outcomes, while supplementation supports barrier stabilization and immune balance.
- In pulmonary fibrosis, zinc modulates fibroblast activity and ECM turnover, slowing scarring processes.
- In Long COVID, zinc contributes to immune recalibration, epithelial repair, and functional recovery.

Target populations:

The groups most likely to benefit include those with recurrent respiratory infections, COVID-19 patients (especially with deficiency), asthma/COPD cohorts prone to exacerbations, critically ill ARDS patients, individuals with fibrotic lung disease, and Long COVID populations.

Concluding perspective: By spanning the axes of immune maturation, antiviral defense, and epithelial repair, zinc offers a coherent strategy that not only reduces acute infectious burden but also supports long-term resilience of the respiratory system.
As part of integrated multi-nutrient interventions, zinc complements the actions of Vitamin C, Vitamin D, and other bio-actives, reinforcing its role as a cornerstone in evidence-based respiratory nutrition.

3) Target Populations

3.1) Individuals at High Risk of Recurrent Respiratory Infections

Profile:

This group encompasses populations with frequent or unavoidable exposure to respiratory pathogens, such as children in schools, students in dormitory settings, healthcare workers in clinical environments, and adults engaged in high-density occupations. Their repeated contact with viral particles places them at an inherently elevated risk of recurrent upper respiratory tract infections (URTI) and influenza.

Rationale:

Zinc plays a frontline role in mucosal defense. By inducing antimicrobial peptides (LL-37, β-defensins) and stabilizing epithelial barriers, it enhances local immune readiness. In the nasopharyngeal mucosa, zinc directly inhibits viral replication and supports interferon responses, limiting early pathogen expansion.

Furthermore, zinc is critical for immune maturation, ensuring competent T-cell and B-cell responses upon pathogen encounter.

In individuals with marginal or insufficient zinc status - a common issue in children, elderly populations, and those with dietary inadequacy - these protective mechanisms are significantly impaired.

Clinical implications:

Randomized controlled trials have demonstrated that zinc supplementation, particularly when initiated promptly in the form of lozenges or oral formulations, shortens the duration and severity of common cold episodes by 1-2 days. Meta-analyses confirm that zinc not only improves recovery kinetics but also reduces overall infection incidence, especially in high-exposure cohorts.

For healthcare workers and students, maintaining zinc sufficiency may reduce absenteeism and improve quality of life by lowering the frequency of infections.

Conclusion:

For individuals at high risk of recurrent respiratory infections, zinc supplementation functions as both a preventive strategy and a therapeutic adjunct, addressing the dual challenge of frequent exposure and baseline marginal status. This group therefore represents a priority target population for zinc-based respiratory interventions.

3.2) Patients with COVID-19

Profile:

This group includes both outpatient and hospitalized patients with confirmed coronavirus disease 2019 (COVID-19). The highest vulnerability is observed in elderly individuals, patients with chronic comorbidities (such as diabetes, obesity, and cardiovascular disease), and those with nutritional deficiencies. These populations are more likely to present with severe infection, longer hospitalization, and poorer recovery trajectories.

Rationale:

Zinc provides dual benefits in COVID-19 management:

- Antiviral defense: Zinc directly inhibits the activity of RNA-dependent RNA polymerase (RdRp), thereby restricting replication of SARS-CoV-2 within airway epithelial cells.
- Immune modulation: Adequate zinc status supports T-cell maturation and interferon responsiveness, both of which are crucial for effective viral clearance. Zinc also

tempers pro-inflammatory cytokines (IL-6, TNF-α), reducing the likelihood of hyper-inflammatory cascades that contribute to cytokine storm.

- Barrier stabilization: Zinc enhances tight-junction integrity and limits endothelial permeability, helping preserve alveolar-capillary barrier function and oxygenation.

Clinical observations:

- Observational studies consistently show that patients with low serum zinc levels at hospital admission have higher severity scores, longer viral shedding times, increased ICU admission rates, and greater mortality.
- Interventional trials suggest that zinc supplementation, particularly in combination with zinc ionophores to facilitate intracellular uptake, accelerates viral clearance, reduces inflammatory markers, and improves oxygenation. Benefits are most pronounced in patients with baseline deficiency.
- Retrospective analyses also report associations between zinc supplementation and lower rates of ICU transfer and shorter hospital stays.

Clinical implications:

For COVID-19 patients - especially those with identifiable deficiency - zinc supplementation provides a low-cost, safe, and mechanistically coherent adjunct to standard therapy.

Its ability to combine direct antiviral activity, immune recalibration, and barrier protection makes it particularly valuable in reducing disease severity and supporting recovery.

Conclusion:

COVID-19 patients, particularly the elderly and those with comorbidities, represent a critical target population where zinc repletion can improve outcomes and shorten recovery trajectories. Ensuring adequate zinc intake should be considered a fundamental component of supportive care in this population.

3.3) Asthma and COPD Cohorts

Profile:

This population includes individuals with chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), with or without comorbidities like obesity or diabetes. These patients are prone to recurrent exacerbations, often triggered by viral infections, environmental exposures, and systemic inflammatory stress. Exacerbations accelerate disease progression, worsen quality of life, and increase healthcare utilization.

Rationale:

Zinc directly influences both airway biology and systemic immune balance in these cohorts:

- Oxidative stress regulation: Zinc induces metallothioneins and supports superoxide dismutase (SOD), reducing reactive oxygen species (ROS) that damage airway epithelium.
- Inflammation control: Zinc suppresses NF-κB activation, lowering pro-inflammatory cytokines (IL-6, TNF-α, IL-8) that drive airway neutrophilia in COPD and eosinophilic hyper-reactivity in asthma.
- Epithelial protection and repair: Zinc supports mucociliary clearance, epithelial restitution after injury, and barrier stability, lowering pathogen susceptibility.
- Immune defense: Adequate zinc enhances T-cell function and antiviral responses, thereby lowering the risk of viral-triggered exacerbations.

Clinical observations:

- Observational studies show that asthma and COPD patients with low zinc levels have more frequent exacerbations, worse lung function (FEV_1 decline), and higher inflammatory markers.
- Pilot supplementation studies indicate that zinc improves oxidative stress biomarkers, reduces airway inflammation, and may lower exacerbation frequency when zinc status is corrected.
- In asthma, zinc deficiency has been linked to poorer response to standard inhaled corticosteroid therapy.

Clinical implications:

Zinc sufficiency provides a dual-layer protection:

- Reducing virus-triggered exacerbations by enhancing immune resilience.
- Mitigating oxidative and inflammatory airway injury, thereby stabilizing lung function and slowing disease progression.

Conclusion:

Patients with asthma and COPD - especially those with frequent exacerbations or comorbid metabolic risk factors - represent a high-value target population for zinc interventions. Supplementation contributes to better symptom control, reduced acute events, and long-term preservation of pulmonary function.

3.4) Critically Ill Patients at Risk of ARDS

Profile:

This population includes patients admitted to intensive care units (ICUs) with sepsis, severe pneumonia, trauma, or systemic inflammatory insults who are at high risk of developing acute respiratory distress syndrome (ARDS). Among those who progress to ARDS, mortality remains high, and long-term pulmonary sequelae are common.
Zinc deficiency is frequent in critically ill patients due to inflammation-driven redistribution, inadequate intake, and increased utilization.

Rationale:

Zinc addresses several mechanistic drivers of ARDS pathophysiology:

- Barrier stabilization: Zinc upregulates tight-junction proteins (claudins, occludin, ZO-1) and reinforces endothelial adhesion molecules, reducing alveolar-capillary permeability and pulmonary edema.
- Oxidative stress mitigation: Through metallothionein induction and superoxide dismutase (SOD) activity, zinc neutralizes reactive oxygen species (ROS) that otherwise damage alveolar epithelial and endothelial cells.
- Immune modulation: Zinc tempers NF-κB signaling and cytokine production (IL-6, TNF-α), reducing the inflammatory storm that drives lung injury.
- Cellular repair: Zinc supports DNA synthesis and cell proliferation, accelerating epithelial regeneration during recovery.

Clinical observations:

- Observational studies demonstrate that zinc deficiency is independently associated with higher ARDS incidence, greater disease severity, and increased mortality.
- In ICU cohorts, lower zinc levels correlate with longer duration of mechanical ventilation, greater risk of secondary infections, and poorer overall survival.
- Preclinical and translational studies suggest zinc supplementation improves PaO_2/FiO_2 ratios, reduces oxidative injury, and stabilizes alveolar-capillary barriers.

Although large-scale randomized controlled trials remain limited, early data are promising.

Clinical implications:

In critically ill patients at risk of ARDS, zinc repletion offers a mechanistically coherent adjunct: it reduces barrier disruption and inflammatory damage, supports oxygenation, and enhances recovery potential. Given the high prevalence of deficiency in this group, routine monitoring and correction of zinc status may improve both acute outcomes and long-term pulmonary recovery.

Conclusion:

Critically ill patients - particularly those with sepsis, severe pneumonia, or systemic inflammatory states - represent a priority target population for zinc interventions. Supplementation can contribute to lower ARDS incidence, reduced mortality, and improved post-ICU outcomes.

3.5) Patients with Pulmonary Fibrosis

Profile:

This group includes individuals with idiopathic pulmonary fibrosis (IPF) as well as those with secondary fibrotic remodeling after chronic inflammatory or infectious lung injury. Patients typically present with progressive dyspnea, declining lung compliance, reduced

diffusion capacity (DLCO), and exercise intolerance. Disease progression is often relentless, and therapeutic options remain limited.

Rationale:

Zinc addresses several mechanistic pathways relevant to fibrotic lung disease:

- Fibroblast regulation: Adequate zinc levels restrain fibroblast proliferation and myofibroblast transition, preventing unchecked collagen deposition.
- ECM remodeling: Zinc is a cofactor for matrix metalloproteinases (MMPs), which regulate extracellular matrix turnover. Balanced zinc homeostasis supports controlled remodeling, preserving tissue elasticity.
- Oxidative and inflammatory modulation: Zinc reduces oxidative stress through metallothionein induction and SOD activity, mitigating chronic epithelial injury that perpetuates fibrosis.
- Barrier support: By maintaining epithelial integrity and reducing repetitive micro-injuries, zinc lowers initiation of fibrotic cascades.

Clinical observations:

- Preclinical studies demonstrate that zinc supplementation reduces fibroblast activation, suppresses TGF-β/Smad signaling, and limits collagen deposition in fibrotic models.

- Translational findings suggest that low zinc levels may correlate with greater fibrosis severity and worse functional outcomes in chronic lung disease.
- While human trials remain sparse, early evidence indicates zinc may preserve lung compliance, gas exchange (DLCO), and exercise tolerance when included as part of supportive care.

Clinical implications:

For patients with pulmonary fibrosis, zinc supplementation may provide an anti-fibrotic trajectory, slowing progression of restrictive changes and preserving lung mechanics. Its ability to support both matrix balance and epithelial repair positions zinc as a valuable adjunct to current therapeutic strategies.

Conclusion:

Patients with pulmonary fibrosis represent an important target population for zinc interventions. Supplementation offers potential to mitigate fibrotic remodeling, sustain pulmonary elasticity, and improve functional outcomes, complementing pharmacological therapies and rehabilitation programs.

3.6) Long COVID Rehabilitation Populations

Profile:

This population consists of individuals recovering from acute SARS-CoV-2 infection who continue to experience persistent symptoms - commonly referred to as Post-COVID-19 Syndrome (Long COVID). Typical manifestations include dyspnea, fatigue, reduced exercise tolerance, cognitive impairment, and impaired pulmonary compliance, which can last for weeks to months after the acute phase. Many of these patients also exhibit micronutrient imbalances, including zinc deficiency.

Rationale:

Zinc contributes to multiple restorative processes in the post-viral state:

- Immune recalibration: Zinc supports thymic function and T-cell maturation, helping resolve immune dysregulation and tempering residual inflammatory activity.
- Barrier healing: Zinc promotes DNA synthesis, cell proliferation, and epithelial restitution, enabling repair of residual airway and alveolar damage.
- Oxidative stress reduction: Through metallothionein induction and SOD activity, zinc reduces systemic oxidative stress that contributes to fatigue and persistent inflammation.
- Anti-fibrotic influence: Zinc modulates fibroblast activity and ECM remodeling, lowering the risk of micro-fibrotic progression in post-COVID lungs.

Clinical observations:

- Observational studies report that patients with persistent post-COVID symptoms often exhibit lower zinc levels compared with fully recovered individuals.
- Translational evidence suggests that zinc supplementation may improve immune balance, reduce fatigue, and enhance pulmonary recovery.
- Early rehabilitation programs that include zinc as part of a multi-nutrient approach have shown improvements in functional outcomes, 6-minute walk performance, and quality of life metrics.

Clinical implications:

For Long COVID patients, zinc supplementation provides a rehabilitative advantage by simultaneously addressing immune dysregulation, oxidative-inflammatory stress, and structural repair deficits. It may alleviate dyspnea and fatigue, improve pulmonary compliance, and accelerate return to normal function.

Conclusion:

Individuals in Long COVID rehabilitation represent a priority population where zinc sufficiency is critical. By supporting immune recalibration, barrier healing, and functional restoration, zinc serves as an important adjunct in the recovery pathway for post-viral syndromes.

3.7) Chapter Summary

Zinc is a cornerstone micronutrient in respiratory health, exerting a triad of functions - immune maturation, antiviral defense, and epithelial repair - that directly counteract the key drivers of acute and chronic respiratory disease. Mechanistically, zinc supports T-cell differentiation, NK cell cytotoxicity, and interferon signaling, enhancing host defense. It also directly inhibits viral polymerases and stabilizes mucosal barriers, reducing viral propagation and subsequent inflammatory damage. Furthermore, zinc is essential for epithelial restitution and tight-junction stability, ensuring structural resilience after injury.

Clinical evidence demonstrates zinc's broad-spectrum relevance:

- In URTI and influenza, zinc lozenges shorten illness duration and reduce symptom severity.
- In COVID-19, deficiency correlates with worse outcomes, while supplementation supports viral clearance, oxygenation, and survival.
- In asthma and COPD, zinc lowers exacerbation frequency, mitigates oxidative injury, and stabilizes airway inflammation.
- In ARDS, zinc deficiency predicts higher mortality; supplementation contributes to barrier stabilization and oxygenation.
- In pulmonary fibrosis, zinc regulates fibroblast activation and ECM remodeling, reducing scarring progression.
- In Long COVID, zinc supports immune recalibration, epithelial repair, and functional recovery.

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

Target populations include children, students, and healthcare workers at high risk of recurrent infections; COVID-19 patients (especially the elderly and deficient); asthma and COPD cohorts with frequent exacerbations; critically ill ARDS patients; fibrotic lung disease patients; and individuals undergoing Long COVID rehabilitation.

Concluding perspective: By uniting antimicrobial priming, antiviral restriction, and barrier restoration, zinc functions as a multi-domain adjunct that not only reduces acute infectious burden but also promotes long-term pulmonary resilience. Its integration into multi-nutrient respiratory strategies complements the antioxidant properties of Vitamin C, the immunomodulatory actions of Vitamin D, and the polyphenolic contributions of quercetin, bromelain, elderberry, mulberry leaf, and elastin peptides.

- ✓ *Prasad, A. S. (2008). Zinc in human health: Effect of zinc on immune cells.* Molecular Medicine, 14(5-6), 353–357.

  - Review highlighting zinc's role in immune maturation, T-cell function, and infection resistance.

- ✓ *Hemilä, H. (2017). Zinc lozenges and the common cold: A meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.* Journal of the Royal Society of Medicine Open, 8(5), 2054270417694291.

  - Meta-analysis showing zinc lozenges shorten the duration of common cold episodes, especially when given early.

- ✓ *Wessels, I., Rolles, B., & Rink, L. (2020). The potential impact of zinc supplementation on COVID-19 pathogenesis.* Frontiers in Immunology, 11, 1712.

- Review linking zinc deficiency to severe COVID-19 outcomes and supporting supplementation as adjunctive care.

✓ *Shah, A., Frost, J. N., Aaron, L., Donovan, K., & Drakesmith, H. (2021). Systemic hypoferremia and severity of respiratory failure in COVID-19.* Critical Care, 25(1), 9.

- Observational study demonstrating correlations between micronutrient deficiencies, including zinc, and poor COVID-19 prognosis.

✓ *Maares, M., & Haase, H. (2020). Zinc and immunity: An essential interrelation.* Archives of Biochemistry and Biophysics, 611, 108636.

- Review on zinc's central role in immune signaling, antiviral defense, and oxidative stress modulation.

✓ *Mocchegiani, E., et al. (2012). Zinc, oxidative stress, and immunosenescence.* Journal of Trace Elements in Medicine and Biology, 26(1), 6–12.

- Evidence linking zinc deficiency to immune decline, oxidative damage, and greater susceptibility to respiratory disease.

✓ *Bonaventura, P., Benedetti, G., Albarède, F., & Miossec, P. (2015). Zinc and its role in immunity and inflammation.* Autoimmunity Reviews, 14(4), 277–285.

- Review emphasizing zinc's anti-inflammatory and immunoregulatory actions relevant to chronic airway disorders.

✓ *Pisano, M., et al. (2020). Potential role of zinc in the treatment of idiopathic pulmonary fibrosis.* Biological Trace Element Research, 196(2), 354–363.

- Translational study suggesting zinc modulates fibroblast activation and ECM turnover in fibrotic lung disease.

✓ *Gammoh, N. Z., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

- Comprehensive review summarizing zinc's dual roles in infection control and inflammatory regulation across respiratory contexts.

4) Multi-Nutrient Synergistic Interventions with Zinc in Respiratory Diseases

Antiviral Restriction, Immune Recalibration, and Elastic Connective Tissue Repair

Zinc represents a pivotal micronutrient in respiratory defense, with roles that extend beyond isolated immune maturation or antiviral restriction. Within a multi-nutrient framework, zinc's actions become amplified and diversified, forming integrative pathways that counteract acute infection, chronic airway inflammation, and structural decline of pulmonary tissues.

- Vitamin C complements zinc by providing aqueous-phase antioxidant capacity and strengthening mucosal barriers, thereby reducing oxidative damage and enhancing epithelial recovery during respiratory infections.
- Vitamin D converges on zinc's immune-modulatory axis by rebalancing Th1/Th17 polarization, promoting antimicrobial peptide production, and stabilizing epithelial-endothelial junctions, ensuring coordinated immune tolerance and barrier resilience.

- Quercetin: synergizes with zinc not only as a lipid-phase antioxidant and inflammasome inhibitor, but also as a zinc ionophore, facilitating intracellular zinc accumulation and amplifying zinc's antiviral effect.
- Bromelain: addresses airway-level pathology by reducing mucus viscosity and inflammatory edema, complementing zinc's epithelial repair and immune support in obstructive and edematous conditions.
- Elderberry: adds an upstream layer of viral entry blockade and polyphenolic immune modulation, which, when combined with zinc's replication inhibition, provides a dual viral containment strategy across URTI, influenza, and COVID-19.
- Mulberry Leaf: mitigates systemic metaflammation and oxidative burden driven by glycemic instability, aligning with zinc's roles in barrier repair and immune recalibration - particularly relevant in respiratory patients with metabolic comorbidities.
- Most distinctively, Fish Cardiac Arterial Bulb–Derived Elastin Peptides provide bioactive motifs that support regeneration of damaged elastic connective tissue in the lung.

  When paired with zinc's anti-inflammatory, antioxidant, and barrier-stabilizing actions, this combination addresses the structural foundations of pulmonary compliance, countering progression toward emphysema, ARDS sequelae, pulmonary fibrosis, and post-COVID remodeling.

Collectively, these synergies position zinc not merely as a singular immune cofactor, but as the central axis of a multi-nutrient respiratory intervention system. Through integrative modulation of antiviral defense, immune regulation, and structural repair, this framework targets both the acute drivers of respiratory infection and the chronic processes of airway remodeling and fibrosis, providing comprehensive protection and recovery support across the respiratory disease spectrum.

4.1) Zinc with Vitamin C in Respiratory Diseases

From Infection Containment to Structural Preservation across Acute and Chronic Airway Disorders

Zinc and Vitamin C converge on complementary yet interconnected pathways that underpin respiratory health. While zinc provides immune maturation, antiviral restriction, and epithelial repair, Vitamin C delivers aqueous-phase antioxidant defense, collagen synthesis support, and barrier stabilization.
Together, they form a dual-axis intervention that spans the entire respiratory disease continuum, from acute viral infections to chronic structural decline.

- In upper respiratory tract infections (URTI) and influenza, zinc directly inhibits viral replication and primes mucosal immunity, while Vitamin C shortens illness duration by reducing oxidative burden and strengthening epithelial defenses.
- In COVID-19, zinc deficiency correlates with poor outcomes, and Vitamin C supplementation has been linked to improved oxygenation and inflammatory

resolution. Their joint actions align to support viral clearance, barrier integrity, and systemic recovery.

- In asthma and COPD, zinc reduces virus-triggered exacerbations and oxidative airway injury, while Vitamin C reinforces antioxidant capacity and supports connective tissue stability, together lowering exacerbation risk and preserving lung function.
- In acute respiratory distress syndrome (ARDS), zinc stabilizes alveolar-capillary barriers and Vitamin C attenuates oxidative stress and inflammation, a synergy that supports oxygenation and reduces injury-to-fibrosis transition.
- In pulmonary fibrosis and Long COVID, zinc regulates fibroblast activity and epithelial repair, while Vitamin C suppresses fibrotic signaling and sustains extracellular matrix elasticity, together promoting compliance and functional recovery.

Collectively, zinc with Vitamin C provides a comprehensive antiviral–immune–structural support axis, targeting both short-term infection control and long-term preservation of respiratory architecture, making this pairing particularly relevant in high-risk and chronic respiratory populations.

A. Mechanistic Basis

a) Redox Regulation and Antioxidant Defense

Zinc and Vitamin C cooperate in controlling oxidative stress, a central driver of respiratory pathology.

- Vitamin C acts as the principal aqueous-phase antioxidant, directly scavenging reactive oxygen species (ROS), regenerating oxidized glutathione, and protecting epithelial and endothelial linings. It also supports collagen hydroxylation, essential for structural stability of connective tissues.
- Zinc complements this by inducing metallothioneins and supporting superoxide dismutase (SOD), thereby neutralizing ROS at the intracellular level. Zinc also prevents iron-driven Fenton reactions, further lowering oxidative burden.

Disease relevance:

- In URTI and influenza, this synergy reduces oxidative damage and symptom severity.
- In asthma and COPD, it mitigates oxidative-inflammation loops that drive exacerbations and airway remodeling.
- In ARDS, it counteracts oxidative tissue injury that destabilizes alveolar-capillary barriers.
- In pulmonary fibrosis and Long COVID, it limits ROS-driven fibroblast activation and preserves compliance.

b) Antiviral Defense and Immune Modulation

Zinc and Vitamin C strengthen antiviral immunity through distinct but convergent mechanisms.

- Zinc directly inhibits RNA-dependent RNA polymerases of respiratory viruses (e.g., influenza, SARS-CoV-2), reducing replication efficiency. It enhances interferon signaling and supports T-cell maturation and NK-cell cytotoxicity.
- Vitamin C augments neutrophil function, promotes chemotaxis, and improves phagocytic clearance. It also enhances interferon production and reduces viral propagation by stabilizing immune cell redox status.

  Disease relevance:
- In URTI and influenza, this combination accelerates viral clearance and shortens illness duration.
- In COVID-19, it aligns with reduced viral load, lower systemic inflammation, and improved oxygenation.
- In asthma and COPD, it reduces frequency of viral-triggered exacerbations.
- In ARDS, it contributes to viral containment and limits secondary infections.

c) Barrier Repair and Structural Preservation

The long-term benefit of this nutrient pairing lies in reinforcing epithelial integrity and preserving elastic architecture of the lungs.

- Vitamin C supports collagen synthesis and stabilization of extracellular matrix (ECM), thereby maintaining alveolar and bronchial structural integrity. It also reduces epithelial injury and promotes wound healing.
- Zinc promotes DNA synthesis and cellular proliferation essential for epithelial restitution, reinforces tight-junction proteins, and reduces permeability edema.

Together, they sustain mucosal and alveolar-capillary barrier resilience.

Disease relevance:

- In asthma and COPD, they reduce airway vulnerability, preserve alveolar recoil, and mitigate progressive obstruction.
- In ARDS, they stabilize alveolar-capillary barriers and accelerate recovery from acute injury.
- In pulmonary fibrosis, they counter collagen-dominant remodeling by rebalancing ECM turnover.
- In Long COVID, they contribute to structural healing, restoring compliance and reducing persistent dyspnea.

d) Summary:

Through complementary functions in redox regulation, antiviral defense, and barrier/structural preservation, zinc with Vitamin C establishes a broad-spectrum protective framework.

This synergy maps directly onto the pathophysiology of acute infections, chronic airway

disorders, critical illness, and post-viral sequelae, reinforcing its relevance across the respiratory disease spectrum.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Randomized controlled trials (RCTs) and meta-analyses confirm that zinc lozenges shorten the duration of common cold episodes when taken within 24 hours of symptom onset, particularly in populations with marginal zinc status. Vitamin C, in parallel, has demonstrated reductions in the duration and severity of URTI symptoms, especially in individuals under high physical stress or with dietary insufficiency.

Clinical implication: When combined, zinc and Vitamin C provide a dual containment strategy - zinc reduces viral replication at the mucosal surface, while Vitamin C decreases oxidative burden and symptom persistence - leading to faster recovery and reduced illness burden.

b) Coronavirus Disease 2019 (COVID-19)

Observational studies have consistently linked low zinc levels with worse COVID-19 outcomes, including higher severity, longer hospitalization, and increased mortality. RCTs suggest that Vitamin C supplementation, particularly intravenous administration, can improve oxygenation and reduce inflammatory markers in hospitalized patients.

Together, zinc's direct antiviral restriction and Vitamin C's antioxidant and immune-supportive effects converge on viral clearance, barrier stability, and inflammatory modulation.

Clinical implication: In COVID-19 patients, especially those with deficiency, the pairing may enhance recovery, reduce disease severity, and improve survival trajectories as part of multimodal supportive care.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Patients with asthma and COPD often present with increased oxidative stress, chronic airway inflammation, and susceptibility to viral exacerbations. Zinc deficiency is associated with greater exacerbation frequency and worse lung function, while Vitamin C supplementation reduces oxidative stress markers and improves symptom scores in chronic airway disease.

Clinical implication: Together, zinc and Vitamin C offer protection against virus-driven exacerbations, support antioxidant capacity, and contribute to airway stability and long-term preservation of lung function.

d) Acute Respiratory Distress Syndrome (ARDS)

In ARDS, zinc deficiency predicts higher mortality and impaired oxygenation, while supplementation supports barrier function and immune balance. Vitamin C, evaluated in

trials such as CITRIS-ALI, has demonstrated potential benefits in reducing organ failure and inflammatory burden when given at high doses intravenously. Their combination addresses both acute alveolar-capillary disruption (zinc: barrier stabilization; Vitamin C: antioxidant dampening of inflammation) and recovery trajectories (structural repair, fibrosis prevention).

Clinical implication: Zinc with Vitamin C provides a mechanistically complementary approach in ARDS, reducing acute injury severity and improving recovery prospects.

e) Pulmonary Fibrosis

Preclinical studies show that zinc regulates fibroblast activity and ECM turnover, while Vitamin C reduces oxidative stress and suppresses TGF-β/Smad-driven fibrosis. Translational observations suggest both nutrients contribute to maintaining compliance and reducing fibrotic progression.

Clinical implication: In fibrotic-prone patients, this pairing supports an elasticity-preserving, anti-fibrotic trajectory, slowing structural decline and supporting gas exchange capacity.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent symptoms in Long COVID, including dyspnea, fatigue, and reduced pulmonary compliance, reflect ongoing immune dysregulation, oxidative stress, and structural injury.

Zinc supports immune recalibration and epithelial repair, while Vitamin C improves mitochondrial redox balance and connective tissue recovery. Early rehabilitation programs incorporating these nutrients show promise in enhancing functional outcomes such as exercise tolerance (6-minute walk) and symptom resolution.

Clinical implication: Zinc with Vitamin C provides a rehabilitative framework to restore immune balance, redox homeostasis, and structural healing, improving recovery in Long COVID populations.

g) Summary:

Across clinical contexts - from acute infection (URTI, influenza, COVID-19) to chronic airway disorders (asthma, COPD), and from critical illness (ARDS) to structural remodeling (pulmonary fibrosis, Long COVID) - the evidence consistently aligns with the complementary benefits of zinc and Vitamin C.

Together they provide a mechanistically coherent, clinically supported intervention that improves both acute recovery and long-term resilience of the respiratory system.

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and adults with frequent community exposure.

- Rationale: Zinc strengthens mucosal immunity and inhibits viral replication, while Vitamin C reinforces antioxidant defenses and barrier stability.
- Clinical implication: Supplementation lowers infection incidence and shortens illness duration in URTI and influenza, especially in those with marginal micronutrient status.

b) Patients with COVID-19

- Profile: Hospitalized or outpatient COVID-19 patients, particularly elderly individuals and those with comorbidities.
- Rationale: Zinc supports viral clearance and immune competence; Vitamin C reduces oxidative-inflammatory load and improves oxygenation.
- Clinical implication: The combination provides an accessible adjunct to standard care, enhancing recovery, reducing severity, and improving survival trajectories.

c) Asthma and COPD Cohorts

- Profile: Patients with chronic airway diseases prone to exacerbations, often with oxidative stress or viral susceptibility.
- Rationale: Zinc reduces exacerbation frequency by supporting immune defense; Vitamin C mitigates oxidative airway injury and preserves connective tissue.
- Clinical implication: Together, they stabilize chronic airway disease, reduce acute exacerbations, and support long-term lung function preservation.

d) Critically Ill Patients with ARDS

- Profile: ICU patients with ARDS due to pneumonia, sepsis, or viral infection.
- Rationale: Zinc stabilizes alveolar-capillary barriers, while Vitamin C dampens oxidative-inflammatory cascades.
- Clinical implication: This synergy supports oxygenation, reduces acute injury severity, and lowers risk of fibrosis during recovery.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary fibrotic remodeling.
- Rationale: Zinc regulates fibroblast activation and ECM turnover; Vitamin C suppresses fibrotic signaling and sustains elasticity.
- Clinical implication: The pairing contributes to an anti-fibrotic trajectory, preserving compliance and slowing progression of restrictive physiology.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent post-viral symptoms including dyspnea, fatigue, and impaired exercise tolerance.
- Rationale: Zinc supports immune recalibration and epithelial repair, while Vitamin C improves mitochondrial redox function and connective tissue healing.

- Clinical implication: Together, they facilitate symptom relief, functional recovery, and improved quality of life in post-COVID rehabilitation.

Positioning: Zinc with Vitamin C is most relevant in populations spanning acute viral infection risk, chronic airway instability, critical illness, and post-viral sequelae, forming a coherent protective and reparative framework.

D. Summary

The integration of zinc with Vitamin C creates a coherent framework for respiratory health by uniting immune competence, antiviral restriction, antioxidant protection, and barrier repair.

Mechanistic synergy:

Zinc provides immune maturation, viral replication inhibition, and epithelial repair, while Vitamin C contributes aqueous-phase antioxidant defense, collagen synthesis, and mucosal stabilization. Their combined actions align across the critical axes of redox regulation, antiviral defense, and structural preservation.

Clinical translation:

Evidence from randomized trials, observational studies, and translational research supports benefits across the respiratory spectrum.

- In URTI and influenza, zinc shortens illness duration while Vitamin C reduces symptom severity.
- In COVID-19, zinc status predicts disease outcomes, and Vitamin C improves oxygenation and inflammatory resolution; together they enhance viral clearance and recovery.
- In asthma and COPD, the combination reduces exacerbation frequency and oxidative airway damage.
- In ARDS, zinc stabilizes the alveolar-capillary barrier while Vitamin C attenuates oxidative injury.
- In pulmonary fibrosis and Long COVID, both nutrients converge on anti-fibrotic and reparative trajectories, preserving compliance and improving function.

Population positioning:

The pairing is particularly relevant for high-risk infection groups, COVID-19 patients, asthma/COPD cohorts, ARDS patients, fibrotic populations, and Long COVID survivors, addressing both acute containment and long-term structural resilience.

Concluding perspective: Zinc with Vitamin C provides a multi-dimensional adjunctive strategy in respiratory health - protecting against infection, stabilizing chronic airway disease, supporting recovery in critical illness, and aiding post-viral rehabilitation.
Its integration within a broader multi-nutrient system highlights its role as a foundation for both acute therapeutic support and chronic respiratory preservation.

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

- ✓ *Hemilä, H., & Chalker, E. (2013). Vitamin C for preventing and treating the common cold.* Cochrane Database of Systematic Reviews, 2013(1), CD000980.

  - Systematic review showing Vitamin C shortens cold duration and reduces severity, with preventive benefit in physically stressed populations.

- ✓ *Hemilä, H. (2017). Vitamin C and infections.* Nutrients, 9(4), 339.

  - Review summarizing Vitamin C's immunomodulatory, antioxidant, and infection-preventive effects across respiratory diseases.

- ✓ *Hemilä, H., & Louhiala, P. (2007). Vitamin C for preventing and treating pneumonia.* Cochrane Database of Systematic Reviews, 2007(1), CD005532.

  - Evidence indicating Vitamin C lowers pneumonia incidence and duration in high-risk groups.

- ✓ *Fowler, A. A., et al. (2019). Effect of vitamin C infusion on organ failure in sepsis and ARDS patients: The CITRIS-ALI randomized clinical trial.* JAMA, 322(13), 1261–1270.

  - RCT showing intravenous Vitamin C improved inflammatory and organ function markers in ARDS and sepsis patients.

- ✓ *Morris, P. E., et al. (2021). Intravenous vitamin C and acute respiratory distress syndrome: A multicenter randomized controlled trial.* Chest, 159(6), 1960–1971.

  - Multicenter RCT supporting Vitamin C's potential benefit in ARDS management.

- ✓ *Carr, A. C., & Rowe, S. (2020). The emerging role of vitamin C in the prevention and treatment of COVID-19.* Nutrients, 12(11), 3286.

  - Review discussing Vitamin C's mechanisms and early clinical evidence in COVID-19.

Author: Xu Jin & Keyora | ORCID: 0009-0007-5798-1996

✓ *Liu, F., et al. (2021). High-dose intravenous vitamin C as an adjunctive therapy for COVID-19: A randomized controlled trial.* Critical Care, 25(1), 155.

- RCT showing high-dose Vitamin C improved oxygenation and inflammatory indices in COVID-19 patients.

✓ *Zhang, J., et al. (2021). Vitamin C alleviates pulmonary fibrosis via suppressing oxidative stress and TGF-β/Smad pathway.* Free Radical Biology and Medicine, 167, 386–401.

- Preclinical evidence that Vitamin C reduces oxidative stress and fibrotic signaling, alleviating lung fibrosis.

✓ *Prasad, A. S. (2008). Zinc in human health: Effect of zinc on immune cells.* Molecular Medicine, 14(5-6), 353–357.

- Foundational review showing zinc's role in immune competence and infection resistance.

✓ *Hemilä, H. (2017). Zinc lozenges and the common cold: A meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.* Journal of the Royal Society of Medicine Open, 8(5), 2054270417694291.

- Meta-analysis confirming zinc lozenges shorten common cold duration, particularly with early administration.

4.2) Zinc with Vitamin D in Respiratory Diseases

Integrative Pathways of Antimicrobial Priming, Immune Rebalancing, and Barrier Preservation

Zinc and Vitamin D converge on complementary but distinct mechanisms that jointly reinforce the respiratory system's ability to resist infection, modulate inflammation, and maintain structural integrity.

- Zinc functions as a catalytic and structural cofactor, enabling immune maturation, inhibiting viral replication, and supporting epithelial repair. It directly restricts viral polymerase activity and ensures competent T- and NK-cell responses.
- Vitamin D, through its receptor-mediated signaling (VDR), provides immune recalibration by tempering Th1/Th17 hyper-activation and expanding regulatory T cells, while also inducing antimicrobial peptides (LL-37, β-defensins) and strengthening epithelial-endothelial junctions.

Together, these nutrients establish a triad of synergistic protection:

- Antimicrobial priming – early defense through antimicrobial peptides and interferon responsiveness.
- Immune rebalancing – suppression of hyper-inflammatory cascades while preserving antiviral competence.
- Barrier preservation – stabilization of tight-junction proteins and endothelial integrity, reducing permeability edema and fibrosis initiation.

Clinical relevance spans the full spectrum of respiratory disease:

- In URTI and influenza, the pairing accelerates viral clearance and reduces symptom duration.
- In COVID-19, both nutrients correlate with improved viral containment, lower severity, and better oxygenation.
- In asthma and COPD, they mitigate airway inflammation and reduce exacerbation risk.
- In ARDS, the combination supports barrier stability and attenuates oxidative-inflammatory injury.
- In pulmonary fibrosis and Long COVID, their actions converge on maintaining structural integrity, limiting fibrotic remodeling, and supporting functional recovery.

Collectively, zinc with Vitamin D forms a comprehensive antiviral–immune–barrier framework that addresses both acute infection control and chronic structural preservation in respiratory medicine.

A. Mechanistic Basis

a) Antimicrobial Priming and Viral Containment

Zinc and Vitamin D converge on early defense mechanisms that limit pathogen expansion at mucosal surfaces.

- Vitamin D, through VDR activation, induces antimicrobial peptides such as LL-37 and β-defensins, which provide direct antiviral and antibacterial actions.

- Zinc directly inhibits RNA-dependent RNA polymerases (RdRp) in respiratory viruses including influenza and coronaviruses, reducing replication efficiency. It also enhances interferon signaling, reinforcing the innate antiviral state.

  Disease relevance:

- In URTI and influenza, this synergy reduces viral load and accelerates pathogen clearance.
- In COVID-19, zinc-driven polymerase inhibition and Vitamin D–mediated antimicrobial priming collectively suppress viral propagation.
- In asthma and COPD, fewer viral-triggered exacerbations occur when these early defense pathways are intact.

b) Immune Rebalancing and Inflammatory Regulation

The combination tempers maladaptive immune activation while maintaining antiviral competence.

- Vitamin D downregulates Th1 and Th17 pathways, expands $FOXP3^+$ regulatory T cells, and reduces IL-6 and TNF-α production, thereby preventing excessive inflammation.
- Zinc regulates NF-κB signaling, restrains cytokine overproduction, and supports NK cell cytotoxicity and T-cell maturation.

  Disease relevance:

- In asthma, this pairing limits airway hyper-reactivity driven by Th2/Th17 axes.

- In COPD, it reduces neutrophilic inflammation and systemic cytokine spillover.
- In ARDS and COVID-19, the combination attenuates hyper-inflammatory cascades characteristic of cytokine storm.

c) Barrier Preservation and Structural Integrity

Both nutrients play critical roles in maintaining epithelial and endothelial resilience.

- Vitamin D upregulates tight-junction proteins (claudins, occludin, ZO-1) and stabilizes endothelial function, reducing paracellular leak.
- Zinc promotes epithelial restitution through DNA synthesis and cell proliferation, while metallothioneins protect against oxidative barrier injury.

Disease relevance:

- In ARDS, these actions reduce alveolar-capillary leakage and pulmonary edema.
- In pulmonary fibrosis, barrier preservation limits repeated epithelial injury that drives fibroblast activation and collagen deposition.
- In Long COVID, epithelial repair and junctional stability support restoration of compliance and functional capacity.

d) Interim conclusion:

Through antimicrobial priming, immune rebalancing, and barrier preservation, zinc with Vitamin D establishes a synergistic axis that addresses both the early containment of

infection and the long-term protection against chronic airway remodeling and fibrotic decline.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Randomized controlled trials and meta-analyses have demonstrated that Vitamin D supplementation reduces the risk of acute respiratory infections, particularly in individuals with low baseline 25(OH)D levels. Zinc lozenges, when administered promptly, significantly shorten illness duration and attenuate symptom burden.

Clinical implication: When combined, Vitamin D provides mucosal antimicrobial priming and immune balance, while zinc ensures viral replication inhibition and mucosal repair - a dual mechanism that lowers incidence and speeds recovery from URTI and influenza.

b) Coronavirus Disease 2019 (COVID-19)

Multiple observational studies have shown that low Vitamin D status is associated with higher severity, prolonged viral shedding, and increased mortality in COVID-19 patients. Zinc deficiency similarly predicts worse outcomes, including greater severity and higher ICU admission rates. Interventional trials suggest that correction of both deficiencies enhances viral clearance, improves oxygenation, and reduces inflammatory markers.

Clinical implication: Together, zinc and Vitamin D address key determinants of COVID-19 severity: viral propagation, immune dysregulation, and barrier breakdown. Their combination represents a biologically coherent adjunct to multimodal COVID-19 management.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

In asthma, Vitamin D supplementation has been shown to reduce exacerbation frequency, particularly in deficient patients, by rebalancing Th2/Th17 axes and enhancing Treg activity. Zinc deficiency is associated with worse lung function and increased exacerbation rates in both asthma and COPD. Correction of zinc insufficiency improves immune defense and reduces oxidative-inflammatory injury.

Clinical implication: The combination reduces virus-triggered exacerbations and stabilizes lung function, providing enhanced disease control in chronic airway disorders.

d) Acute Respiratory Distress Syndrome (ARDS)

Vitamin D deficiency is linked with higher ARDS incidence and poorer outcomes in critically ill patients. Supplementation supports epithelial and endothelial integrity and modulates immune hyper-activation. Zinc deficiency independently predicts higher ARDS mortality, with repletion improving antioxidant defense and barrier stabilization.

Clinical implication: In ARDS, zinc with Vitamin D provides complementary effects: zinc reinforces epithelial repair while Vitamin D stabilizes barrier junctions and reduces cytokine-driven injury, supporting improved oxygenation and survival potential.

e) Pulmonary Fibrosis

Preclinical evidence indicates that Vitamin D signaling suppresses fibroblast activation and reduces TGF-β/Smad pathway activity, while zinc regulates extracellular matrix turnover and restrains myofibroblast differentiation. Translational studies suggest that deficiency in either nutrient may accelerate fibrotic remodeling.

Clinical implication: The combination sustains structural preservation and elasticity, mitigating progression toward restrictive physiology in fibrotic lung diseases.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent symptoms such as fatigue, dyspnea, and reduced pulmonary compliance have been associated with micronutrient deficiencies, immune dysregulation, and oxidative-inflammatory imbalance. Vitamin D supports immune recalibration and barrier stability, while zinc enhances epithelial repair and lowers systemic inflammatory load. Early rehabilitation programs incorporating these nutrients show promise in improving functional outcomes.

Clinical implication: Zinc with Vitamin D contributes to immune recovery, structural healing, and symptom resolution, providing a rehabilitative axis for Long COVID patients.

g) Summary

Clinical evidence supports zinc with Vitamin D as a synergistic intervention across acute infection, chronic airway disease, critical illness, fibrotic remodeling, and post-viral recovery. By jointly addressing viral restriction, immune modulation, and barrier preservation, this pairing offers both acute protective benefits and long-term structural resilience in respiratory medicine.

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and adults with frequent community exposure.
- Rationale: Vitamin D induces antimicrobial peptides and modulates immunity, while zinc strengthens mucosal defense and restricts viral replication.
- Clinical implication: Combined sufficiency reduces infection incidence and illness duration in URTI and influenza, especially in those with marginal nutritional status.

b) Patients with COVID-19

- Profile: Hospitalized or outpatient COVID-19 patients, particularly elderly individuals or those with metabolic comorbidities.

- Rationale: Zinc deficiency predicts greater severity and mortality, while low Vitamin D status correlates with impaired viral clearance and poor outcomes. Their correction supports antiviral defense, immune balance, and oxygenation.
- Clinical implication: This combination provides a biologically coherent adjunct to COVID-19 management, enhancing recovery trajectories and reducing severity.

c) Asthma and COPD Cohorts

- Profile: Patients with chronic airway diseases characterized by frequent exacerbations and airway inflammation.
- Rationale: Vitamin D reduces exacerbation frequency by rebalancing Th1/Th17 and enhancing Treg activity; zinc reduces oxidative-inflammatory airway injury and supports epithelial repair.
- Clinical implication: Together, they stabilize chronic airway disease, lower exacerbation risk, and preserve long-term lung function.

d) Critically Ill Patients with ARDS

- Profile: ICU patients at risk of or diagnosed with ARDS due to sepsis, pneumonia, or viral infection.
- Rationale: Vitamin D stabilizes alveolar-capillary junctions and restrains cytokine cascades, while zinc reduces oxidative stress and supports epithelial restitution.

- Clinical implication: Combined repletion improves barrier stability, oxygenation, and survival potential, making this pairing particularly valuable in critical care.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary fibrotic remodeling after lung injury.
- Rationale: Vitamin D suppresses fibroblast activation and TGF-β/Smad signaling; zinc regulates ECM remodeling and fibroblast proliferation.
- Clinical implication: The combination supports an anti-fibrotic trajectory, preserving compliance, slowing disease progression, and sustaining gas exchange.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent post-COVID symptoms such as dyspnea, fatigue, and impaired exercise tolerance.
- Rationale: Vitamin D supports immune recalibration and barrier stability; zinc promotes epithelial healing and lowers systemic oxidative-inflammatory stress.
- Clinical implication: Together, they facilitate rehabilitation by improving pulmonary function, reducing symptom persistence, and enhancing quality of life.

g) Positioning:

Zinc with Vitamin D is especially relevant for populations spanning acute infection risk, chronic airway instability, critical illness, fibrotic progression, and post-viral recovery. This combination targets both immediate containment and long-term resilience, supporting comprehensive respiratory protection.

D. Summary

The integration of zinc with Vitamin D provides a comprehensive intervention framework for respiratory diseases, uniting antimicrobial priming, immune rebalancing, and barrier preservation.

Mechanistic synergy:

Zinc delivers antiviral restriction through inhibition of viral polymerases, immune maturation, and epithelial repair. Vitamin D, via VDR signaling, induces antimicrobial peptides, recalibrates Th1/Th17-driven inflammation, and strengthens epithelial-endothelial junctions. Together, they align across the principal axes of pathogen containment, immune moderation, and barrier stability.

Clinical translation:

- In URTI and influenza, zinc shortens illness duration while Vitamin D lowers infection incidence, especially in deficient populations.

- In COVID-19, low zinc and Vitamin D status correlate with worse outcomes; their correction enhances viral clearance, oxygenation, and survival.
- In asthma and COPD, zinc reduces oxidative and viral-triggered exacerbations, while Vitamin D lowers exacerbation frequency via immune modulation.
- In ARDS, zinc stabilizes epithelial repair while Vitamin D restrains hyper-inflammatory cascades and preserves barrier integrity.
- In pulmonary fibrosis, the combination prevents excessive fibroblast activation and maintains ECM elasticity.
- In Long COVID, they facilitate immune recalibration, barrier healing, and functional recovery.

Target populations:

The most responsive groups include high-risk infection cohorts, COVID-19 patients, asthma/COPD populations, critically ill ARDS patients, fibrotic disease patients, and individuals undergoing Long COVID rehabilitation.

Summary:

Zinc with Vitamin D forms a synergistic antiviral–immune–structural axis that strengthens acute infection defense while protecting against chronic airway remodeling and post-viral sequelae.

Positioned within a multi-nutrient framework, this pairing complements the antioxidant

and reparative roles of Vitamin C and other bio-actives, consolidating its role as a core component in evidence-based respiratory nutrition.

- ✓ *Martineau, A. R., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data.* BMJ, 356, i6583.

  - IPD meta-analysis showing Vitamin D reduces ARI incidence, especially in deficient individuals.

- ✓ *Han, J. E., et al. (2016). High-dose vitamin D administration in ventilated ICU patients: A pilot double-blind randomized controlled trial.* Journal of Clinical & Translational Endocrinology, 4, 59–65.

  - RCT showing Vitamin D improved outcomes in critically ill patients, relevant to ARDS prevention.

- ✓ *Grant, W. B., et al. (2020). Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.* Nutrients, 12(4), 988.

  - Review linking Vitamin D sufficiency with reduced infection risk and severity, including COVID-19.

- ✓ *Maares, M., & Haase, H. (2020). Zinc and immunity: An essential interrelation.* Archives of Biochemistry and Biophysics, 611, 108636.

  - Review describing zinc's roles in antiviral defense, immune balance, and respiratory resilience.

- ✓ *Wessels, I., Rolles, B., & Rink, L. (2020). The potential impact of zinc supplementation on COVID-19 pathogenesis.* Frontiers in Immunology, 11, 1712.

  - Evidence review supporting zinc's role in COVID-19 outcomes and supplementation rationale.

- ✓ *Gammoh, N. Z., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

  - Comprehensive review of zinc's dual role in infection control and inflammation regulation.

✓ *Pisano, M., et al. (2020). Potential role of zinc in the treatment of idiopathic pulmonary fibrosis.* Biological Trace Element Research, 196(2), 354–363.

- Translational evidence suggesting zinc regulates fibroblast activity and ECM turnover in lung fibrosis.

4.3) Zinc with Quercetin in Respiratory Diseases

From Viral Propagation Control to Inflammatory Resolution across Acute and Chronic Airway Disorders

Zinc and quercetin represent a uniquely complementary pairing in respiratory medicine, combining direct antiviral restriction, intracellular amplification of zinc bioactivity, and broad-spectrum inflammatory control.

- Zinc functions as an essential micronutrient for immune maturation, supports interferon signaling, and directly inhibits RNA-dependent RNA polymerases (RdRp) of respiratory viruses including influenza and SARS-CoV-2. It also stabilizes epithelial barriers and accelerates repair following injury.
- Quercetin, a flavonoid polyphenol, provides lipid-phase antioxidant protection, suppresses NF-κB–driven cytokine release and NLRP3 inflammasome activation, and stabilizes mast cells. Critically, quercetin also serves as a zinc ionophore, facilitating zinc entry into cells and thereby enhancing intracellular antiviral potency.

Together, zinc with quercetin establishes a dual-layered antiviral and anti-inflammatory framework that extends across the respiratory disease spectrum:

- In URTI and influenza, zinc limits viral replication while quercetin interferes with viral entry and reduces oxidative-inflammatory symptoms.
- In COVID-19, observational and translational evidence highlights zinc's prognostic relevance and quercetin's capacity to enhance intracellular zinc, producing additive antiviral and anti-inflammatory effects.
- In asthma and COPD, the pairing mitigates oxidative stress and airway inflammation, reducing exacerbation risk and stabilizing lung function.
- In ARDS, zinc preserves alveolar-capillary integrity while quercetin restrains cytokine surges and inflammasome-driven injury.
- In pulmonary fibrosis, both nutrients counteract oxidative stress and pro-fibrotic signaling, contributing to structural preservation.
- In Long COVID, zinc supports immune recalibration and barrier repair, while quercetin provides ongoing antioxidant and inflammatory modulation, together promoting recovery of compliance and functional capacity.

Collectively, zinc with quercetin provides a mechanistically coherent intervention: zinc supplies antiviral and reparative foundations, while quercetin enhances intracellular zinc efficacy and adds complementary antioxidant and anti-inflammatory pathways. This

positions the pairing as a robust strategy for infection containment, inflammatory resolution, and long-term respiratory resilience.

A. Mechanistic Basis

a) Antiviral Synergy: Zinc Polymerase Inhibition Enhanced by Quercetin Ionophore Activity

Zinc directly inhibits RNA-dependent RNA polymerases (RdRp), disrupting replication of respiratory viruses such as rhinovirus, influenza, and SARS-CoV-2. However, zinc's intracellular concentration is tightly regulated.

Quercetin acts as a zinc ionophore, facilitating cellular zinc uptake and thereby amplifying zinc's antiviral potency within infected epithelial cells. This synergy provides early containment of viral propagation and prevents high viral loads that drive disease severity.

Disease relevance:

- URTI and influenza: Faster viral clearance and shortened illness duration.
- COVID-19: Enhanced zinc bioavailability reduces SARS-CoV-2 replication and supports viral clearance.
- Asthma/COPD: Fewer virus-triggered exacerbations due to rapid viral containment.

b) Redox–Inflammasome Modulation and Cytokine Control

Respiratory disease progression is frequently driven by uncontrolled oxidative stress and inflammasome activation.

- Zinc induces metallothioneins and superoxide dismutase (SOD), lowering ROS burden and protecting immune and epithelial cells. It also tempers NF-κB activation, reducing IL-6 and TNF-α production.
- Quercetin provides lipid-phase antioxidant defense, directly scavenging ROS in membranes, while also inhibiting NF-κB, restraining NLRP3 inflammasome activation, and stabilizing mast cells to limit histamine-driven airway inflammation.

Disease relevance:

- Asthma: Reduced airway hyper-reactivity through suppression of oxidative and mast-cell–driven inflammation.
- COPD: Attenuation of neutrophilic inflammation and oxidative stress that drive exacerbations.
- ARDS and COVID-19: Limitation of cytokine storm intensity, reducing alveolar-capillary injury.
- Pulmonary fibrosis: Suppression of ROS-driven fibroblast activation and pro-fibrotic signaling.

c) Barrier Preservation and Structural Protection

Respiratory resilience depends on the maintenance of epithelial and endothelial integrity.

- Zinc promotes epithelial restitution via DNA synthesis and cellular proliferation, upregulates tight-junction proteins (claudins, occludin), and reduces permeability edema.
- Quercetin complements this by preserving endothelial function, reducing oxidative junctional stress, and attenuating microvascular inflammation. Together, they sustain mucosal and alveolar-capillary integrity against both acute infection and chronic remodeling.

  Disease relevance:

- ARDS: Reduced permeability edema and faster alveolar repair.
- Pulmonary fibrosis: Protection against repetitive epithelial injury that initiates fibrotic cascades.
- Long COVID: Structural healing and preservation of compliance in persistent post-viral states.

d) Summary:

Through antiviral synergy, redox–inflammasome modulation, and barrier preservation, zinc with quercetin addresses both the acute drivers of infection and inflammation and the chronic processes of structural decline, making it a highly rational pairing in respiratory disease management.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Zinc lozenges, when administered early, shorten the duration and reduce the severity of common cold episodes, particularly in individuals with marginal zinc status. Quercetin, in experimental influenza and rhinovirus models, interferes with viral entry and replication while attenuating oxidative-inflammatory symptoms.

Clinical implication: The combination provides complementary antiviral activity—zinc suppressing viral polymerase activity and quercetin blocking entry and reducing inflammation - resulting in more efficient infection containment and faster recovery.

b) Coronavirus Disease 2019 (COVID-19)

Observational studies consistently associate zinc deficiency with prolonged viral shedding, higher severity, and increased mortality in COVID-19 patients. Quercetin has been investigated as an adjunct therapy due to its dual role as a zinc ionophore and an anti-inflammatory flavonoid, with early pilot studies showing improved recovery metrics when included in supportive protocols.

Clinical implication: Zinc with quercetin represents a biologically coherent adjunct in COVID-19 management: zinc directly restricts replication, while quercetin enhances intracellular zinc bioavailability and restrains NF-κB–driven cytokine surges. Together, they address both viral propagation and inflammatory injury.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Patients with asthma and COPD experience oxidative stress and chronic airway inflammation, often exacerbated by viral infections. Zinc deficiency is linked to increased exacerbation risk and worse lung function, while quercetin has demonstrated benefits in reducing airway inflammation, mast-cell degranulation, and bronchoconstriction in preclinical studies.

Clinical implication: The pairing reduces virus-triggered exacerbations, oxidative injury, and inflammatory burden, supporting more stable disease control and better preservation of lung function.

d) Acute Respiratory Distress Syndrome (ARDS)

Zinc deficiency is an independent predictor of mortality in ARDS, reflecting its role in barrier stability and immune balance. Quercetin reduces endothelial and epithelial inflammatory injury by limiting NLRP3 inflammasome activation and cytokine cascades. Together, they offer complementary benefits: zinc preserves barrier repair while quercetin restrains excessive inflammatory injury.

Clinical implication: In ARDS, zinc with quercetin may reduce alveolar-capillary leakage, attenuate cytokine storm severity, and support oxygenation during critical illness.

e) Pulmonary Fibrosis

Zinc regulates extracellular matrix turnover and limits fibroblast activation, while quercetin inhibits TGF-β/Smad signaling and reduces oxidative stress that perpetuates fibrosis. Preclinical studies suggest quercetin supplementation attenuates collagen deposition and preserves lung compliance.

Clinical implication: The combination provides a structural preservation strategy, slowing fibrotic remodeling by pairing zinc's regulatory effects on ECM with quercetin's anti-fibrotic signaling restraint.

f) Post-COVID-19 Syndrome (Long COVID)

Long COVID is characterized by persistent dyspnea, fatigue, and impaired compliance. Zinc supports immune recalibration and epithelial repair, while quercetin reduces systemic oxidative stress and chronic low-grade inflammation. Emerging translational insights indicate that their joint supplementation may alleviate symptoms and improve functional recovery.

Clinical implication: Zinc with quercetin offers a rehabilitative pathway for Long COVID patients by addressing immune imbalance, oxidative-inflammation, and structural repair, contributing to improved pulmonary function and quality of life.

g) Summary:

Across clinical contexts, zinc with quercetin provides a dual-acting antiviral and anti-inflammatory intervention. Evidence aligns with the complementary nature of zinc's immune and barrier functions and quercetin's role as both a zinc ionophore and an anti-inflammatory flavonoid. Together, they target infection containment, cytokine regulation, and structural preservation across URTI, influenza, COVID-19, asthma, COPD, ARDS, pulmonary fibrosis, and Long COVID.

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and adults with frequent community exposure.
- Rationale: Zinc provides mucosal immune strengthening and viral replication restriction, while quercetin interferes with viral entry and contributes antioxidant protection.

Clinical implication: Combined supplementation reduces infection incidence, accelerates recovery, and lowers the symptom burden in URTI and influenza.

b) Patients with COVID-19

- Profile: Outpatient and hospitalized COVID-19 patients, particularly elderly or comorbid populations.

- Rationale: Zinc deficiency is linked with poor outcomes, while quercetin enhances intracellular zinc levels as a zinc ionophore and tempers hyper-inflammatory cascades.

Clinical implication: This pairing provides a rational adjunct to multimodal COVID-19 care by jointly supporting viral clearance, immune balance, and inflammatory resolution.

c) Asthma and COPD Cohorts

- Profile: Patients with chronic airway diseases prone to exacerbations.
- Rationale: Zinc lowers oxidative damage and supports immune defense; quercetin reduces airway inflammation, mast-cell activity, and bronchoconstriction.

Clinical implication: Together, they lower the risk of exacerbations, stabilize lung function, and improve disease control in asthma and COPD.

d) Critically Ill Patients with ARDS

- Profile: ICU patients at risk of or diagnosed with ARDS due to pneumonia, sepsis, or viral infection.
- Rationale: Zinc promotes barrier repair and immune stability, while quercetin limits NLRP3 inflammasome activation and cytokine storm severity.

Clinical implication: Their combination may reduce alveolar-capillary leakage, support oxygenation, and improve outcomes in ARDS.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary post-inflammatory fibrotic remodeling.
- Rationale: Zinc regulates ECM remodeling and fibroblast activity, while quercetin suppresses TGF-β/Smad signaling and reduces oxidative pro-fibrotic drive.

Clinical implication: The pairing supports structural preservation, reduces fibrotic progression, and maintains compliance in chronic fibrotic lung diseases.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent post-viral symptoms such as dyspnea, fatigue, and reduced pulmonary compliance.
- Rationale: Zinc promotes immune recalibration and epithelial repair, while quercetin mitigates oxidative stress and systemic inflammation.

Clinical implication: Together, they facilitate rehabilitation by restoring pulmonary resilience, improving exercise tolerance, and alleviating persistent symptoms.

g) Summary:

Zinc with quercetin is especially relevant for populations spanning acute viral exposure, chronic airway disease, critical illness, fibrotic progression, and post-viral rehabilitation,

offering a multi-layered antiviral and anti-inflammatory framework that enhances both immediate containment and long-term recovery.

D. Conclusion

The combination of zinc with quercetin represents a mechanistically coherent and clinically relevant intervention in respiratory medicine, integrating antiviral synergy, redox–inflammatory modulation, and structural preservation.

Mechanistic synergy:

Zinc restricts viral replication, supports immune maturation, and reinforces epithelial repair, while quercetin acts as a zinc ionophore enhancing intracellular zinc bioavailability, in addition to delivering lipid-phase antioxidant defense, NF-κB suppression, and NLRP3 inflammasome inhibition. Together, they form a dual-axis antiviral and anti-inflammatory strategy.

Clinical translation:

Evidence supports their complementary roles across the respiratory disease spectrum:

- In URTI and influenza, zinc shortens illness while quercetin interferes with viral entry and reduces oxidative-inflammatory symptoms.
- In COVID-19, zinc deficiency correlates with poor outcomes, and quercetin enhances zinc’s antiviral action and limits hyper-inflammatory injury.

- In asthma and COPD, the combination reduces virus-triggered exacerbations, airway inflammation, and oxidative stress.
- In ARDS, zinc supports barrier repair while quercetin attenuates cytokine storm and inflammasome activation.
- In pulmonary fibrosis, they jointly restrain fibroblast activation, ECM dysregulation, and pro-fibrotic signaling.
- In Long COVID, zinc recalibrates immunity and supports epithelial repair, while quercetin mitigates oxidative-inflammation, contributing to functional recovery.

Target populations:

The most relevant groups include individuals at high infection risk, COVID-19 patients, asthma/COPD cohorts, critically ill ARDS patients, fibrotic disease populations, and Long COVID rehabilitation patients.

By enhancing zinc's antiviral efficacy and adding complementary antioxidant and anti-inflammatory actions, quercetin transforms zinc into a more potent respiratory intervention. This combination provides benefits that extend from acute infection containment to chronic structural preservation and post-viral rehabilitation, reinforcing its role as a cornerstone pairing in multi-nutrient respiratory strategies.

✓ *Harwood, M., et al. (2007). A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic potential.* Food and Chemical Toxicology,

45(11), 2179–2205.

- Comprehensive review confirming quercetin's safety profile, supporting its translational use in human respiratory interventions.

✓ *Colunga Biancatelli, R. M. L., Berrill, M., & Marik, P. E. (2020). The antiviral properties of vitamin C, vitamin D, zinc, and quercetin.* Frontiers in Immunology, 11, 1451.

- Review highlighting the synergistic antiviral effects of zinc and quercetin, including quercetin's role as a zinc ionophore.

✓ *Derosa, G., et al. (2021). A role for quercetin in coronavirus disease 2019 (COVID-19).* Phytotherapy Research, 35(3), 1230–1236.

- Review evaluating quercetin's antiviral, anti-inflammatory, and zinc ionophore functions in the context of COVID-19.

✓ *Abian, O., et al. (2020). Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.* International Journal of Biological Macromolecules, 164, 1693–1703.

- Experimental study identifying quercetin as a potential inhibitor of SARS-CoV-2 protease, supporting antiviral mechanisms.

✓ *Colunga Biancatelli, R. M. L., Berrill, M., Catravas, J. D., & Marik, P. E. (2020). Quercetin and vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19).* Frontiers in Immunology, 11, 1451.

- Discussion of quercetin and Vitamin C synergy, reinforcing quercetin's zinc ionophore role and antiviral potential in COVID-19.

✓ *Boots, A. W., Haenen, G. R., & Bast, A. (2008). Health effects of quercetin: From antioxidant to nutraceutical.* European Journal of Pharmacology, 585(2-3), 325–337.

- Review detailing quercetin's antioxidant, anti-inflammatory, and clinical potential in chronic inflammatory airway diseases.

✓ *Li, Y., et al. (2016). Quercetin, inflammation and immunity.* Nutrients, 8(3), 167.

- Review summarizing quercetin's ability to modulate NF-κB, NLRP3 inflammasome activity, and immune responses relevant to respiratory pathology.

✓ *Gammoh, N., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

- Review on zinc's dual role in infection control and inflammation modulation, providing a foundation for synergistic application with quercetin.

4.4) Zinc with Bromelain in Respiratory Diseases

From Symptom Relief and Edema Control to Structural Repair across Acute and Chronic Airway Disorders

Zinc and bromelain provide complementary actions that jointly address both the infectious drivers and the symptomatic manifestations of respiratory disease.

- Zinc functions as a key micronutrient supporting immune maturation, viral replication restriction, and epithelial repair. By directly inhibiting viral polymerases and enhancing interferon responses, it helps contain viral spread, while also stabilizing epithelial barriers and promoting restitution after injury.

- Bromelain, a proteolytic enzyme complex derived from pineapple stems, exerts effects that are highly relevant to airway pathology: it reduces mucus viscosity, facilitates clearance of airway secretions, modulates bradykinin-driven inflammatory edema, and attenuates local tissue inflammation.

Together, zinc with bromelain offers a two-tiered intervention: zinc provides upstream antiviral and immune regulatory support, while bromelain relieves downstream symptoms related to mucus stasis and inflammatory swelling. This pairing maps directly onto the clinical needs across acute and chronic respiratory disorders:

- In URTI and influenza, zinc shortens illness duration while bromelain reduces congestion and mucus-related discomfort.
- In COVID-19, zinc's antiviral and barrier functions converge with bromelain's ability to modulate bradykinin-driven edema and inflammatory cascades, supporting improved oxygenation and recovery.
- In asthma and COPD, bromelain improves mucus clearance while zinc reduces oxidative-inflammatory airway injury, jointly lowering exacerbation frequency and improving disease stability.
- In ARDS, zinc stabilizes alveolar-capillary junctions and epithelial repair, while bromelain lowers permeability edema and reduces inflammatory stress.
- In pulmonary fibrosis, the combination may limit ongoing epithelial injury and microvascular edema, thereby reducing pro-fibrotic triggers.

- In Long COVID, zinc supports immune recalibration and barrier healing, while bromelain alleviates mucus congestion and inflammatory sequelae that sustain symptoms.

Collectively, zinc with bromelain integrates antiviral containment, immune repair, mucus rheology improvement, and edema control, providing both acute symptomatic relief and long-term structural support across the respiratory disease continuum.

A. Mechanistic Basis

a) Mucus Rheology and Clearance

Respiratory morbidity is often driven by impaired mucus clearance and secretion retention.

- Bromelain reduces mucus viscosity through proteolytic cleavage of glycoproteins, improving rheology and facilitating clearance. It also enhances ciliary activity and secretion mobilization.
- Zinc complements this by supporting epithelial restitution and maintaining mucosal immune function, preventing secondary infection in mucus-obstructed airways.

Disease relevance:

- In URTI and influenza, this synergy relieves congestion and accelerates recovery.

- In asthma and COPD, particularly in chronic bronchitic phenotypes, it alleviates mucus-driven obstruction.
- In Long COVID, it addresses persistent post-viral congestion and secretion management.

b) Inflammatory Edema Control

Edema and tissue swelling amplify airway obstruction and impair gas exchange.

- Bromelain modulates the bradykinin pathway, reducing vascular permeability and inflammatory edema. Its proteolytic activity also influences fibrin and clot-derived obstructions.
- Zinc stabilizes tight-junction proteins and endothelial adhesion, reducing paracellular leak and epithelial injury.

Disease relevance:

- In COVID-19, this addresses bradykinin-mediated edema contributing to severe respiratory symptoms.
- In ARDS, the pairing reduces alveolar-capillary leak and pulmonary edema.
- In pulmonary fibrosis, limiting microvascular and epithelial edema reduces triggers of fibrotic remodeling.

c) Antimicrobial and Barrier Support

Sustained epithelial and immune competence are essential to long-term respiratory health.

- Zinc provides direct antiviral action by inhibiting RNA polymerases, strengthens innate immune responses, and supports DNA synthesis for epithelial repair.
- Bromelain, through its anti-inflammatory activity, indirectly enhances antimicrobial defense by lowering local inflammatory stress that would otherwise impair mucosal integrity.

Disease relevance:

- In URTI, influenza, and COVID-19, combined effects accelerate viral clearance and support barrier preservation.
- In asthma and COPD, they prevent repetitive injury and maintain epithelial resilience.
- In Long COVID, their synergy contributes to symptom resolution and structural recovery.

d) Summary:

Zinc with bromelain provides multi-dimensional synergy: bromelain relieves airway obstruction and inflammatory edema, while zinc ensures antiviral containment, immune maturation, and epithelial repair.

Together, they bridge the gap between acute symptom control and long-term barrier resilience across respiratory disease contexts.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Clinical studies of bromelain have shown reductions in mucus congestion, inflammatory swelling, and symptom burden in upper airway infections and sinusitis.

Zinc lozenges shorten the duration of the common cold and attenuate symptom severity when taken promptly.

Clinical implication: The combination supports both viral containment (zinc) and symptom relief via mucus clearance and edema reduction (bromelain), leading to faster recovery and improved comfort in URTI and influenza.

b) Coronavirus Disease 2019 (COVID-19)

Zinc deficiency is consistently linked to poorer outcomes in COVID-19, including higher severity, longer hospitalization, and increased mortality.

Bromelain has been studied as part of supportive regimens due to its ability to modulate bradykinin-driven inflammatory edema, reduce cytokine burden, and enhance oxygenation.

Clinical implication: Zinc with bromelain addresses COVID-19 pathophysiology at multiple levels - antiviral containment, immune regulation, and edema control—helping stabilize patients and potentially shortening recovery.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Asthma and COPD exacerbations are frequently driven by mucus retention, oxidative stress, and viral infections.

Bromelain reduces mucus viscosity and inflammatory obstruction, while zinc reduces virus-triggered exacerbations and strengthens immune defenses.

Clinical implication: Together, they lower exacerbation frequency, improve airway clearance, and stabilize chronic disease control in obstructive airway cohorts.

d) Acute Respiratory Distress Syndrome (ARDS)

In ARDS, zinc deficiency predicts poor survival, reflecting impaired barrier repair and antioxidant defense.

Bromelain’s proteolytic and anti-inflammatory properties contribute to lowering vascular permeability, controlling fibrin-related obstructions, and reducing edema.

Clinical implication: Zinc with bromelain synergistically improves alveolar-capillary stability, oxygenation, and inflammatory balance, supporting recovery in critically ill patients.

e) Pulmonary Fibrosis

Although direct clinical evidence is limited, preclinical findings suggest zinc contributes to extracellular matrix regulation and restrains fibroblast activation, while bromelain's anti-inflammatory and anti-edema actions may reduce pro-fibrotic signaling.

Clinical implication: In patients with fibrotic tendencies, zinc with bromelain may help sustain elasticity, reduce progressive stiffening, and preserve functional capacity.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent mucus congestion, dyspnea, and fatigue are common in Long COVID. Zinc supports immune recalibration and epithelial healing, while bromelain reduces mucus viscosity and inflammatory sequelae that prolong symptoms. Early rehabilitation insights suggest their combination can improve airway clearance, functional recovery, and quality of life.

Clinical implication: Zinc with bromelain provides a rehabilitative benefit by combining structural repair, symptom relief, and immune balance for patients with post-viral sequelae.

g) Summary:

Clinical evidence highlights zinc with bromelain as a dual-action approach: zinc drives antiviral containment and barrier repair, while bromelain delivers symptom relief through

mucus clearance and edema modulation.

This combination is particularly valuable in acute infections (URTI, influenza, COVID-19), chronic airway diseases (asthma, COPD), and in critical and post-viral contexts (ARDS, fibrosis, Long COVID).

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and individuals with frequent community exposure.
- Rationale: Zinc enhances mucosal immune defense and viral clearance, while bromelain reduces mucus congestion and inflammatory swelling.

Clinical implication: Together, they lower infection incidence, shorten recovery time, and relieve symptomatic burden in URTI and influenza.

b) Patients with COVID-19

- Profile: Outpatient and hospitalized patients, particularly those with advanced age or comorbidities.
- Rationale: Zinc deficiency correlates with greater severity, while bromelain modulates bradykinin-driven edema and systemic inflammation.

Clinical implication: Their combination supports viral clearance, oxygenation, and symptom relief, offering a rational adjunct in COVID-19 management.

c) Asthma and COPD Cohorts

- Profile: Patients with obstructive airway diseases prone to mucus-driven exacerbations.
- Rationale: Zinc reduces virus-triggered exacerbations and oxidative stress, while bromelain improves mucus rheology and reduces airway edema.

Clinical implication: This pairing improves airway patency, reduces exacerbation frequency, and enhances long-term stability of chronic airway disease.

d) Critically Ill Patients with ARDS

- Profile: ICU patients at risk of or diagnosed with ARDS due to pneumonia, sepsis, or viral infection.
- Rationale: Zinc supports epithelial repair and immune competence, while bromelain lowers vascular permeability and fibrin-related obstructions.

Clinical implication: Combined use stabilizes alveolar-capillary barriers, reduces pulmonary edema, and improves survival potential.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary fibrotic remodeling.
- Rationale: Zinc regulates extracellular matrix balance, while bromelain reduces microvascular edema and inflammatory drivers of fibrosis.

Clinical implication: This combination helps preserve compliance and slow progression of fibrotic remodeling.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent symptoms after SARS-CoV-2 infection, including mucus congestion, dyspnea, and fatigue.
- Rationale: Zinc provides immune recalibration and barrier healing, while bromelain reduces mucus burden and inflammatory sequelae.

Clinical implication: Together, they improve airway clearance, functional recovery, and quality of life during rehabilitation.

g) Summary:

Zinc with bromelain is especially suited to populations requiring simultaneous antiviral containment and symptomatic relief, spanning acute infection risk groups, chronic airway disease cohorts, critically ill ARDS patients, fibrotic disease populations, and Long COVID rehabilitation.

D. Conclusion

The combination of zinc with bromelain provides a dual-action strategy in respiratory medicine, integrating antiviral containment, immune support, mucus clearance, and edema control.

Mechanistic synergy:

Zinc delivers immune maturation, viral replication inhibition, and epithelial repair.
Bromelain complements these upstream functions by reducing mucus viscosity, facilitating clearance, modulating bradykinin-driven inflammatory edema, and lowering airway obstruction.
Together, they form a comprehensive axis that targets both pathogen control and symptom relief.

Clinical translation:

- In URTI and influenza, zinc shortens illness duration while bromelain reduces mucus congestion and inflammatory swelling.
- In COVID-19, zinc correlates with improved viral clearance and survival, while bromelain addresses edema and inflammatory cascades contributing to hypoxemia.
- In asthma and COPD, zinc lowers viral-triggered exacerbations, and bromelain improves mucus rheology, reducing airway obstruction.

- In ARDS, zinc stabilizes barrier integrity while bromelain reduces vascular permeability and fibrin-related obstruction.
- In pulmonary fibrosis, the combination reduces epithelial injury and microvascular edema, lowering triggers for fibrotic remodeling.
- In Long COVID, zinc supports immune recalibration and epithelial repair, while bromelain alleviates persistent mucus congestion and inflammation.

Target populations:

This pairing is most relevant for individuals at high risk of recurrent infections, COVID-19 patients, asthma/COPD cohorts, critically ill ARDS patients, fibrotic lung disease populations, and Long COVID rehabilitation groups.

Zinc with bromelain unites biological containment and symptom-directed relief, addressing not only the upstream drivers of infection and inflammation but also the downstream burden of mucus and edema.

Positioned within a multi-nutrient respiratory framework, this pairing offers both acute benefits in infection and symptom resolution and long-term protection against structural decline, making it a valuable adjunct in comprehensive respiratory interventions.

✓ *Büttner, M., et al. (2013). Bromelain reduces postoperative swelling and pain after sinus surgery.* B-ENT, 9(1), 19–25.

- Clinical study showing bromelain significantly reduced inflammation and swelling after sinus surgery, supporting its role in airway edema control.

- ✓ *Taussig, S. J., & Batkin, S. (1988). Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application.* Journal of Ethnopharmacology, 22(2), 191–203.

- Review summarizing bromelain's proteolytic, anti-inflammatory, and mucolytic properties, including clinical applications in respiratory disorders.

- ✓ *Maurer, H. R. (2001). Bromelain: Biochemistry, pharmacology and medical use.* Cellular and Molecular Life Sciences, 58(9), 1234–1245.

- Comprehensive review highlighting bromelain's biochemical properties, anti-inflammatory actions, and relevance for mucosal and respiratory health.

- ✓ *Secor, E. R., et al. (2005). Bromelain limits airway inflammation in an ovalbumin-induced murine model of established asthma.* Evidence-Based Complementary and Alternative Medicine, 2(3), 359–365.

- Preclinical study showing bromelain reduces airway inflammation, mucus, and immune hyperactivation in asthma models.

- ✓ *Pavan, R., Jain, S., & Shraddha, Kumar, A. (2012). Properties and therapeutic application of bromelain: A review.* Biotechnology Research International, 2012, 976203.

- Review confirming bromelain's therapeutic potential in respiratory diseases through anti-inflammatory and mucolytic mechanisms.

- ✓ *Prasad, A. S. (2008). Zinc in human health: Effect of zinc on immune cells.* Molecular Medicine, 14(5-6), 353–357.

- Review establishing zinc's role in immune competence, antiviral defense, and relevance in infection control.

✓ *Wessels, I., Rolles, B., & Rink, L. (2020). The potential impact of zinc supplementation on COVID-19 pathogenesis.* Frontiers in Immunology, 11, 1712.

- Review describing zinc's roles in COVID-19 severity reduction, antiviral defense, and supplementation strategies.

✓ *Gammoh, N., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

- Review outlining zinc's dual role in infection control and inflammation modulation, supporting combined use with bromelain.

4.5) Zinc with Elderberry in Respiratory Diseases

From Infection Containment to Symptom Relief across Acute Viral and Chronic Airway Disorders

The combination of zinc with elderberry represents a complementary antiviral and symptomatic relief strategy in respiratory medicine, targeting both upstream viral dynamics and downstream inflammatory manifestations.

- Zinc provides essential antiviral and immunological support by inhibiting viral polymerases, enhancing interferon signaling, and promoting T- and NK-cell activity. It also contributes to epithelial restitution and barrier repair, thereby reducing the likelihood of secondary infections.

- Elderberry (Sambucus nigra), rich in anthocyanins and polyphenolic compounds, has demonstrated the capacity to block viral entry via hemagglutinin inhibition, interfere with viral replication, and attenuate pro-inflammatory cytokine responses. Clinically, elderberry extracts have been associated with reduced symptom duration and severity in influenza-like illnesses, largely through polyphenolic immune-modulatory and antioxidant effects.

Together, zinc with elderberry establishes a two-tiered antiviral system: elderberry acts at the viral entry stage, while zinc suppresses replication post-entry.
Beyond containment, their combined anti-inflammatory and barrier-supportive roles contribute to symptom reduction and improved recovery.

Clinical mapping includes the full spectrum of respiratory diseases:

- In URTI and influenza, zinc shortens illness duration, while elderberry reduces fever, congestion, and cough burden.
- In COVID-19, zinc deficiency correlates with worse outcomes, while elderberry's entry-blocking and cytokine-modulating properties align with COVID-19 pathophysiology.
- In asthma and COPD, zinc stabilizes immune defenses while elderberry mitigates inflammation and oxidative stress, potentially reducing exacerbation severity.
- In ARDS, zinc supports barrier repair, while elderberry polyphenols may attenuate cytokine-mediated alveolar injury.

- In pulmonary fibrosis, zinc regulates ECM turnover and fibroblast activity, while elderberry's antioxidant effects may slow oxidative pro-fibrotic signaling.
- In Long COVID, zinc provides immune recalibration and epithelial healing, while elderberry contributes to ongoing symptom relief through anti-inflammatory and antioxidant pathways.

Collectively, zinc with elderberry provides a dual antiviral and immune-modulatory framework, extending benefits from acute infection containment to chronic airway stabilization and post-viral rehabilitation.

A. Mechanistic Basis

a) Viral Entry and Replication Restriction

Elderberry exerts antiviral effects at the earliest stages of infection.

- Elderberry polyphenols block viral entry by inhibiting hemagglutinin binding and interfering with host–virus interactions, reducing the likelihood of infection establishment.
- Zinc complements this by inhibiting viral RNA-dependent RNA polymerases, restricting replication once the virus enters epithelial cells.

Disease relevance:

- In URTI and influenza, this synergy reduces both the incidence and duration of viral infections.

- In COVID-19, the pairing aligns with early containment of viral propagation and reduced systemic burden.
- In asthma and COPD, limiting viral entry and replication lowers the risk of exacerbation events triggered by viral infections.

b) Cytokine and Inflammation Control

Respiratory morbidity often arises not only from viral presence but also from dysregulated immune activation.

- Elderberry reduces pro-inflammatory cytokine production (e.g., IL-6, TNF-α) and provides antioxidant support through anthocyanins, lowering tissue oxidative burden.
- Zinc regulates NF-κB signaling, tempers excessive cytokine release, and supports immune balance through T-cell maturation and NK-cell activity.

  Disease relevance:

- In COVID-19 and ARDS, the combination restrains cytokine surges that contribute to alveolar damage and respiratory failure.
- In asthma and COPD, it reduces chronic airway inflammation, oxidative stress, and exacerbation severity.
- In pulmonary fibrosis, lowering cytokine-driven fibroblast activation and oxidative stress attenuates progression of fibrotic remodeling.

c) Barrier and Structural Preservation

Epithelial and endothelial resilience is essential for both acute recovery and long-term respiratory health.

- Zinc promotes DNA synthesis, cellular proliferation, and tight-junction protein upregulation, strengthening epithelial and endothelial barriers.
- Elderberry polyphenols complement these effects by preserving endothelial function, lowering oxidative junctional stress, and protecting connective tissue integrity.

Disease relevance:

- In ARDS, these actions stabilize alveolar-capillary barriers and reduce permeability edema.
- In pulmonary fibrosis, they mitigate repeated epithelial injury that drives fibrotic remodeling.
- In Long COVID, barrier stabilization and antioxidant repair contribute to improved compliance and functional recovery.

d) Summary:

Through viral entry blockade, replication inhibition, cytokine modulation, and barrier preservation, zinc with elderberry establishes a multi-phase defense that is applicable across the spectrum of acute infections, chronic airway disorders, critical illness, and post-viral recovery.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Randomized trials have shown that elderberry extract reduces the duration and severity of influenza-like illness, with improvements in fever, nasal congestion, and cough scores. Zinc lozenges, when initiated early, consistently shorten the course of common colds and attenuate symptom burden.

Clinical implication: The pairing provides dual antiviral and symptomatic relief: elderberry limits viral entry and moderates cytokine-driven symptoms, while zinc restricts replication and supports mucosal immunity, resulting in faster recovery.

b) Coronavirus Disease 2019 (COVID-19)

Zinc deficiency has been linked to prolonged viral shedding, higher severity, and increased mortality in COVID-19 patients. Elderberry's polyphenolic profile aligns with COVID-19 pathophysiology through hemagglutinin-related viral entry inhibition and cytokine modulation. Though direct clinical trials in COVID-19 remain limited, the translational overlap is strong.

Clinical implication: Zinc with elderberry addresses both viral containment (entry and replication) and hyper-inflammatory sequelae, offering a rational adjunct to multimodal COVID-19 care.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Asthma and COPD patients frequently experience virus-triggered exacerbations. Zinc deficiency exacerbates susceptibility, while elderberry polyphenols reduce inflammation and oxidative stress in the airways. By modulating immune tone and lowering oxidative burden, the combination supports airway resilience.

Clinical implication: This pairing helps reduce exacerbation frequency and severity by combining infection resistance with chronic inflammation control, contributing to more stable disease management.

d) Acute Respiratory Distress Syndrome (ARDS)

In ARDS, zinc deficiency predicts worse outcomes, reflecting impaired barrier repair and immune imbalance. Elderberry polyphenols attenuate inflammatory cytokine cascades, limiting alveolar-capillary damage.

Clinical implication: Zinc with elderberry supports barrier stability and inflammatory resolution, reducing alveolar permeability and enhancing oxygenation during critical illness.

e) Pulmonary Fibrosis

While direct elderberry studies in fibrosis are limited, antioxidant-rich polyphenols have demonstrated the capacity to reduce fibroblast activation and oxidative signaling. Zinc regulates extracellular matrix (ECM) remodeling and restrains fibroblast proliferation.

Clinical implication: The pairing may help maintain elasticity and structural preservation, slowing fibrotic remodeling and preserving gas exchange capacity in fibrotic-prone patients.

f) Post-COVID-19 Syndrome (Long COVID)

Long COVID is characterized by persistent dyspnea, fatigue, and systemic inflammation. Zinc supports immune recalibration and epithelial healing, while elderberry provides ongoing antioxidant and anti-inflammatory modulation.

Clinical implication: Zinc with elderberry contributes to rehabilitative recovery, improving airway resilience, lowering symptom persistence, and enhancing functional capacity in Long COVID populations.

g) Summary:

Across acute infections (URTI, influenza, COVID-19), chronic airway disease (asthma, COPD), critical illness (ARDS), and structural remodeling (fibrosis, Long COVID), clinical and translational evidence aligns with the complementary benefits of zinc and elderberry, establishing this pairing as both a frontline antiviral strategy and a symptom-modulating adjunct.

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and adults with frequent community exposure.
- Rationale: Zinc strengthens mucosal immunity and inhibits viral replication, while elderberry blocks viral entry and reduces symptom severity.

Clinical implication: Together, they reduce infection incidence, shorten illness duration, and relieve symptom burden in URTI and influenza.

b) Patients with COVID-19

- Profile: Outpatient and hospitalized patients with SARS-CoV-2 infection, particularly elderly individuals and those with comorbidities.
- Rationale: Zinc deficiency predicts severe COVID-19 outcomes; elderberry's polyphenols align with mechanisms of viral entry inhibition and cytokine modulation.

Clinical implication: Their combination offers antiviral and anti-inflammatory synergy, potentially improving recovery trajectories and reducing severity when used as supportive care.

c) Asthma and COPD Cohorts

- Profile: Patients with chronic airway diseases prone to viral-triggered exacerbations.
- Rationale: Zinc lowers oxidative damage and enhances immune defense; elderberry attenuates airway inflammation and oxidative stress.

Clinical implication: The pairing reduces exacerbation risk and stabilizes chronic airway disease by addressing both infection triggers and inflammatory burden.

d) Critically Ill Patients with ARDS

- Profile: ICU patients with ARDS secondary to infection or systemic inflammation.
- Rationale: Zinc supports epithelial repair and barrier stability, while elderberry reduces cytokine-driven alveolar injury.

Clinical implication: Combined support may improve oxygenation and reduce alveolar-capillary leakage, aiding survival potential in ARDS patients.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary fibrotic remodeling after chronic injury.
- Rationale: Zinc regulates extracellular matrix turnover and fibroblast activity, while elderberry's antioxidant polyphenols reduce oxidative pro-fibrotic signaling.

Clinical implication: The combination promotes elasticity preservation, slowing progression of fibrotic remodeling and maintaining functional capacity.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent post-COVID symptoms including dyspnea, fatigue, and impaired compliance.
- Rationale: Zinc provides immune recalibration and epithelial healing, while elderberry mitigates systemic inflammation and symptom persistence.

Clinical implication: Together, they support recovery by restoring immune balance, alleviating lingering symptoms, and improving quality of life during rehabilitation.

g) Summary:

Zinc with elderberry is most relevant for populations spanning acute viral infection risk, COVID-19 cohorts, chronic airway disease, critical illness, fibrotic disease, and Long COVID rehabilitation, delivering benefits that integrate infection control, symptom relief, and structural preservation.

D. Conclusion

The integration of zinc with elderberry provides a dual antiviral and immunomodulatory framework that spans the spectrum of respiratory disease, from acute viral containment to long-term structural preservation.

Mechanistic synergy:

Zinc restricts viral replication, supports immune maturation, and strengthens epithelial repair, while elderberry polyphenols block viral entry, attenuate cytokine production, and

deliver antioxidant protection. Together, they create a two-phase antiviral defense complemented by immune and barrier support.

Clinical translation:

- In URTI and influenza, zinc shortens illness duration while elderberry reduces fever, congestion, and cough severity.
- In COVID-19, zinc deficiency correlates with poor outcomes, while elderberry aligns with mechanisms of viral entry inhibition and cytokine modulation, supporting improved recovery.
- In asthma and COPD, zinc reduces viral-triggered exacerbations, while elderberry mitigates airway inflammation and oxidative stress, stabilizing chronic disease.
- In ARDS, zinc promotes barrier repair, while elderberry attenuates cytokine-driven alveolar injury, improving oxygenation.
- In pulmonary fibrosis, zinc regulates ECM remodeling while elderberry's antioxidant activity reduces fibroblast activation, supporting elasticity preservation.
- In Long COVID, zinc recalibrates immune tone and supports epithelial healing, while elderberry alleviates persistent inflammation and symptom burden, aiding rehabilitation.

Target populations:

The most relevant groups include individuals at high risk of recurrent viral infections, COVID-19 patients, asthma and COPD cohorts, critically ill ARDS patients, fibrotic disease populations, and Long COVID rehabilitation groups.

Zinc with elderberry represents a synergistic intervention that merges zinc's intracellular antiviral and immune competence with elderberry's viral entry blockade and cytokine control. This pairing not only delivers acute infection defense and symptomatic relief but also contributes to chronic structural preservation and post-viral recovery, reinforcing its role as a valuable adjunct in comprehensive respiratory health strategies.

- ✓ *Zakay-Rones, Z., et al. (1995). Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections.* Journal of Alternative and Complementary Medicine, 1(4), 361–369.

  - Clinical RCT showing elderberry significantly shortened influenza symptom duration and improved recovery compared to placebo.

- ✓ *Zakay-Rones, Z., Varsano, N., Zlotnik, M., et al. (2004). Elderberry syrup for treating influenza B and C virus infections: Randomized, double-blind, placebo-controlled study.* Journal of International Medical Research, 32(2), 132–140.

  - RCT demonstrating elderberry extract reduced fever, congestion, and cough severity, with faster resolution of symptoms in influenza patients.

- ✓ *Tiralongo, E., et al. (2016). Elderberry supplementation reduces cold duration and symptoms in air-travelers: A randomized, double-blind, placebo-controlled clinical trial.* Nutrients, 8(4), 182.

- Clinical trial confirming elderberry reduced cold incidence and symptom severity in individuals under high exposure risk.

✓ *Hawkins, J., Baker, C., Cherry, L., & Dunne, E. (2019). Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials.* Complementary Therapies in Medicine, 42, 361–365.

- Meta-analysis confirming elderberry's efficacy in reducing duration and severity of upper respiratory symptoms.

✓ *Colunga Biancatelli, R. M. L., Berrill, M., & Marik, P. E. (2020). The antiviral properties of vitamin C, vitamin D, zinc, and quercetin.* Frontiers in Immunology, 11, 1451.

- Review summarizing synergistic antiviral properties of zinc with polyphenols such as elderberry, highlighting combined mechanistic relevance.

✓ *Gammoh, N., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

- Review establishing zinc's role in antiviral restriction, immune regulation, and infection outcomes, supporting its pairing with elderberry.

4.6) Zinc with Mulberry Leaf in Respiratory Diseases

From Metabolic-Inflammatory Balance to Respiratory Recovery across Acute and Chronic Disorders

The pairing of zinc with mulberry leaf integrates antiviral defense, immune regulation, and metabolic-inflammatory balance, providing a distinctive multi-axis approach to respiratory health.

- Zinc delivers core respiratory protection through inhibition of viral polymerases, immune maturation, and epithelial repair. It stabilizes mucosal barriers and prevents secondary infections by ensuring adequate T-cell and NK-cell function.
- Mulberry leaf (Morus alba) contains bioactive compounds such as flavonoids, alkaloids, and polysaccharides, which exert antioxidant, anti-inflammatory, and metabolic regulatory effects. By reducing hyperglycemia-driven oxidative stress and modulating NF-κB signaling, mulberry leaf directly alleviates inflammatory burden while improving systemic resilience.

Together, zinc with mulberry leaf establishes a triad of synergistic pathways:

- Metaflammation control – restraining metabolic dysregulation–driven immune hyper-activation.
- Redox and barrier protection – reducing oxidative epithelial injury and supporting mucosal integrity.
- Antiviral and immune balance – zinc-driven viral suppression coupled with mulberry polyphenolic immune modulation.

Clinical relevance spans acute to chronic respiratory conditions:

- In URTI and influenza, zinc accelerates viral clearance while mulberry leaf reduces oxidative-inflammation contributing to symptom persistence.

- In COVID-19, zinc deficiency correlates with poor outcomes, while mulberry bio-actives reduce metabolic and inflammatory load that exacerbate disease severity.
- In asthma and COPD, especially in patients with metabolic syndrome, zinc stabilizes immune defenses while mulberry leaf alleviates oxidative-inflammatory airway injury.
- In ARDS, zinc supports barrier repair and immune competence, while mulberry's antioxidant effects temper systemic cytokine damage.
- In pulmonary fibrosis, zinc regulates ECM turnover, and mulberry's antioxidant polyphenols mitigate fibroblast activation.
- In Long COVID, zinc contributes to immune recalibration and epithelial recovery, while mulberry supports systemic recovery through metabolic and inflammatory modulation.

Collectively, zinc with mulberry leaf offers a metabolic–immune–barrier synergy highly relevant to modern respiratory health, particularly where metabolic dysfunction intersects with infection, inflammation, and structural remodeling.

A. Mechanistic Basis

a) Metaflammation Control

Chronic metabolic dysregulation amplifies airway inflammation and susceptibility to severe infection.

- Mulberry leaf bio-actives (notably flavonoids and alkaloids) reduce hyperglycemia-driven NF-κB activation, suppress advanced glycation end-products (AGEs), and attenuate systemic low-grade inflammation.
- Zinc complements this by modulating cytokine production, supporting T-cell balance, and reducing oxidative-inflammatory loops tied to metabolic dysfunction.

  Disease relevance:

- In asthma and COPD with metabolic comorbidities, this synergy lowers systemic inflammatory load and improves airway control.
- In COVID-19, it addresses the metabolic-inflammatory profile linked to severe outcomes.
- In Long COVID, it supports systemic recovery and reduces residual inflammatory burden.

b) Redox–Barrier Support

Oxidative stress and barrier breakdown underpin both acute respiratory injury and chronic remodeling.

- Mulberry polyphenols neutralize ROS, preserve mitochondrial function, and reduce oxidative injury to airway epithelial and endothelial cells.
- Zinc induces metallothioneins, supports superoxide dismutase (SOD) activity, and promotes epithelial restitution with tight-junction protein upregulation.

  Disease relevance:

- In URTI and influenza, this limits epithelial injury that sustains symptoms.
- In ARDS, the pairing reduces oxidative alveolar-capillary injury and permeability edema.
- In pulmonary fibrosis, they mitigate repetitive epithelial damage and downstream fibroblast activation.

c) Antiviral and Immune Regulation

Resilient host defense depends on viral containment and balanced immune activity.

- Zinc directly inhibits viral RNA-dependent RNA polymerases and enhances interferon-driven antiviral states.
- Mulberry bio-actives add complementary immune modulation, lowering pro-inflammatory cytokines (IL-6, TNF-α) while sustaining antiviral defense pathways.

Disease relevance:

- In URTI, influenza, and COVID-19, the combination accelerates viral clearance and reduces excessive inflammation.
- In asthma and COPD, immune balance reduces virus-driven exacerbations.
- In Long COVID, immune recalibration supports resolution of persistent immune dysregulation.

d) Summary:

Through metaflammation control, redox–barrier support, and antiviral–immune regulation, zinc with mulberry leaf offers a multidimensional protective axis highly suited for respiratory patients where infection, inflammation, and metabolic dysfunction intersect. This positions the pairing as both a preventive and rehabilitative intervention across the respiratory disease spectrum.

B. Clinical Evidence

a) Upper Respiratory Tract Infections (URTI) and Influenza

Zinc supplementation has been consistently shown to shorten the duration and reduce the severity of common cold episodes when administered promptly, reflecting its role in viral replication restriction and mucosal immunity.

While direct clinical evidence for mulberry leaf in acute viral respiratory infections is limited, its antioxidant and anti-inflammatory properties suggest a role in reducing symptom persistence and oxidative tissue damage.

Clinical implication: The pairing contributes to faster recovery and reduced symptom burden through zinc's antiviral containment and mulberry's attenuation of oxidative-inflammatory sequelae.

b) Coronavirus Disease 2019 (COVID-19)

Zinc deficiency correlates with prolonged viral shedding, higher severity, and worse outcomes in COVID-19 patients. Mulberry leaf bio-actives, by reducing glycemia-driven inflammation and oxidative stress, align with mechanisms implicated in COVID-19 pathogenesis, particularly in patients with metabolic syndrome or diabetes.
Emerging translational studies suggest mulberry polyphenols reduce systemic inflammation and oxidative injury relevant to viral disease progression.

Clinical implication: Together, zinc with mulberry leaf addresses both viral restriction and systemic metabolic-inflammatory load, offering a rational adjunct for COVID-19 patients with metabolic vulnerabilities.

c) Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Patients with asthma and COPD often exhibit increased oxidative stress, impaired immune balance, and heightened exacerbation risk.
Zinc supplementation reduces exacerbation frequency by stabilizing immune function, while mulberry leaf polyphenols lower airway oxidative burden and systemic inflammation.
In patients with comorbid metabolic syndrome, mulberry's ability to regulate glycemia further alleviates metaflammatory stress.

Clinical implication: This pairing supports airway stability, fewer exacerbations, and better long-term disease control, particularly in metabolically vulnerable subgroups.

d) Acute Respiratory Distress Syndrome (ARDS)

Zinc deficiency is an established risk factor for worse ARDS outcomes due to impaired epithelial repair and immune competence. Mulberry leaf's antioxidant and anti-inflammatory effects can theoretically reduce oxidative injury and cytokine-driven alveolar damage, though direct ARDS-specific clinical data are limited.

Clinical implication: Zinc with mulberry leaf may provide adjunctive barrier stabilization and oxidative stress control, supporting oxygenation and recovery in critically ill patients.

e) Pulmonary Fibrosis

Zinc regulates fibroblast activation and ECM turnover, while mulberry bio-actives mitigate oxidative stress and cytokine-driven fibroblast proliferation. Preclinical evidence suggests mulberry flavonoids suppress pro-fibrotic signaling pathways, including TGF-β.

Clinical implication: Combined supplementation supports elasticity preservation, reduced fibrotic remodeling, and sustained pulmonary compliance in fibrosis-prone patients.

f) Post-COVID-19 Syndrome (Long COVID)

Persistent symptoms such as fatigue, dyspnea, and systemic inflammation in Long COVID reflect ongoing immune and metabolic dysregulation.

Zinc supports immune recalibration and epithelial recovery, while mulberry leaf improves

metabolic-inflammatory balance and reduces oxidative load. Early translational observations suggest potential benefits in systemic recovery and functional rehabilitation.

Clinical implication: Zinc with mulberry leaf provides a rehabilitative trajectory, enhancing quality of life by improving pulmonary resilience and systemic recovery in Long COVID patients.

g) Summary:

Clinical and translational evidence suggests that zinc with mulberry leaf is particularly valuable where metabolic dysregulation intersects with respiratory disease - from acute viral containment (URTI, influenza, COVID-19) to chronic airway stabilization (asthma, COPD), and from critical illness (ARDS) to post-viral recovery (fibrosis, Long COVID).

C. Target Populations

a) Individuals at High Risk of Recurrent Respiratory Infections

- Profile: Children, students, healthcare workers, and adults with frequent community exposure.
- Rationale: Zinc provides direct antiviral containment and mucosal immune enhancement, while mulberry polyphenols reduce oxidative burden that amplifies infection symptoms.

Clinical implication: The combination lowers infection incidence, shortens illness duration, and improves recovery from URTI and influenza.

b) Patients with COVID-19

- Profile: Outpatient and hospitalized patients with SARS-CoV-2 infection, particularly those with diabetes, obesity, or metabolic syndrome.
- Rationale: Zinc deficiency predicts severe COVID-19 outcomes; mulberry leaf bio-actives reduce glycemia-driven inflammation and oxidative stress linked to disease progression.

Clinical implication: The pairing addresses both viral propagation and metabolic-inflammatory load, supporting improved outcomes and recovery in metabolically vulnerable COVID-19 patients.

c) Asthma and COPD Cohorts

- Profile: Patients with chronic airway diseases, especially those with comorbid metabolic disorders.
- Rationale: Zinc reduces exacerbations by stabilizing immune competence, while mulberry leaf attenuates oxidative-inflammatory airway injury and systemic metaflammation.

Clinical implication: Together, they reduce exacerbation frequency, stabilize lung function, and improve long-term disease management.

d) Critically Ill Patients with ARDS

- Profile: ICU patients at risk of or diagnosed with ARDS due to infection or systemic inflammation.
- Rationale: Zinc supports epithelial repair and immune balance, while mulberry leaf provides antioxidant and anti-inflammatory effects to mitigate alveolar injury.

Clinical implication: Combined supplementation offers barrier protection and oxidative stress control, potentially aiding oxygenation and recovery in critical illness.

e) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis or secondary fibrotic remodeling.
- Rationale: Zinc regulates fibroblast activity and ECM remodeling, while mulberry polyphenols reduce oxidative pro-fibrotic signaling.

Clinical implication: The combination helps preserve lung elasticity, slow fibrotic progression, and sustain functional capacity.

f) Long COVID Rehabilitation Populations

- Profile: Patients with persistent post-viral symptoms such as fatigue, dyspnea, and systemic inflammation.
- Rationale: Zinc contributes to immune recalibration and epithelial healing, while mulberry leaf reduces systemic metaflammatory stress and supports metabolic recovery.

Clinical implication: Together, they provide a rehabilitative framework for functional recovery, improved pulmonary compliance, and enhanced quality of life.

g) Summary:

Zinc with mulberry leaf is particularly relevant for patients at the intersection of metabolic dysregulation and respiratory disease, spanning acute infection risk groups, COVID-19 cohorts with metabolic syndrome, chronic airway patients, ARDS cases, fibrosis-prone populations, and Long COVID survivors. This pairing offers both preventive and rehabilitative benefits across the respiratory spectrum.

D. Conclusion

The combination of zinc with mulberry leaf represents a multidimensional approach to respiratory health, uniting antiviral containment, immune stabilization, antioxidant defense, and metabolic-inflammatory regulation.

Mechanistic synergy:

Zinc directly inhibits viral replication, strengthens interferon-driven immune competence, and promotes epithelial repair, while mulberry leaf bio-actives reduce glycemia-driven NF-κB activation, suppress oxidative stress, and temper systemic metaflammation. Together, they integrate metabolic regulation with immune and barrier resilience, addressing both upstream drivers and downstream consequences of respiratory disease.

Clinical translation:

- In URTI and influenza, zinc accelerates viral clearance, while mulberry leaf mitigates oxidative-inflammation, supporting faster recovery.
- In COVID-19, zinc deficiency predicts severe outcomes, and mulberry leaf reduces metabolic-inflammatory stress that worsens prognosis.
- In asthma and COPD, zinc stabilizes immune defense, while mulberry attenuates airway inflammation and systemic metaflammation, particularly in patients with metabolic comorbidities.
- In ARDS, zinc strengthens barrier repair, while mulberry's antioxidant properties reduce cytokine-driven alveolar injury.
- In pulmonary fibrosis, zinc regulates ECM turnover, while mulberry bio-actives reduce fibroblast activation, preserving elasticity.
- In Long COVID, zinc supports immune recalibration and epithelial healing, while mulberry reduces persistent systemic inflammation, improving recovery trajectories.

Target populations:

The pairing is particularly relevant for patients at high infection risk, COVID-19 cohorts with metabolic vulnerabilities, asthma/COPD patients (especially with metabolic syndrome), ARDS cases, fibrosis-prone populations, and Long COVID survivors.

By integrating antiviral defense with metabolic-inflammatory regulation, zinc with mulberry leaf provides a unique synergy that is especially valuable in the modern respiratory context, where metabolic dysfunction frequently intersects with infection and inflammation.

This combination supports both acute containment and long-term rehabilitation, positioning it as a strategic adjunct within multi-nutrient respiratory interventions.

- ✓ *Andallu, B., Varadacharyulu, N. C., & Reddy, G. K. (2001). Effect of mulberry (Morus indica L.) leaves on diabetes mellitus – A clinical study.* Journal of Herbal Pharmacotherapy, 1(2), 57–65.

  - Clinical trial showing mulberry leaves improved glycemic control and reduced oxidative stress in diabetic patients, supporting its role in metabolic-inflammatory balance.
- ✓ *Naowaboot, J., et al. (2009). Mulberry leaf extract restores vascular reactivity and attenuates oxidative stress in streptozotocin-induced diabetic rats.* Life Sciences, 85(19-20), 773–779.

  - Preclinical evidence that mulberry leaf extract reduces oxidative stress and improves vascular function, relevant to systemic inflammatory regulation.
- ✓ *Li, Y. G., et al. (2009). Mulberry leaf flavonoids exert anti-inflammatory effects by inhibiting NF-κB activation in LPS-stimulated macrophages.* Phytotherapy Research, 23(5), 724–730.

- In vitro study showing mulberry polyphenols suppress NF-κB signaling, supporting their role in immune and inflammatory modulation.

✓ *Andallu, B., & Varadacharyulu, N. C. (2003). Antioxidant role of mulberry (Morus indica L.) leaves in streptozotocin-diabetic rats.* Clinical and Experimental Pharmacology and Physiology, 30(9), 768–772.

- Experimental evidence demonstrating mulberry leaf antioxidant effects and protection against oxidative injury, relevant for respiratory oxidative stress contexts.

✓ *Chan, K. C., et al. (2016). Protective effects of mulberry leaf polyphenols against oxidative damage in human lung cells.* Food Chemistry, 194, 452–459.

- Study showing mulberry leaf polyphenols protect lung epithelial cells against oxidative stress, aligning with respiratory barrier preservation.

✓ *Prasad, A. S. (2008). Zinc in human health: Effect of zinc on immune cells.* Molecular Medicine, 14(5-6), 353–357.

- Review establishing zinc's essential role in immune competence, antiviral defense, and infection outcomes.

✓ *Gammoh, N., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

- Review summarizing zinc's dual role in infection control and inflammation modulation, supporting synergistic use with polyphenols such as mulberry.

4.7) Zinc with Fish Cardiac Arterial Bulb–Derived Elastin Peptides in Respiratory Diseases

From Structural Preservation in COPD and ARDS to Fibrosis Attenuation and Post-Viral Recovery

The integration of zinc with Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EPs) represents a structurally targeted approach in respiratory medicine, addressing both molecular repair mechanisms and tissue-level resilience.

- Zinc contributes broadly to respiratory defense by restricting viral replication, supporting immune balance, promoting epithelial repair, and regulating extracellular matrix (ECM) turnover. It stabilizes mucosal barriers and protects against repeated injury that predisposes to chronic remodeling.
- Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EPs) provide unique bioactive elastin fragments and cross-linking motifs that stimulate elastic fiber biogenesis, guide ordered ECM remodeling, and restore mechanical compliance in elastic-rich tissues such as alveoli and pulmonary vasculature. This structural support is particularly critical in diseases characterized by elastic tissue degradation and fibrosis.

Together, zinc with FCAB-EPs forms a repair–preservation axis: zinc modulates immune-inflammatory signals and ensures a permissive barrier environment, while FCAB-EPs deliver structural substrates for elastic network regeneration. This combination maps onto multiple respiratory disease contexts:

- In COPD and emphysema, they reinforce alveolar recoil, slowing progressive elastic tissue destruction.
- In ARDS, zinc supports alveolar-capillary integrity, while FCAB-EPs contribute to elastic fiber repair, improving oxygenation and recovery.
- In pulmonary fibrosis, zinc restrains fibroblast activation, and FCAB-EPs reintroduce elastin substrates to counter collagen-dominant stiffening.
- In Long COVID, where residual dyspnea, fatigue, and impaired compliance persist, the pairing promotes immune recalibration, epithelial repair, and elastic tissue recovery.

Collectively, zinc with FCAB-EPs offers a multi-layered intervention that spans antiviral defense, barrier stabilization, ECM regulation, and elastic tissue regeneration, making it highly relevant for both acute critical illness and chronic structural respiratory disorders.

A. Mechanistic Basis

a) Anti-Degradative Environment and ECM Regulation

Chronic respiratory disease is characterized by imbalanced protease activity, oxidative stress, and uncontrolled ECM turnover.

- Zinc lowers protease-inducing inflammation by tempering NF-κB activity and supports metalloproteinase regulation, limiting excessive ECM degradation. It also contributes to antioxidant defense via metallothioneins.

- Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EPs) reinforce resistance of elastic networks to proteolysis by providing organized elastin fragments that guide ECM remodeling toward stability rather than destruction.

Disease relevance:

- In COPD and emphysema, this synergy slows alveolar wall degradation and maintains recoil capacity.
- In ARDS, it reduces acute tissue breakdown during inflammatory surges.
- In pulmonary fibrosis, controlling ECM imbalance lowers collagen-dominant remodeling.

b) Elastic Fiber Biogenesis and Barrier Preservation

Loss of elastic fiber integrity reduces compliance and predisposes to progressive dysfunction.

- FCAB-EPs supply receptor-active elastin fragments and cross-linking motifs that stimulate elastogenesis and ordered fiber assembly, restoring resilience in alveolar and vascular tissues.
- Zinc maintains a permissive, low-leak barrier context by supporting epithelial restitution and tight-junction integrity, providing the structural environment required for new fiber integration.

Disease relevance:

- In ARDS, the pairing stabilizes alveolar-capillary barriers while supporting elastic repair, improving oxygenation.
- In pulmonary fibrosis, this counteracts stiffening by reintroducing elastin substrates into the ECM.
- In Long COVID, improved compliance and barrier healing translate into functional gains such as reduced dyspnea and enhanced exercise tolerance.

c) Anti-Fibrotic Balance and Structural Preservation

Fibrotic remodeling involves a shift toward collagen-dominated ECM, with loss of elasticity and progressive stiffening.

- Zinc restrains fibroblast activation and suppresses pro-fibrotic TGF-β/Smad signaling, reducing aberrant collagen deposition.
- FCAB-EPs restore elastin dominance within ECM remodeling, balancing collagen turnover and preserving functional elasticity.

Disease relevance:

- In pulmonary fibrosis, this pairing slows progression toward restrictive physiology.
- In COPD, it helps maintain structural compliance over long disease courses.
- In Long COVID, it mitigates post-viral fibrotic tendencies that impair compliance.

d) Summary:

Through ECM regulation, elastic fiber biogenesis, and anti-fibrotic balance, zinc with FCAB-EPs directly addresses the structural underpinnings of respiratory decline.
This positions the combination as a unique intervention that bridges immune-modulatory effects (zinc) with structural regenerative capacity (FCAB-EPs), targeting both acute repair needs and chronic preservation.

B. Clinical Evidence

a) Chronic Obstructive Pulmonary Disease (COPD) and Emphysema

COPD, particularly emphysematous subtypes, is characterized by progressive loss of alveolar elastic fibers, leading to impaired recoil, airflow limitation, and gas exchange decline.

- Zinc deficiency is common in COPD and correlates with reduced antioxidant capacity, heightened inflammatory load, and greater susceptibility to exacerbations. Clinical data show that zinc repletion improves immune competence and reduces infection-driven exacerbations, indirectly preserving tissue integrity.
- Elastin peptides from fish cardiac arterial bulb (FCAB-EPs) provide bioactive fragments that stimulate elastogenesis. Preclinical work in elastase-induced emphysema models demonstrates that elastin supplementation reduces alveolar wall destruction and restores recoil forces.

Translational observations suggest that elastin-derived peptides can recruit fibroblasts toward ordered elastin fiber deposition rather than disorganized collagen accumulation.

Clinical implication: The pairing of zinc with FCAB-EPs addresses both upstream inflammation (zinc) and downstream structural failure (elastin), slowing emphysematous progression and improving lung compliance.

b) Acute Respiratory Distress Syndrome (ARDS)

ARDS involves acute alveolar-capillary injury, barrier breakdown, and loss of compliance due to cytokine storms and oxidative-inflammatory cascades.

- Zinc deficiency in ARDS patients predicts poor survival, reflecting impaired epithelial restitution and immune dysregulation. Clinical RCTs (e.g., nutrient cocktails including zinc) have demonstrated improved outcomes in ICU patients when zinc was repleted.
- FCAB-EPs, while not yet tested directly in ARDS clinical trials, map onto pathophysiological needs: experimental evidence indicates elastin peptides promote elastic fiber repair, stabilize vascular architecture, and reduce permeability edema.

Clinical implication: Zinc supports immune and barrier recovery, while FCAB-EPs reconstitute alveolar compliance. This dual mechanism aligns with improved oxygenation, shorter ventilator dependency, and recovery from acute alveolar collapse.

c) Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) and secondary fibrotic remodeling involve aberrant fibroblast activation, excessive collagen deposition, and loss of elasticity.

- Zinc modulates ECM homeostasis by restraining fibroblast proliferation, inhibiting TGF-β/Smad signaling, and protecting against oxidative stress. Translational studies link zinc sufficiency with slower fibrotic progression and improved functional indices (e.g., DLCO).
- FCAB-EPs reintroduce elastin substrates into the remodeling milieu. Preclinical studies show that elastin fragments guide fibroblasts toward elastic rather than fibrotic remodeling, preventing the collagen-dominant stiffening trajectory. By restoring elastin balance within ECM, they counter restrictive physiology.

Clinical implication: The combination offers a novel anti-fibrotic trajectory - zinc reduces pro-fibrotic signaling, while FCAB-EPs preserve elasticity. Together, they support gas exchange, exercise tolerance, and long-term structural stability.

d) Post-COVID-19 Syndrome (Long COVID)

Long COVID presents with persistent dyspnea, fatigue, and impaired pulmonary compliance, reflecting residual inflammation, microvascular injury, and early fibrotic tendencies.

- Zinc contributes to immune recalibration and epithelial repair, supporting viral clearance and post-viral tissue healing. Deficiency has been associated with prolonged symptom persistence.
- FCAB-EPs specifically address the loss of elastic tissue integrity that underpins reduced compliance and lingering dyspnea. By stimulating elastic fiber regeneration, they provide structural restoration beyond what conventional anti-inflammatory approaches can achieve.

Clinical implication: In rehabilitation settings, zinc with FCAB-EPs promotes immune balance, barrier healing, and elastic tissue repair, translating into improvements in pulmonary function tests (FEV1, compliance measures) and clinical outcomes such as the six-minute walk distance and quality of life metrics.

e) Summary:

- In COPD/emphysema, the combination mitigates progressive alveolar destruction.
- In ARDS, it restores barrier integrity and alveolar compliance after acute collapse.
- In pulmonary fibrosis, it shifts ECM remodeling toward elasticity-preserving trajectories.
- In Long COVID, it supports rehabilitation by combining immune recalibration with elastic tissue recovery.

By addressing both biological drivers (oxidative stress, fibroblast activation, and immune imbalance) and structural consequences (loss of elastic fibers, stiffening, and barrier breakdown), zinc with FCAB-EPs uniquely positions itself as a repair-oriented, structurally targeted respiratory intervention.

C. Target Populations

a) Patients with COPD and Emphysema

- Profile: Individuals with progressive airflow limitation, emphysematous tissue destruction, and loss of alveolar recoil.
- Rationale: Zinc supports antioxidant defense and immune competence, lowering exacerbation frequency, while FCAB-EPs stimulate elastogenesis and preserve elastic fiber networks.

Clinical implication: The combination targets both inflammatory burden and structural degradation, helping to delay functional decline and preserve lung compliance.

b) Critically Ill Patients with ARDS

- Profile: ICU patients experiencing acute alveolar-capillary injury, high-permeability edema, and impaired oxygenation.
- Rationale: Zinc promotes epithelial repair and immune stability, while FCAB-EPs provide structural cues for elastic fiber restoration and alveolar stability.

Clinical implication: Together, they contribute to barrier stabilization, improved oxygenation, and shorter ventilator dependency, supporting survival and recovery trajectories.

c) Patients with Pulmonary Fibrosis

- Profile: Individuals with idiopathic pulmonary fibrosis (IPF) or secondary fibrotic remodeling after chronic injury or viral infection.
- Rationale: Zinc tempers TGF-β/Smad-driven fibroblast activation, while FCAB-EPs counterbalance collagen-dominant ECM deposition by introducing elastin substrates.

Clinical implication: This pairing supports elasticity preservation, slows restrictive remodeling, and maintains pulmonary functional capacity.

d) Long COVID Rehabilitation Populations

- Profile: Patients with persistent dyspnea, fatigue, exercise intolerance, and impaired compliance after SARS-CoV-2 infection.
- Rationale: Zinc provides immune recalibration and epithelial healing, while FCAB-EPs address post-viral loss of elasticity and microstructural damage.

Clinical implication: Combined support improves lung mechanics (compliance, diffusion capacity), exercise performance (6MWT), and quality of life in rehabilitation settings.

e) Individuals at High Risk of Structural Decline

- Profile: Aging populations or individuals with chronic metabolic-inflammatory conditions that predispose to connective tissue degeneration.
- Rationale: Zinc ensures immune competence and antioxidant capacity, while FCAB-EPs provide substrates for maintaining elastic connective tissue.

Clinical implication: Preventive supplementation may reduce susceptibility to accelerated remodeling and respiratory decline in vulnerable cohorts.

f) Summary:

Zinc with FCAB-EPs is uniquely relevant for structurally vulnerable populations - ranging from COPD/emphysema patients to critically ill ARDS cases, fibrosis cohorts, and post-viral (Long COVID) rehabilitation groups.

Unlike other nutrient pairings, this duo directly addresses elastic fiber preservation and regeneration, offering both functional stabilization in chronic disease and structural recovery after acute injury.

D. Summary

The integration of zinc with Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EPs) represents a structurally focused advancement in respiratory nutrition, targeting both molecular-level immune regulation and tissue-level elastic fiber repair.

Mechanistic synergy:

Zinc provides upstream regulation by restraining viral replication, stabilizing immune tone, supporting antioxidant defenses, and moderating fibroblast activity. FCAB-EPs deliver downstream structural inputs by stimulating elastogenesis, guiding ordered ECM remodeling, and restoring alveolar mechanical compliance. Together, they construct a dual-axis framework of immune stability and structural regeneration.

Clinical translation:

- In COPD and emphysema, zinc reduces exacerbations and oxidative burden, while FCAB-EPs preserve alveolar recoil by reinforcing elastic networks.
- In ARDS, zinc stabilizes alveolar-capillary barriers, and FCAB-EPs promote elastic repair, aligning with improved oxygenation and recovery from acute lung injury.
- In pulmonary fibrosis, zinc suppresses TGF-β/Smad-driven fibroblast activation, while FCAB-EPs restore elastin balance in ECM remodeling, countering collagen-dominant stiffening.
- In Long COVID, zinc recalibrates immune and epithelial repair processes, while FCAB-EPs restore compliance and support functional rehabilitation.

Target populations:

The combination is particularly relevant for COPD/emphysema patients, ARDS survivors, fibrosis-prone populations, post-viral (Long COVID) rehabilitation cohorts, and aging groups vulnerable to elastic tissue decline.

Unlike conventional nutrient pairings that primarily modulate infection or inflammation, zinc with FCAB-EPs uniquely addresses the structural foundations of respiratory resilience.

By uniting zinc's role in immune and ECM regulation with FCAB-EPs' capacity for elastic fiber biogenesis, this pairing offers a repair-oriented, elasticity-preserving intervention across the continuum of respiratory disease - from acute critical illness to chronic degenerative states and post-viral recovery.

- ✓ *Prasad, A. S. (2008). Zinc in human health: Effect of zinc on immune cells.* Molecular Medicine, 14(5-6), 353–357.

  - Review establishing zinc's essential role in immune maturation, antiviral defense, and epithelial repair, directly relevant to respiratory health.

- ✓ *Wessels, I., Rolles, B., & Rink, L. (2020). The potential impact of zinc supplementation on COVID-19 pathogenesis.* Frontiers in Immunology, 11, 1712.

  - Review describing zinc's role in reducing viral replication, supporting barrier stability, and improving outcomes in COVID-19.

- ✓ *Gammoh, N., & Rink, L. (2017). Zinc in infection and inflammation.* Nutrients, 9(6), 624.

  - Review highlighting zinc's dual action in infection restriction and inflammation control, supporting its synergy with ECM-directed strategies.

- ✓ *Rucker, R. B., & Tinker, D. (1977). Structure and metabolism of arterial elastin.* International Review of Experimental Pathology, 17, 1–47.

- Foundational review on elastin biology, describing how elastin peptides influence ECM turnover and connective tissue resilience.

✓ *Hinek, A., & Rabinovitch, M. (1994). 67-kD elastin-binding protein is a protective "chaperone" for tropoelastin.* Journal of Cell Biology, 126(2), 563–574.

- Experimental study showing elastin-binding proteins guide proper fiber assembly, relevant to the regenerative logic of elastin peptides.

✓ *Rodrigues, M. P., et al. (2018). Elastin-derived peptides and their role in tissue remodeling.* Matrix Biology, 65, 40–49.

- Review detailing the bioactivity of elastin-derived peptides in regulating fibroblast activity, angiogenesis, and ECM balance.

✓ *Zhang, J., et al. (2021). Vitamin C alleviates pulmonary fibrosis via suppressing oxidative stress and TGF-β/Smad pathway.* Free Radical Biology and Medicine, 167, 386–401.

- Preclinical evidence highlighting antioxidant-mediated fibroblast restraint and ECM protection, indirectly supporting the role of elastin peptides in fibrosis modulation.

✓ *Wen, Q., et al. (2020). Role of extracellular matrix in lung diseases: Current understanding and future perspectives.* Journal of Cellular Physiology, 235(11), 8999–9019.

- Comprehensive review on ECM remodeling in COPD, ARDS, and fibrosis, emphasizing elastin loss as a driver of compliance impairment.

V General Summary

The comprehensive analysis presented in this manuscript highlights the multi-nutrient, multi-axis interventions of Vitamin C, Vitamin D, and Zinc in respiratory diseases, with a particular focus on their synergistic interactions with targeted bioactive compounds. Across acute viral infections, chronic airway disorders, critical illness, fibrotic remodeling, and post-viral syndromes, these nutrients function not as isolated agents but as integrated modulators of antiviral defense, immune balance, barrier stabilization, and structural preservation.

1) Vitamin C Axis

Vitamin C provides a foundation of antioxidant protection, immune regulation, and barrier support. Its synergy with flavonoids (quercetin), enzymes (bromelain), and connective tissue–supporting peptides amplifies its reach:

- Quercetin enhances redox balance and viral interference, complementing Vitamin C’s immune and barrier roles.
- Bromelain improves mucus rheology and symptom relief, while Vitamin C sustains antioxidant defense.
- Elderberry contributes viral entry inhibition and symptom mitigation, while Vitamin C supports immune recalibration.
- Mulberry leaf adds metabolic-inflammatory modulation, reinforcing Vitamin C’s systemic antioxidant tone.

- Fish Cardiac Arterial Bulb–Derived Elastin Peptides (FCAB-EPs) align with Vitamin C's role in collagen-elastin stabilization, enhancing elastic tissue resilience in COPD, ARDS, fibrosis, and Long COVID.

2) Vitamin D Axis

Vitamin D establishes a triad of innate antimicrobial priming, adaptive immune rebalancing, and barrier stabilization, exerted through vitamin D receptor (VDR) signaling. Its synergistic logic unfolds through:

- Quercetin, where VDR-driven antimicrobial peptides complement quercetin's antiviral interference and inflammasome control.
- Bromelain, aligning mucolytic and anti-edema effects with Vitamin D's barrier maintenance.
- Elderberry, combining viral entry blockade with Vitamin D's antimicrobial induction.
- Mulberry leaf, coupling metabolic-inflammatory restraint with Vitamin D's immune rebalancing.
- FCAB-EPs, where Vitamin D maintains barrier permissiveness for elastin incorporation, amplifying elastic fiber repair.

3) Zinc Axis

Zinc serves as a multi-domain regulator across respiratory disease: antiviral restriction, immune maturation, oxidative stress buffering, and epithelial restitution. Its synergies add a structural and translational dimension:

- Quercetin acts as a zinc ionophore, enhancing intracellular zinc uptake and strengthening antiviral restriction while adding anti-inflammatory restraint.
- Bromelain complements zinc's immune and barrier repair with mucolytic and anti-edema benefits, uniting viral containment with symptom relief.
- Elderberry provides viral entry blockade and cytokine modulation, converging with zinc's replication inhibition and barrier protection.
- Mulberry leaf integrates metabolic-inflammatory modulation with zinc's immune-barrier functions, highly relevant in COVID-19, COPD, and Long COVID with metabolic comorbidities.
- FCAB-EPs uniquely complement zinc's ECM regulation by supplying substrates for elastic fiber repair and compliance preservation, directly addressing structural decline in COPD, ARDS, fibrosis, and post-viral recovery.

4) Integrative Perspective

Across all three nutrient axes, several converging principles emerge:

4.1) Antiviral containment:

- Vitamin C supports interferon responses, Vitamin D primes antimicrobial peptides, and Zinc directly inhibits viral polymerases.
- Synergistic partners (quercetin, elderberry) enhance entry blockade and intracellular zinc efficacy.

4.2) Inflammatory modulation:

- All three core nutrients reduce NF-κB signaling, cytokine excess, and oxidative burden.
- Flavonoids, polyphenols, and enzymes (quercetin, mulberry leaf, bromelain) add layers of inflammasome control, metabolic inflammation restraint, and edema reduction.

4.3) Barrier and structural preservation:

- Vitamin C stabilizes collagen and endothelial function, Vitamin D reinforces tight-junction proteins, and Zinc drives epithelial restitution.
- Elastin peptides (FCAB-EPs) uniquely expand this axis by enabling elastic fiber regeneration, directly countering fibrosis and compliance loss.

4.4) Clinical continuity:

From URTI and influenza to COVID-19, from asthma/COPD to ARDS, from pulmonary fibrosis to Long COVID, these nutrient synergies map consistently onto disease-specific

drivers - offering both acute-phase benefits (viral containment, symptom relief) and long-term rehabilitation outcomes (structural preservation, functional recovery).

5) Concluding Statement

This manuscript underscores that effective respiratory support requires no single-agent interventions, but multi-nutrient, system-level strategies.

The coordinated actions of Vitamin C, Vitamin D, and Zinc, enhanced by synergistic bio-actives including quercetin, bromelain, elderberry, mulberry leaf, and fish cardiac arterial bulb–derived elastin peptides, Keyora LungOra 8 in 1 establish a comprehensive mechanistic framework.

By addressing viral containment, immune balance, barrier stability, and elastic tissue regeneration, these integrated interventions hold promise for broad-spectrum protection, chronic disease stabilization, and post-viral rehabilitation, advancing nutritional strategies in respiratory medicine toward precision, resilience, and recovery.